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ABSTRACT 
 
SYNTHESIS AND APPLICATION OF BIOMATERIALS CONTAINING THE 1,3,5-
TRIAZAADAMANTANE MOIETY OR FUNCTIONALIZED ALGINATE 
 
Richie Edward Kohman 
Department of Chemistry 
University of Illinois at Urbana-Champaign, 2009 
Professor Steven C. Zimmerman and Professor Hyun Joon Kong, Advisors 
 
 
 This thesis describes the synthesis and study of novel biomaterials. This work can 
be broadly divided into two groups of projects based on the compounds and materials that 
were used. 
  The first group involves a class of compounds called substituted 1,3,5-
triazaadamantanes (TAAs).  Formed from the condensation between 
tris(aminomethyl)methane and substituted benzaldehydes, these compounds possess 
tunable degradation rates that depend on the substituents on the aromatic aldehydes.  
TAAs possess a branched architecture that was utilized in a variety of projects.  TAA 
monomers were synthesized that were used for the preparation of degradable dendrimers.  
Using an iterative, divergent strategy, dendrimers up to three generations were 
synthesized that contained 39 TAA monomer units, displayed 81 functional groups on its 
periphery, and had a molecular weight above 35 kDa.  End group modification with 
propargyl alcohol initiated hyperbranched polyglycerol rendered the compounds water 
soluble creating nanomaterials capable of encapsulating and releasing small molecule 
guests.  Water soluble TAA cross-linkers were used to make degradable hydrogels by 
performing photo initiated polymerization and in situ cross-linking with hydrophilic 
monomers.  Hydrogel degradation rates depended on the cross-linker used with 
degradation times varying from less than one day to as long as several months.  Gels 
 iii
discs were implanted in chicken embryos and shown to be nontoxic and were shown to 
release protein in a controlled fashion.  Finally, TAA cross-linkers were also reacted with 
low molecular weight polyethyleneimine (PEI) to synthesize degradable gene delivery 
vehicles.  Degradable PEIs had varying gene delivery efficiencies and cell toxicities 
based on the cross-linker used.  A polymer was made that produced comparable gene 
delivery efficiency to high molecular weight PEI, a standard in polymeric gene delivery, 
but with significantly lower toxicity. 
 The second group of projects involves the synthesis of hydrogels from 
polyethylene glycol and alginate.  Both polymers can be synthetically functionalized to 
allow gel formation under physiological conditions, without the addition of reagents, and 
without the production of by-products.  Photoresponsive gels have also been made that 
degrade upon exposure to light.  This material can be patterned and post functionalized to 
display desired chemical cues. 
 
 
 
 
 
 
 
 
 
 
 iv
 
 
 
 
 
 
 
 
 
 
 
Dedicated to my friends and family 
 
 
 
 
 
 
 
 
 
 
 
 v
ACKNOWLEDGEMENTS 
 I would like to thank my research advisors, Professor Steven C. Zimmerman and 
Professor Hyun Joon Kong.  Together they have provided me with support and guidance 
throughout my graduate career.  In addition they have given me the freedom to grow and 
develop as a scientist.  I would also like to thank my doctoral committee members Prof. 
Daniel Pack and Jianjun Cheng and former committee members Prof. Robert Coates and 
Prof. Mary Gin for their useful encouragement during my years of study at University of 
Illinois. 
 I have had the fortune of working with many helpful group members.  This long 
list includes Dr. Gabriel Lemcoff, Dr. Michael Mayer, Dr. Amy Balija, Dr. Jim Beil, Dr. 
Hugo Ong, Dr. Eric Todd, Dr. Akihito Hashidume, Dr. Jonathan Arambula, Dr. Nathan 
Gabrielson, Kwansima Quansah, Brandon Lange, Darrell Kuykendall, Cyrus Anderson, 
Chun-Ho Wong, Dr. Jaehyun Jeong, Cathy Chu, John Schmidt, Chaenyung Cha, and 
Ross DeVolder.  I would also like to specifically thank my lab partners Dr. Stephanie 
Elmer and Andrew Zill.  In addition I would like to thank Dr. Terry Moore, Dr. Eric 
Leshikar, Serena Wee, and LumOr Chet for their loyal friendship during my years in 
graduate school. 
 Finally I would like to thank my extremely supportive family, especially my 
brother Andy and parents Andrew and Mary Kohman for their love and support. 
 
 
 
 
 vi
TABLE OF CONTENTS 
 
CHAPTER 1. APPLICATIONS OF BIOMATERIALS.....................................................1 
1.1 Introduction........................................................................................................1 
1.2 Drug Delivery ....................................................................................................1 
1.3 Gene Delivery ....................................................................................................5 
1.4 Tissue Engineering/Regenerative Medicine ......................................................9 
 
CHAPTER 2. SUBSTITUTED 1,3,5-TRIAZAADAMANTANES (TAAs) ....................13 
2.1 Introduction......................................................................................................13 
2.2 TAA-Containing Dendrimers ..........................................................................20 
2.3 TAA-Containing Hydrogels.............................................................................56 
2.4 TAA-Containing Gene Delivery Vehicles.......................................................71 
 
CHAPTER 3. FUNCTIONALIZED ALGINATE ............................................................85 
3.1 Project Goals....................................................................................................85 
3.2 Conjugate Addition Alginate/PEG Hydrogels.................................................86 
3.3 Photodegradable Hydrogels .............................................................................90 
3.4 Conclusion .......................................................................................................94 
 
CHAPTER 4. EXPERIMENTAL......................................................................................96 
4.1. General Methods.............................................................................................96 
4.2 Synthesis and Characterization ........................................................................97 
4.3. Analytical Techniques ..................................................................................159 
4.4. Spectra...........................................................................................................164 
 
REFERENCES ................................................................................................................168 
 
AUTHOR’S BIOGRAPHY.............................................................................................174 
 
 
 
 
 
 
 
 
 1
CHAPTER 1 
APPLICATIONS OF BIOMATERIALS 
 
1.1 Introduction 
 Biomaterials are naturally or synthetically created materials that come in contact 
with biological systems.1  Although examples exist throughout human history, the formal 
field of research has only arisen recently from the combination of medicine, chemistry, 
biology, and material science.  The research discussed in this dissertation pertains to the 
synthesis and application of novel biomaterials.  The purpose of this chapter is to give a 
brief overview of the applications that are relevant to the projects discussed.  This 
description is not intended to be exhaustive and will only discuss the fields generally.  A 
description of the key design principles will be discussed as well. 
 
1.2 Drug Delivery 
 Despite the enormous benefit to human health that drugs provide, many problems 
still remain.  Many drugs, especially anticancer drugs, have undesirable side effects that 
often result from localizing in off-target locations within the body.  Additionally, 
biological therapeutics, such as proteins, are rapidly degraded in the body.  This results in 
the need for repeated administration of the treatment.  Noncompliance is a common 
problem and can result in further deterioration of health.  For all these reasons controlled 
drug release strategies are being pursued.2  The goal of drug delivery is to improve the 
effectiveness of the drug by delivering the appropriate amount solely to the site of action 
at the appropriate time. 
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 Drug delivery strategies can be classified into two categories: localized and 
systemic.1  The therapeutic is administered to the site of interest for localized treatment 
while for system delivery it is administered to the whole organism commonly orally or 
intravenously.  Localized treatment commonly entails the implantation of a polymer 
matrix containing the drug of interest where it is released in a controlled fashion over the 
desired time period. The most common mechanism of release is by diffusion out of the 
matrix as the biomaterial degrades.  Polymer degradation can be initiated by a variety of 
stimuli however the most common means is by hydrolysis due the ubiquitous presence of 
water in the body.  Compared to systemic delivery, localized delivery has fewer 
challenges however is usually more invasive. 
 A large diversity of approaches has been developed for systemic drug delivery.  
All of the systems involve materials that have to circulate in the body.  Two key factors 
in this approach are circulation time and biodistribution.  Both of these are heavily 
influenced by the size of the carrier.3  The larger the materials are the longer they remain 
in the blood stream and the longer they can effectively release their cargo.  However if 
they are too large they cannot effectively be removed from the body, therefore there is a 
size window that is desirable.  Most administered materials distribute to all regions in the 
body with the exception of the brain due to their inability to cross the blood-brain barrier.  
Active targeting of specific tissues has been accomplished by the attachment of targeting 
groups such as peptides to the carrier.4  It has been discovered that material size can have 
an effect when targeting tumor tissue.5  The physiology of tumor tissue is different than 
that of normal tissue in that it has altered vasculature and impaired lymphatic drainage.  
Due to this effect, polymers of a large enough size (> 20 kDa) can passively accumulate 
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in tumors.  This enhanced permeation and retention (EPR) effect can be used to passively 
target tumors without the use of additional targeting molecules. 
 Many systemic drug delivery designs have been demonstrated.  One category 
involves polymers that physically entrap their cargo.  Liposomes are commonly used as 
this type of drug delivery vehicle.6  Drugs are encapsulated in the interior and are 
released upon disruption of the membrane.  Polymer microspheres that hydrolyze to 
release their payload have been extensively investigated as well.7 Often times these are 
made in an emulsion process, trapping the compound of interest inside the polymer.  
Unimolecular micelles in the form of dendrimers have also been shown to entrap drugs.8  
These polymers have hydrophobic interiors in which certain drugs can partition into.  
During this equilibration process drugs slowly diffuse out of the carrier. 
 The second category of systemic drug delivery vehicles is comprised of polymer-
drug conjugates in which the drug is covalently bonded to the polymer through a 
temporary linker.9  This linker is commonly cleaved by hydrolysis but other mechanisms 
have been reported such as enzymatic cleavage.10  Because many acidic 
microenvironments exist in the body such as tumor tissues11 or in endosomes,12 acid 
catalyzed hydrolysis has been used as a mechanism to release drugs from their carrier.13  
Covalent attachment is advantageous because it ensures that the drug will not diffuse 
away from the polymer unless the linker is cleaved.  Different polymer architectures have 
also been investigated from linear polymers to perfectly branched dendrimers.14 
 Many different polymers have been developed for drug delivery.15  A significant 
majority are hydrolytically labile to ensure that they are effectively removed from the 
body.  Figure 1 shows a sample of some commonly used materials.  Polyesters such as 
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poly(lactic acid), poly(glycolic acid), and poly(caprolactone) as well as poly(anhydrides) 
have been studies extensively as biomaterials.16  These polymers are hydrolytically labile 
and degrade to produce carboxylic acids that have been known be harmful to tissues.17  
Additionally, their bulk degradation properties have traditionally been hard to control.  
Despite these drawbacks, these polymers are widely being used because of their 
precedent.  Also, polymer methodology has been developed that can produce controlled, 
monodisperse polymers, especially for polyesters.18  Other polymers such as poly(ortho 
esters)19 and poly(phosphazenes)20 have been developed that can hydrolyze to produce 
neutral or basic by produces respectively. 
 In the research presented in this dissertation, the sections pertaining to drug 
delivery are Chapter 2.2 and 2.3.  In both these sections, the compounds of interest are 
noncovalently incorporated into a material and released upon degradation. In 2.2, 
dendritic nanocarriers are described that encapsulate small molecules and in 2.3 a cross-
linked polymer network is described that can release proteins.  In both of these examples, 
Figure 1. Structures of several common polymers used in drug 
delivery. 
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degradation control was the property that was focused on.  The materials described in 
those sections demonstrate tunable control of hydrolysis rates. 
 
1.3 Gene Delivery 
 Gene delivery involves the administration of therapeutic DNA for the treatment of 
hereditary or acquired diseases.  Although genes can be delivered directly, the efficiency 
of this process is extremely low and a delivery agent is necessary.  Traditionally viral 
delivery systems have been used because of their high efficiency, however safety issues 
have arisen due to human casualties during clinical trials and alternate methods are being 
investigated.21 
 Nonviral delivery systems are usually comprised of either liposomes22 or 
polymers.23  These systems are generally safer than viral strategies however are much 
less efficient.  The current challenge is to design vehicles that maintain an acceptable 
level of safety but are significantly more efficient.  There are several barriers to efficient 
gene delivery.  In addition to the challenges encountered in the circulation and targeting 
of the vectors many hurdles are encountered at the cellular level.   
 Figure 2 shows a generalized depiction of polymeric gene delivery from cellular 
delivery to nuclear localization of DNA.  Because of its size and charge, DNA is poorly 
internalized by cells.  Polymer/DNA complexes, or polyplexes, are formed by mixing 
cationic polymers with anionic nucleic acids (Figure 3).  Electrostatic attraction creates 
particles that are capable of being administered as gene delivery vehicle.  Most 
polyplexes are prepared so that they contain a net positive charge.  This allows binding to 
cell membrane which contains a net negative charge leading to cellular internalization.  
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Polyplexes commonly enter the cell via endocytosis and partake in a complex trafficking 
process.24  Initially present in an endosome, this vesicle becomes acidified and eventually 
transitions into a lysosome that digests its contents.  Gene delivery vehicles that are 
unable to escape the endosome are eventually degraded in this fashion.  If the vehicle 
manages to escape out of the endosome it still must enter into the nucleus and eventually 
become unpacked from the polyplex.  It is unclear as to whether unpacking should be 
done before or after entering the nucleus however it is known that the cytosol contains 
nucleases that are capable of degrading any DNA found there. 
 
Figure 2.  Schematic depiction of the cellular delivery of polymeric gene delivery vehicles. 
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 Overall the two largest barriers to efficient cellular gene delivery are endosomal 
escape and nuclear localization.  The nuclear entry step remains mysterious, however, it 
has been shown that the attachment of nuclear localization signals to the polyplex can 
increase the efficiency of nuclear entry.25  It has been found that endosomal escape can be 
enhanced by the use of polymers that are capable of buffering the increased acidification 
of the endosome.  This “proton sponge” effect is believed to occur because of an increase 
in osmotic pressure within the vesicle.26  As protons are pumped inside the endosome 
chloride ions enter as well.  This increases the osmotic pressure eventually leads to the 
rupture of the vesicle and release of its contents into the cytosol.  These cellular hurdles 
are a major consideration in the design of polymers for gene delivery. 
Figure 3. Schematic depiction of polyplex formation. 
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 Although numerous polymers have been developed to complex and deliver DNA, 
all share the common property of being positively charged (Figure 4).27 Also it is 
advantageous to posses buffering capacity to facilitate endosomal release and undergo 
degradation to reduce toxicity.  Molecular weight is also a factor.  Larger polycations 
often deliver DNA more efficiently however are more toxic as well.28  Figure 4 shows the 
structures of some common gene delivery polymers.  Poly(L-lysine) was one of the first 
polymers used and is relatively inefficient.29  It has been suggested that this is due to its 
inability to escape endosomal compartments due to its lack of buffering capacity.  
Polymethacrylate such as poly[2-(dimethylamino)ethyl methacrylate] have been used due 
to their ease of preparation and the diversity of monomers available.30  Polyethyleneimine 
(PEI) has been extensively used and is considered the “gold standard” among gene 
Figure 4.  Structures of several common polymers used in gene delivery. 
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delivery polymers.31  It is available in a variety of molecular weights and can be made in 
a branched and linear form.  Commercially available poly(amido amine) dendrimers are 
used as gene delivery vehicles.32  Like PEI, these dendrimers are relatively efficient 
which has been attributed to their high buffering capacity.  To date some of the most 
effective polymers synthesized have been poly(β-amino esters).33  These polymers posses 
degradable ester groups in the backbone as well as tertiary amines.  They are synthesized 
by the condensation of commercially available amino groups with diacrylates.  Because 
of their simple synthesis, libraries of polymers can be made in parallel and tested in a 
high throughput fashion.  This approach overcomes many of the design hurtles for 
effective gene delivery because of the large amount of polymers that were made. 
 Chapter 2.4 of this dissertation applies directly to the synthesis of gene delivery 
vehicles.  In this section cationic polymers are synthesized that have tunable degradation 
rates.  Additionally Chapter 3 discusses materials that may be useful for the controlled 
release of polyplexes. 
 
1.4 Tissue Engineering/Regenerative Medicine 
 Tissue engineering is an interdisciplinary field that combines three dimensional 
matrices and cells to create functional living tissue.34  The goal may be to synthesize full 
organs to remove the need for human organ transplants, or, more realistically, to help 
restore, maintain, or improve current tissue function.  Traditionally the approach has been 
to culture cells in a three dimensional material or scaffold meant to mimic the 
extracellular matrix surrounding cells.  As cells proliferate and form new tissue the 
scaffold degrades leaving behind functioning tissue.  The microenvironment surrounding 
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cells is complex and dynamic making the creation of a synthetic analogue a large 
challenge.35 
 The cellular component is an area of active research.  Because it is necessary for 
the cells to differentiate into a desired cell type, progenitor cells or stem cells are 
commonly used because they possess this ability.36  The type of cell used depends on the 
application however it is always desirable for the cell to eventually differentiate into the 
desired tissue type.  Adult36 as well as embryonic37 stems have been used.  One area of 
concern is immunorejection of cells that did not come from the same individual.  The 
discovery of induced pluripotent stem (iPS)38 cells may alleviate this issue because the 
cells could be obtained from the same person needing the treatment. 
 The scaffold component is also a large area of research because it provides 
important chemical and mechanical cues to the cells that it contains.  The materials used 
can broadly be broken up into two categories: natural or synthetic, both of which have 
their advantages and disadvantages.39  Natural polymers such as collagen, hyaluronate, or 
alginate contain a large amount of synthetic complexity.  Especially with the case of 
collagen, chemical cues recognized by cells are already installed on the polymer.  For this 
reason these materials have been pursued in clinical research.  The disadvantage is that it 
is difficult to obtain a consistent quality of material because they are obtained from 
natural sources.  Batch to batch variation can be a problem and natural materials have 
been known to illicit an immune response. Synthetic materials are highly reproducible 
because they are made in a controlled chemical fashion however they are relatively 
simple in comparison to natural materials and have to be modified to interact with cells in 
a functional manner. 
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 The processing of the scaffold also has a large effect on its function.  Earlier 
designs relied on the use of hard, insoluble polymer matrices.  Because of the mismatch 
in material properties of these systems in comparison to natural extracellular matrices the 
overall performance is low.16  More recently hydrogels have been used as scaffolds 
because they are more biomimetic in terms of their physical properties.40  Hydrogels are 
cross-linked polymer networks that contain a large amount of water and are also of a 
similar stiffness to natural tissue.  Another approach has been to use polymer nanofiber 
scaffolds that mimic the fibrous structure of extracellular matrix proteins such as 
collagen.41  These have been prepared by electrospinning methods42 or by self-
assembly.43 
 The design of biomaterials for tissue engineering is a large challenge due to the 
many functions they have to provide.  As with the other discussed applications the 
material must be degradable to be eliminated from the body safely.  This has been 
accomplished by using hydrolytically labile polymers that degrade over time15 as well as 
polymer matrices that contain enzymatically labile peptide sequences.43  The scaffold 
must also be adherent to cells.  Natural polymers often have sequences recognized by 
cells; however synthetic scaffolds need to be functionalized for cells to adhere to them.  
A common strategy is to attach peptides sequences recognized by cell adhesion 
proteins.44  The density and spacing of these sequences has been shown to have a large 
effect on cell behavior.45  Lastly the stiffness of the material has to be appropriate.  Cells 
can sense the stiffness of their substrate and through mechanotransduction this 
information can alter cell behavior and gene expression.46  Different tissues have 
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different elastic moduli and the material must be of a similar stiffness for cells to behave 
naturally.   
 All of these issues combined make the creation of tissue engineering scaffolds a 
significant challenge and there is a need for new chemistry developed towards this end.  
Materials described in Chapters 2.4 and 3 are being pursued towards this end.  The 
materials in Chapter 2.4 were pursued because of their novel control of degradation while 
the system designed in Chapter 3 was designed to be easy to synthesize and process. 
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CHAPTER 2 
SUBSTITUTED 1,3,5-TRIAZAADAMANTANES (TAAs) 
 
2.1 Introduction 
2.1.1 Background 
 This chapter focuses on polymers and materials containing substituted 1, 3,5-
triazaadamantanes (TAAs).   The 1,3,5-triazaadamantane structure consists of an 
adamantane group with three alternating nitrogen atoms in one of the rings.  These 
polymers and materials are being investigated because of their unique degradation 
properties.  The 1,3,5-triazaadamantane unit has been known for 
decades however has received little attention until recently.  The 
first example of a 1,3,5-triazaadamantane was reported in 1951 by 
Stetter and Böckmann who synthesized 1 from the condensation of 
1,1,1-(trisaminomethyl)ethane with three equivalents of 
formaldehyde (Figure 5).47  This compound was shown to be able to tolerate refluxing 
acidic conditions without undergoing degradation.  All reported 1,3,5-triazaadamantanes 
since this example have been formed from aromatic aldehydes, and most were used as 
either precursors to metal coordination complexes or as a means of protecting 
(trisaminomethyl)methane-containing compounds.48   Woulfe and coworkers reported the 
1 
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condensation of benzaldehyde with trisamine pentaerythritol 2 to produce compound 3 
(Scheme 1).48e  This compound was shown to be stable under basic conditions but readily 
degraded to starting materials upon expose to aqueous acidic conditions.  This report did 
not describe the chemical and physical properties or the degradation rates of 3. 
 A detailed investigation of the hydrolysis rates of 3 and its analogs was reported 
by Balija and coworkers.49  It was discovered that 3 is formed under thermodynamic 
control to produce a mixture of two diastereomers as shown in Scheme 1.  The most 
stable structure (3a) contains two aromatic rings that are equatorial to the triazine ring 
and one that is axial, while the minor diastereomer (3b) displays all three rings in the 
equatorial position.  The relative energies of 3a and 3b were confirmed by ab initio 
calculations and the exact structures of the diastereomers were conclusively established 
by nuclear Overhauser enhancement experiments, COSY spectroscopy, and X-ray 
analysis of the chromatographically separated compounds.  1H NMR spectroscopy easily 
distinguishes between the two diastereomers (Figure 6).  Because of the symmetry 
present in 3b, all three triazine protons appear as one singlet (Ha), as compared to 
Figure 6. Partial 1H NMR spectra of diastereomeric mixture of 3a and 3b in CDCl3. 
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compound 3a which shows two singlets in a 2 to 1 ratio (Hc and Hb).  Any aldehyde 
present can easily be detected due to the presence of a downfield singlet peak.  It should 
be noted that this diastereomeric distribution is general to all 1,3,5-triazaadamantanes 
presented herein and depicted in this dissertation are isolated as a mixture of 
diastereomers unless stated otherwise. 
 The hydrolysis rates of substituted 1,3,5-triazaadamantanes (TAAs) could be 
altered by changing the substituents on the aromatic ring (Figure 7).49  Electron donating 
groups accelerated degradation while TAAs possessing electron donating substituents 
were found to be relatively robust.  This is consistent with the mechanism partially 
displayed in Figure 8 where triazine ring opening is the rate determining step of TAA 
degradation.  Electron donating groups stabilize this intermediate leading to an increase 
in the rate of this step.  In this fashion it is possible to tune TAA degradation by altering 
Figure 7. Degradation rates of water soluble substituted TAAs. 
4a 4c 
4b 
 
4b 
4c 
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substitution patterns.  In addition, because Hammett substituent constants are known for a 
large variety of common substitution patterns, it is possible to predict relative degradation 
rates of a series of TAAs.50 
 Although not studied by Balija, it was discovered that rate of TAA isomerization 
during synthesis is also affected by the substitution pattern.  TAA formation occurs, for 
all practical purposes, instantly.  Initially a mixture of many diastereomers is formed and 
equilibration eventually produces a 9:1 ratio of the two most stable isomers.  For TAAs 
containing electron donating groups the equilibration is instantaneous, however when 
electron withdrawing groups are present the process requires more time.  This is 
presumably because of the increased energy barrier in the rate determining step because 
of destabilization of the intermediate.   When benzaldehyde derivatives containing amide 
or ester groups in the para position are used, the equilibration process takes 
approximately 1 h.  Previously unnecessarily long reaction times (overnight) were used.  
Additionally because the reaction is under thermodynamic control and produces three 
equivalents of water per TAA, there was a large amount of effort put into using dry 
solvents and removing water from the reaction.  This was accomplished by addition of 
Figure 8.  Partial hydrolysis mechanism of compound 3. 
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crushed molecular sieves into the reaction mixture.  It was discovered that these 
conditions are unnecessary.  As stated, reaction times need not exceed one hour.  Also 
isolated yields were roughly the same without sieves and when solvent was used that had 
not been rigorously dried.  The claim that yields were higher when sieves were used is 
expected to be the result of general yield fluctuations and from material being lost during 
column chromatography. 
 The final contribution of Balija was the creation of a TAA-containing dendrimer 5 
(Figure 9).49  This compound was fully water soluble and readily degradable.  It was also 
capable of encapsulating a small molecule guest as determined by 1,8-ANS fluorescence 
studies.  However, release of guests upon degradation was not conclusively demonstrated.  
 In addition to the tunable degradation rates of TAAs, there are several additional 
properties that make them a useful motif to incorporate into biomaterials. They degrade 
in acidic conditions to produce basic by-products, potentially creating a buffering effect. 
They are branched and therefore lend themselves to the synthesis of dendrimers or 
dendronized structures.  TAAs also have a variety of convenient synthetic advantages.  
Their synthesis is generally high yielding and requires short reaction times (~1 h or less).  
Characterization if facile due to signature peaks present in 1H NMR spectra in regions 
that are typically devoid of other peaks. Finally, TLC characterization is facilitated by the 
presence of stains that can be used to detect TAA degradation properties.  Ninhydrin stain 
can be used to detect amino groups and dinitrophenyl hydrazone stain can be used to 
detect aldehyde groups.  Acidic solutions of these stains can be used to detect TAAs by 
the presence of their degradation products. 
 18
 
2.1.2 General Synthetic Comments 
 The synthesis of TAAs requires the preparation of two types of compounds: 
substituted benzaldehydes and trisamine pentaerythritols.  The chemistry necessary to 
prepare the desired benzaldehyde derivatives was developed on a case-by-case basis.  To 
maintain a consistent branching pattern, benzaldehydes were functionalized in the para 
position.  For functionalized trisamine pentaerythritol derivatives the strategy used by 
Woulfe and coworkers was adopted in which compound 3 was synthesized to protect the 
amino functional groups.48e  The use of this reaction is highly advantageous because of its 
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short reaction time (~5 min), quantitative conversion, and ease of purification (extraction 
only).  The free hydroxyl group can then be functionalized and purified before hydrolysis 
is performed to give the desired tris amine salt. 
 Compound 2 is not commercially available and needs to be synthesized.  This 
procedure begins with commercially available compound 6 which can be converted to 
trisamine 2 in two steps by azide displacement followed by Staudinger reduction 
(Scheme 2).48f  This was done at twice the concentration and on an approximately 50 g 
scale of 6.  It should be noted that intermediate 7 is potentially explosive and the original, 
more dilute conditions may be more desirable for this reason.  Caution should be taken 
when following this procedure due to the high potential for personal harm. 
 
2.1.3 Project Goals 
 The goals of the projects in this chapter are to synthesize TAA-containing 
macromolecules that are useful for a variety of biological applications.  The branched 
nature of the TAAs and their tunable degradation kinetics are the properties that are most 
highly utilized.  These biomaterials are targeted as drug/gene delivery vehicles and 
scaffolds for tissue engineering and regenerative medicine (Chapter 1). 
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2.2 TAA-Containing Dendrimers 
 Taking advantage of the branched, unsymmetric display of functionality, 
degradable TAA-containing dendrimers were synthesized.  Methodology was developed 
to synthesize TAA monomers and to incorporate them into dendrimers.51  In 
collaboration with graduate student Andrew Zill and undergraduate Alexandra Rutz, 
dendrimer surfaces were functionalized to produce water soluble nanocarriers that were 
capable of encapsulating and releasing small molecule guests. 
 
2.2.1 Degradable Dendrimer Background 
 Many dendrimers have been synthesized that can degrade in either water or 
organic solvents by a variety of means.52  Numerous strategies have been developed in 
which full degradation can be initiated by an external trigger.  The first example was 
demonstrated by Seebach and coworkers who synthesized a dendrimer composed of ester 
groups which would cleave in the presence of poly-β-hydroxybutyrate depolymerase.53  
Shabat, deGroot, and McGrath independently reported dendritic structures which degrade 
through a cascade process upon liberation of a hydroxyl or amino group.54  Systems have 
been developed in which this unmasking process was triggered by light,54b,c acid,54b or 
enzymes.55  Additionally, McGrath and coworkers have synthesized photolabile 
dendrimers by utilizing o-nitrobenzyl linkages between the dendrons and dendrimer 
core.56 
 Dendrimers that can degrade via hydrolysis are particularly interesting because of 
their potential use in biological applications.  Several examples of degradable dendrimers 
that utilize hydrolyzable functional groups have been demonstrated.  Fréchet and 
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coworkers57 as well as Grinstaff and coworkers58 have synthesized polyester dendrimers 
while Fuchs and coworkers have synthesized dendrimers containing acetal groups.59  One 
drawback to these approaches is the lack of control over degradation kinetics.  A notable 
exception involves the use of acetals prepared from substituted benzaldehydes presented 
by Fréchet and coworkers.60  The substitution pattern on the aromatic ring was shown to 
influence the hydrolysis rate.  Dendritic structures containing these functional groups 
were synthesized and shown to undergo triggered hydrolytic degradation in acidic 
conditions. 
 
2.2.2 General Design 
 Although a TAA-containing dendrimer had already been synthesized by Balija 
and co-workers,49 a different strategy was developed and implemented for several reasons.  
The previous synthesis was lengthy and difficult.  It required the condensation of a 
nonamine core with a water soluble benzaldehyde dendron.  Both of these components 
require multi-step syntheses with difficult purification steps required.  Although TAA 
formation is generally rapid and high yielding, isolated yields for dendrimer formation 
were low possibly because of the purification difficulties.  Also the benzaldehyde groups 
were comprised of Fréchet-type dendrons with polyethylene glycol chains attached.  This 
produced a dendrimer possessing only three TAAs with a significant amount of its mass 
taken up by non-TAA components. 
 A new strategy was devised with the goal of minimizing extensive synthetic effort.  
Instead of making specialized precursors that that would only give rise to only one 
dendrimer, general TAA monomers were created that could be incorporated in an 
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iterative fashion to rapidly produce a variety of dendrimers.  Because of the challenges of 
performing multivalent chemistry, only very robust and reliable reactions were chosen for 
the dendrimer methodology.  Kinetic transformations were preferred over thermodynamic 
ones to eliminate any undesirable side products.  The displacement of a chloride with 
azide and the copper catalyzed cycloaddition between azide and alkyne groups61 were 
chosen because they fulfilled this criterion.   
 Two routes were investigated in the synthesis of TAA dendrimers.  Initially a 
convergent route towards dendrimers was pursued.  Producing dissatisfactory results, it 
was abandoned for a divergent route.  A schematic depiction of the methodology is 
shown in Figure 10.  The general convergent strategy was demonstrated by Hawker, 
Fréchet, and Sharpless.62  Soon after, Wooley and coworkers published a divergent 
route.63 
  
2.2.3 Convergent Dendrimer Approach 
 Convergent dendrimer strategies begin by synthesizing the exterior of the 
dendrimer first and adding monomer units iteratively growing towards the interior of the 
Figure 10. Schematic depiction of a) divergent vs. b) convergent dendrimer synthesis.
a) b) 
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polymer (Figure 10b).  This approach creates larger dendrons after each iteration which 
are eventually attached to a core to produce a complete dendrimer.  Because the by-
products in this methodology have substantial molecular weight differences, purification 
is relatively easy because they can be removed by preparative size exclusion 
chromatography or conventional absorption chromatography.  As a result convergent 
dendrimer schemes often are pursued because they can produce “perfect” structures that 
are defect-free.  The drawback to this approach is that there is usually a limit to the size 
of the dendrons that can be prepared.  A convergent strategy was initially chosen for 
making TAA dendrimers because of the appeal of producing perfect structures. 
 
2.2.3.1 Monomer and Core Synthesis 
 Difunctional and trifunctional alkyne cores were synthesized (Scheme 3).  This 
was pursued to test the limits of the methodology in terms of steric congestion when the 
dendrons were attached to the core.  Both cores were relatively easy to synthesize.  
Reaction of propargyl bromide with 1,4-dihydroxybenzene (8) in basic conditions was 
able to produce difunctional core 9 and trifunctional core 11 was synthesized using a 
literature procedure62 in which cyanuric chloride (10) was reacted with propargyl alcohol. 
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 The initial monomer synthesis is depicted in Scheme 4.  Aldehyde 12 was chosen 
because of literature precedent for its synthesis.64 Thus, propargylation of 4-
hydroxybenzaldehyde formed 12 in high yield.  Condensation with tris amine 2 produced 
TAA 13.  Tosylation produced the desired monomer 14.  This monomer was used for 
preliminary investigation of the dendrimer methodology, however the substitution pattern 
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the TAAs were quite acid labile and difficult to work with.  TLC plates and silica had to 
be basified prior to use otherwise they would catalyze TAA degradation.  Another 
monomer was synthesized that was more robust. 
 Synthesis of this monomer began with reaction of 4-carboxybenzaldehyde with 
thionyl chloride to produce an acid chloride (Scheme 5).  Esterification with propargyl 
alcohol afforded the desired benzaldehyde 15.  Condensation with 2 produced TAA 16, 
which could be converted to the desired monomer 17 by reaction with tosyl chloride.  
Because of the electron withdrawing groups on the aromatic rings, this monomer was 
much easier to work with and did not require any special considerations to avoid 
undesired degradation. 
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2.2.3.2 Dendrimer Synthesis 
 Because convergent dendrimer syntheses begin by attachment of the peripheral 
groups first, azide-containing TAAs were synthesized (Scheme 6).  Initially compound 
19 was used which can be prepared by tosylation of compound 3 followed by azide 
displacement.  Later compound 23 was made to keep a consistent substitution pattern 
throughout the dendrimer.  Synthesis began by reacting 4-carboxybenzaldehyde with 
thionyl chloride in methanol to produce methyl ester 20.  Condensation with 2 produced 
TAA 21.  The desired azido TAA 23 was prepared by tosylation of 21 to afford 22 
followed by azide displacement.  Although the reactions proceeded as expected, it was 
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discovered that 21-23 displayed inconvenient physical properties.  With the exception of 
TAAs possessing substituents with distinct physical properties, such as long alkyl of 
poly(ethylene glycol) chains, TAAs are white foams that dissolve readily in many 
organic solvents.  TAAs 21-23 were solids that were poorly soluble in many solvents and 
resembled chalk.  This made the dendrimer synthesis more inconvenient than necessary.  
It is recommended that this substitution pattern be avoided if necessary. 
 The initial dendrimer synthesis began by reaction of compounds 19 and 14 in the 
presence of a copper catalyst (Scheme 7).  Initially the reactions conditions that were 
originally published for the “click chemistry” reaction (tert-BuOH/water solvent with 
CuSO4/sodium ascorbate catalyst)61 were used without success.  Although examples were 
given of the reaction working despite the reagents being insoluble in the reaction medium, 
compounds 19 and 14 were not soluble in tert-butanol and no conversion was observed.  
Using conditions in which all of the reagents were soluble including the catalyst, 
quantitative conversion to dendron 24 was obtained.  Displacement of the tosyl group 
with sodium azide produced the desired dendron 25.  However upon reaction with TAA 
14 no reaction was observed. 
 The methodology was reinvestigated with the more robust monomer and 
performing reaction in a microwave reactor (Scheme 8).  As in the case with the previous 
attempt, attachment of three equivalents of 23 onto 17 proceeded smoothly as did the 
subsequent azide displacement which produced dendron 27.  However, similar to the 
previous synthesis, the second iteration in the synthesis did not produce the second 
generation dendrimer. 
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 To further investigate the limits of the chemistry, attempts were made to prepare 
the full dendrimers.  First generation dendrimers were successfully synthesized using 
both bifunctional core 9 and trifunctional core 11 (Scheme 9).  This was expected 
because of the small size of the dendrimers and therefore lack of steric congestion.  
Somewhat unexpectedly because of the failure of producing a second generation dendron, 
second generation dendrimers were also obtained using both cores however high 
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conversions were not obtained (Scheme 10 and Scheme 11).  No larger dendrimers could 
be synthesized. 
 Based on these results, it appears the convergent dendrimer strategy was limited 
to two growth cycles.  It should be noted that the conditions used in this exploration 
utilized a very large catalyst (Cu(PPh3)3Br) which may be sterically inaccessible to the 
desired sites of reactivity.  Conditions used in the divergent dendrimer strategy (see 
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Chapter 2.2.4) may be able to produce larger dendritic structures.  Although the structures 
synthesized were smaller than desired, they were still in a size range to be useful for 
biological applications.  Particularly for gene delivery, there is precedent for successful 
delivery vehicles made from dendronized spermine65 that were approximately the same 
size as the TAAs dendrons and dendrimers synthesized by the convergent strategy.  
Based on this, end group functionalization was explored to try to attach amino groups to 
the dendrimers and dendrons. 
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2.2.3.3 End Group Functionalization 
 Because the peripheral groups become attached first in a convergent dendrimer 
synthesis, two options were available.  The first involved attachment of functional groups 
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inert to the dendrimer methodology which could be reacted in the final step to produce 
product.  The second was to attach protected amino groups at the beginning of the 
synthesis and then do a global deprotection as the final step.  Because of the necessity to 
purity each step, protecting groups would be necessary because polyamines would be 
impossible to purity by column chromatography.  The first strategy was initially 
attempted.  Based on a successful report of dendrimer periphery functionalization using 
cross-metathesis,66 alkene groups were chosen as the functionality to install on the TAAs. 
 Synthesis of alkene containing TAAs was relatively straightforward because of its 
similarity to the synthesis of the alkyne containing TAAs already reported.  Formation of 
the acid chloride of 4-carboxybenzaldehyde using oxalyl chloride followed by ester 
formation with allyl alcohol with triethylamine in THF produced the desire aldehyde 32 
(Scheme 12).  Reaction of 2 with 32 produced the desired TAA 33 in poor yields.  This 
was because of the non-standard reaction conditions used.  Ester substituted 
benzaldehyde groups underwent transesterification when methanol was used as the 
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solvent and reactions were performed overnight.  To prevent this, the solvent was 
switched to dimethyl sulfoxide because it is one of the few solvents that compound 2 
dissolves into in the presence of triethylamine.  However, the DMSO solvent made 
extractive work-up problematic because it let to emulsions and was in general difficult to 
work with do to its high boiling point.  These issues may be partially responsible for the 
low yield.  A possible alternative that was not investigated is to use the standard 
condition but keep the reaction time to one or two.  Tosylation of 33 produced TAA 34 
which could be converted to polyazide 35 by reaction with sodium azide.  This 
compound was also incorporated into a second generation dendron by reacting three 
equivalents with compound 17 (Scheme 13). 
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 To determine if the cross-metathesis reaction would be an effective means to 
functionalize the dendrimer periphery with amino groups, a test reaction was performed 
with compound 33 (Scheme 14).  Reaction with ethyl acrylate using second generation 
Grubb’s catalyst produced the desired product 37, however the isolated yield was low and 
it was determined that the reaction conversion was not high enough to easily produce the 
desired compounds.  For this reason, this approach was abandoned for a protecting group 
strategy. 
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 The amino group motif chosen for this strategy was a derivative of trisamine 
pentaerythritol.  When this group is used, the periphery and the interior of the dendrimer 
produce the same degradation by-products.   The synthesis began by performing acid 
hydrolysis on compound 19 to produce azide 38 (Scheme 15).  Protection of all three 
amino groups with Cbz groups proceeded smoothly to give compound 39.  Attachment to 
alkyne-containing benzaldehyde 15 produced the desired TAA precursor 40 which upon 
condensation with 2 afforded 41.  However, full deprotection of this compound was 
unsuccessful.  Upon using a palladium catalyst and either hydrogen gas or 1,4-
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cycolhexadiene as a hydrogen source at most two of the Cbz groups were removed.  For 
this reason, alternate protecting groups were investigated. 
 The 2-trimethylsilylethyl carbamate (Teoc) protecting group was investigated 
because it can be removed upon reaction with fluoride and has the advantage that the 
deprotection produces no soluble by-products.  Trimethylmonofluorosilane, carbon 
dioxane, and ethane are all produced but are gasses and leave the reaction vessel.  
Synthesis of the Teoc protected TAA dendron proceeded similarly to the previous 
scheme.  Reaction of 38 with 1-[2-(trimethysilyl)ethoxycarbonyloxy]pyrrolidin-2,5-dione 
(42) produced product (43) in high yield (Scheme 16).  Attachment to 15 produced the 
desired aldehyde 44 which, once condensed with 2, gave the desired protected TAA 45.  
Upon treatment of this compound with tetrabutylammonium fluoride (TBAF) full 
deprotection was achieved.  However, despite the fact that the protecting group by-
N3
H2N NH2
NH2
.3HCl
FmocOSu
Na2CO3
H2O/DMF
0 oC
89 %
N3
FmocHN NHFmoc
NHFmoc
N3
FmocHN NHFmoc
NHFmoc
OH
O O
O
H
O
O
N N
NFmocHN
FmocHN
FmocHN
NaAsc
DMF/H2O
60 oC
CuSO4 . 5H2O
79 %
OH
H2N NH2
NH2
.3HCl
TEA, DMSO
100 oC
Deprotection
Scheme 17 
38 46 
46 15 47 
47 
2 
 37
products were not problematic, it was found to be difficult to remove the TBAF reagent.  
Attempts were made using precipitations and preparative size exclusion chromatography 
but none were successful.  Because of this difficulty, this route was abandoned as well 
and another protecting group was pursued.  An option that was not investigated at the 
time was purification by dialysis.  If the product was formed, this technique may be able 
to purify the compound. 
 The third and final protecting group that was investigated was Fmoc.  Initially the 
same general strategy as the previous two protecting groups was followed (Scheme 17).  
Protection of 38 proceeded smoothly to produce compound 46.  Subsequent attachment 
to 15 produced aldehyde 47.  This compound was taken forward to produce the desired 
TAA however the reactions condition induced Fmoc deprotection.  Because of this 
problem an alternate strategy was pursued to avoid basic conditions (Scheme 18).  By 
performing the click chemistry step after TAA formation the desired compound (48) was 
able to be synthesized.  Problems however rose again upon attempted deprotection.  The 
protecting groups seemed to come off readily upon reaction with piperidine however the 
dibenzlfulvalene by-product was difficult to remove in order to obtain pure product.  A 
solid phase deprotection resin was also attempted was supposed to scavenge the by-
product in addition to removing the protecting group but only partial deprotection was 
achieved.  During a scale up of compound 48, nearly all of the material was destroyed in 
the reaction step shown in Scheme 18 due to deprotection and subsequent polymerization 
of dibenzlfulvalene.  It was at this stage that the entire convergent dendrimer route was 
abandoned to pursue a divergent route. 
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2.2.4 Divergent Dendrimer Approach 
 After the unsatisfactory results of the convergent dendrimer synthesis, a divergent 
strategy was pursued.  Divergent dendrimer strategies begin by attaching monomer units 
to the dendrimer core and iteratively adding generations away from the center of the 
polymer (Figure 10a).  These schemes often produce relatively large dendrimers.  The 
drawback is that the structures often acquire defects that are difficult or impossible to 
purify away from the desired perfect compound.  This strategy was utilized because the 
need for functional materials was greater than the need for perfect structures. 
 
2.2.4.1 Monomer and Core Synthesis 
 The goal of this divergent route was to synthesize larger dendrimers than those 
made by the convergent approach.  To achieve this goal it was decided that more 
flexibility would need to be present in the core and monomer units to accommodate the 
anticipated steric crowding. A 1,1,1-tris(4-hydroxyphenyl)ethane (49) based core was 
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chosen because of its precedent as a dendrimer core. The desired triazido derivative was 
synthesized in two steps via alkylation with 1,3-dibromopropane followed by azide 
displacement of the tribromo intermediate 50 (Scheme 19).  The conditions used in the 
first step resulted in elimination side reactions.  Purification of the desired product from 
the partially allylated side product was difficult to achieve by chromatography and as a 
result the overall yield for the core was low.  Because only small amounts of dendrimer 
core are required, optimization of this synthesis was not pursued; however one could 
imagine routes that would alleviate the issues with this general approach.  For instance, 
alkylation could be accomplished with 1-bromo-3-hydroxypropane.  Tosylation followed 
by azide displacement should give core 51 with much higher overall yield. 
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 The monomer was designed so that there was more flexibility at both reactive 
sites.  By simply replacing the azide group with a propargyl group instantly removed the 
steric congestion at the neopentyl site.  The aromatic rings were functionalized with a 
diethylene glycol chain to put more space between the adamantane and the reactive 
groups.  Also an amide substituent was used instead of the ester group because it would 
not be subject to hydrolysis and the TAA would be relatively stable to cleavage.  The 
streamlined synthesis is shown in Scheme 20.  Propargylation of 3 followed by acid 
hydrolysis afforded the desired trisamine salt 53.  Benzaldehyde 55 was synthesized by 
activation of 5467 using DCC/NHS followed by amide formation with 2-(2-
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chloroethoxy)ethylamine hydrochloride and acetal hydrolysis.  Condensation of 53 with 
55 produced the desired triazaadamantane in multi-gram quantities with no evidence of 
side reaction between the amino and chloro groups during the course of the reaction. This 
step was crucial to the success of the project.  Initially it was assumed that electrophiles 
could not be present on the substituted benzaldehyde groups because they would undergo 
a side reaction with the amino groups during TAA formation however it was discovered 
that this side reaction was of no concern.   
 Several other synthetic routes for preparing 56 were attempted but all were 
inefficient and burdensome.  The seemingly straightforward initial synthesis is shown in 
Scheme 21.  4-carboxybenzaldehye was reacted with Vilsmeier-Haack reagent to 
generate an acid chloride which was reacted with 2-(2-aminoethoxy)ethanol to give 
benzaldehyde 57.  Although the reaction was successful, purification was extremely 
difficult and the product was never isolated in high purity.  This compound was taken on 
and reacted with 2 to produce TAA 58.  This compound was even harder to purify than 
57 and also was never isolated in high purity.  Tosylation of the free hydroxyl groups 
produced the desired monomer (59) however this reaction did not run smoothly.  For 
unknown reasons, these hydroxyl groups seemed to be much less reactive than expected 
and long reaction times were necessary to obtain full functionalization.  In addition, 
during the course of the reaction some of the tosyl groups underwent reactions with 
chloride.  Therefore after column chromatography the product isolated was a mixture of 
tosyl and chloro groups.  This was found not to be a problem in terms of the next step; 
however it was difficult to weigh out stoichiometric amounts of compound due to the 
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complex mixture.  It is recommended that compounds 57 or 58 should not be synthesized 
unless necessary.  They are extremely polar and difficult to purify. 
 To alleviate the problems with the previous scheme, protecting groups were 
employed.  It was decided that although additional steps were added to the scheme in the 
form of protection and deprotection steps, the overall synthesis would be much simpler 
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because of the exclusion of troublesome intermediates (Scheme 22) that could not be 
purified.  Compound 6068 was easily produced by the TBDPS protection of 2-(2-
aminoethoxy)-ethanol which could then be attached to compound 54 by activation with 
DCC/NHS to produce benzaldehyde 62.  This could be done stepwise or in situ.  
Reactions were cleaner if 61 was isolated in advance.  Condensation with 53 produced 
the protected TAA 63.  Overall this scheme proceeded smoothly however one drawback 
was the large size of the protecting groups.  The size did not interfere with the reaction 
conversions but because half of the mass of the compound was comprised of protecting 
groups, purification was tedious.  Column chromatography had to be run on twice the 
scale to purify the material.  In the end this inconvenience would be tolerable if the final 
step of the scheme worked well.  Deprotection proceeded smoothly but compound 58 was 
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still problematic and difficult to purify and functionalize.  Attempts to deprotect and 
tosylated in situ were no better than the stepwise process. At best, the desired monomer 
was isolated in 19% yield.  Because of this difficulty a new strategy was pursued. 
 As previously stated, it was predicted that the leaving groups on the monomer 
would have to be installed after TAA formation because the amino group in the trisamine 
would undergo side reactions with them.  Due to the difficulties with the monomer 
synthesis, this prediction was tested.  Synthesis of aldehyde 64 was accomplished by 
amide formation between 61 and 2-(2-aminoethoxy)ethanol followed by tosylation and 
acetal hydrolysis (Scheme 23).  Upon condensing this compound with 53, it was 
discovered that only product 59 was formed and no side reaction was evident.  This was 
an important discovery because it simplified the necessary synthesis tremendously.  Once 
this was discovered the scheme was streamlined and the tosyl groups were replace with 
chloro groups (Scheme 20).  In comparison to the initial approach depicted in scheme 21, 
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the final methodology is extremely facile and painless.  In this instance the extra work put 
into discovering alternate synthetic routes was worth the effort. 
 
2.2.4.2 Dendrimer Synthesis 
 With monomer in hard, the iterative process similar to that performed for the 
convergent route was accomplished.   Dendrimer synthesis began by reacting three 
equivalents of monomer with tri-azide core 51 (Scheme 24).  Because of the high 
solubility of monomer 56 in dichloromethane, the procedure reported by Lee and co-
workers69 was used and was found to be highly effective. Azide displacement of terminal 
chloro groups produced azide terminated dendrimer 66.  This process was repeated to 
produce second and third generation dendrimers 67-69.  Because the high molecular 
weight of monomer 56 (MW = 884) and overall high reaction yields, large dendrimers 
were synthesized rapidly in this fashion.  This methodology was highly successful.  
Imperfections were only observed upon the synthesis of third generation dendrimers. 
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Table 1. Characterization data for dendrimer 65-69.
Compound Generation Periphery TAAs Yield (%) GPC PDI Theoretical Mass (g/mol) MALDI mass (g/mol)
65 1 9 (-Cl) 3 86 1.01 3207.18 3208.39
66 1 9 (-N3) 3 93 1.02 3266.55 3266.35
67 2 27 (-Cl) 12 93 1.04 11224.29 11227.44
68 2 27 (-N3) 12 96 1.06 11402.39 11407.22
69 3 81 (-Cl) 39 56 1.38 35279.59 35279.06
Scheme 24 
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 Table 1 summarizes the characterization data.  Dendrimers were characterized by 
IR spectroscopy, MALDI-TOF MS, and analytical GPC. 1H NMR was not useful because 
multiple diastereomers led to broad, uninformative spectra. IR spectroscopy conveniently 
monitored the presence and absence of the azide stretch band at ca. 2100 cm-1 (Figure 11).  
Figure 11. IR spectra of core 15 dendrimers 65-69.  Sample dissolved in CH2Cl2 
and evaporated between KBr plates. 
51 
65 
66 
67 
68 
69 
65 66 67 
68 69 
Figure 12. MALDI MS of dendrimers 65-69. 
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This peak completely disappeared after reaction with monomer 56 for each generation. 
MALDI-TOF MS confirmed product by showing mass peaks in good agreement with the 
calculated values (Figure 12). Analytical GPC showed narrow, symmetric peaks 
characteristic of perfect dendrimers (Figure 13).  The characterization showed complete 
conversion of all reactions for the first two dendrimer generations.  Imperfections 
resulting from incomplete conversion, which are a common occurrence when 
synthesizing dendrimers divergently, were only seen in product 69 in which 27 reactions 
per molecule were needed.  Only the trace for dendrimer 69 shows evidence of 
incomplete monomer attachment as evidenced by a shoulder at higher retention times. 
 Addition of HCl to a solution of compound 67 in THF/MeOH confirmed that the 
dendrimers were fully degradable (Scheme 25).  The by-products, which were analyzed 
by 1H NMR and mass spectrometry, corresponded to the aldehyde groups from the 
Figure 13. Normalized GPC traces of monomer 51 and dendrimers 65-69. 
51 66 65 68 67 69 
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periphery of the dendrimer (55), the aldehyde groups from the interior of the dendrimer 
(71), and the core (70).  Amounts and ratios of compounds were in good agreement of 
calculated values (Table 2).  
 This iterative strategy allows for the growth of dendrimers in a generation by 
generation fashion.  The dendrimers presented thus far are comprised of a single 
monomer; however, this strategy would allow the incorporation of different monomers at 
different generations.  Because the degradation rates of TAAs can be tuned, dendrimers 
with a predictable radial control of degradation could be achieved.  Efforts toward this 
goal have been made by the synthesis of an additional, more labile monomer (Scheme 
26).   Reaction of vanillin with compound 72 produced the desired benzaldehyde 
derivative 73.  Condensation with trisamine 53 gave the desired alternate monomer 74 in 
good yields on large scale (6.6 g). 
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Table 2. Amounts and ratios of degradation by-products of 67
Isolated Theoretical Isolated Isolated Theoretical
Mass Mass μmol Mole Ratio Mole Ratio
70 10.95 mg 10.52 mg 7.835 1 1
71 38.29 mg 36.76 mg 70.53 9.002 9
55 49.08 mg 51.94 mg 191.9 24.49 27
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2.2.4.3 End Group Modification 
 The dendrimers synthesized thus far are degradable however are not soluble in 
water and therefore require further functionalization to become biologically relevant.  
This was achieved by attachment of hyperbranched polyglycerol.  In unpublished work 
Andrew Zill has developed methodology to synthesize hyperbranched polyglycerols 
(HPGs) containing a single alkyne functional group.  This was accomplished by using 
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propargyl alcohol to initiate the hyperbranching reaction (Scheme 27).  HPG is an 
appealing polymer because of its high water solubility and excellent biocompatibility.70  
Reaction of one equivalent of 75 per azide group in dendrimer 68 produced degradable, 
water soluble dendritic nanocarriers (DNCs).  Despite IR evidence for unreacted azide 
groups, the DNCs possessed a narrow size distribution (PDI = 1.15) as determined by 
analytical SEC.  Dynamic light scattering of a concentrated DNC solution (2.5 mg/ml) 
indicated that the polymers were monomeric in 100 mM PBS buffer with an average 
radius of 4.2 nm as opposed to aggregating in aqueous solutions.  Figure 14 depicts the 
total transformation from starting materials to nanoparticles. 
Figure 14. Depiction of nanoparticle synthesis from starting materials. 
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 To evaluate the biocompatibility of the DNCs, an MTT cell viability assay was 
performed (Figure 15).  The polymers were well tolerated and showed a similar toxicity 
profile to hyperbranched polyglycerol at concentrations up to 0.75 mg/mL.  This assay 
also verifies that the purification process of the DNCs was also successful and no 
significant amount of copper was present. 
 
2.2.4.4 Small Molecule Encapsulation and Release 
 Because DNCs possess a hydrophobic interior and hydrophilic exterior, they were 
investigated as potential drug delivery vehicles (see Chapter 1.2).  Titration with 1-
anilino-8-sulfonic acid (ANS) indicated that DNSs are capable of encapsulating small 
molecules guests.  ANS is molecular probe with a fluorescence emission that corresponds 
to the polarity of its microenvironment.71  In nonpolar environments emission is high, 
Figure 15. Cytotoxicity of DNCs as determined by the normalized metabolic activity of D1 
cells at varying concentration of polymer. 
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while in aqueous environments it is greatly diminished.  The titration of ANS with DNP 
is shown in Figure 16.  A plot of fluorescence verses [DNP] yields a 1:1 binding isotherm 
with an apparent K = 2.0 E 104.  Upon repeating the experiment at lower concentrations 
Figure 16. (a) DNC titrated into an ANS solution.  Each curve represents 0.48 equivalents 
DNC added.  Inset, fluorescence max verses concentration fit to a 1:1 binding isotherm. 
(b) Log plot of fluorescence verses [DNC] at low concentrations showing no sign of a 
CMC. 
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(20 nM), the linear correlation of fluorescence to concentration further indicated that 
DNCs are not forming aggregates. 
 It was further observed that particle degradation rates could be obtained by 
monitoring ANS fluorescence over time at different pHs.  Because dendrimer 68 contains 
TAAs substituted with amide groups in the para position, particles were expected to be 
relatively stable under neutral conditions and only degrade once acidified.  To a solution 
of ANS in PBS was added 2.4 equivalents of DNC.  Upon addition there was an 
immediate increase in emission indicating a polarity change of the probe most likely 
because of encapsulation (Figure 17a).  The fluorescence decreased over time in a pH 
dependent manner that corresponded to dendrimer degradation.  Under acidic conditions 
(pH = 1.7), full release was observed in under 4 min.  Under more basic condition the 
release was slower which corresponds to the degradation trends of the TAAs. 
 To confirm that the change in ANS fluorescence was due to dendrimer 
degradation, 1H NMR of DNC was performed at pH 4.  Degradation could be monitored 
by the appearance of the aldehyde C-H resonance near 10 ppm. As seen in Figure 17b, 
there is excellent agreement between degradation as determined by 1H NMR and small 
molecule release as determined by the change in fluorescence of ANS.  These data 
confirms that DNCs are capable of encapsulating small molecule guests and releasing 
them upon degradation.  As a result, DNCs prepared here are good candidates for drug 
delivery vehicles.  The tunable nature of TAA degradation should ensure that drug 
release could also be controlled. 
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Figure 17. (a) Fluorescence emission of ANS in the presence of 
DNC over time at varying pHs. Dashed lines represent a fit to a first 
order decay curve. (b) Time dependent NMR in pH 4 PBS 
deuterium oxide. Red and black lines represent the degradation 
determined by NMR and by fluorescence at pH 4 respectively. 
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2.2.5 Conclusion 
 In summary, a successfully methodology was developed to synthesize large 
degradable dendrimers that have potential as drug delivery vehicles.  The final synthetic 
strategy was straightforward and simple however many inefficient routes were explored 
first.  The general synthetic approach involved the synthesis of a TAA monomer that can 
be used to produce dendrimers using an iterative method that solely relied on iterative 
steps of azide displacements and copper catalyzed azide alkyne cycoladditions (“click” 
chemistry). Initially a convergent strategy was pursued with the goal of producing gene 
delivery vehicles.  This approach was moderately successful in terms of producing 
dendrimers however functionalization was unsuccessful.  This approach was abandoned 
for a more fruitful divergent one.  After many difficult routes, a synthesis of a TAA 
monomer was developed that was straightforward and easy to scale up.  Using this 
monomer, large dendrimers were prepared easily that could be made water soluble by 
functionalization with hyperbranched polyglycerol.  These dendritic nanocarriers were 
shown to be non-toxic and capable of encapsulating small molecules and releasing them 
upon degradation.  Future work would involve the synthesis of nanocarriers with 
different degradation kinetics.  An alternate monomer was successfully synthesized that 
could be used for this purpose. 
 
 
2.3 TAA-Containing Hydrogels 
 Again  taking advantage of the branching architecture of TAAs as well as the 
control over degradation, hydrogels were synthesized that retain the properties of the 
TAAs that were used in their synthesis.  This was accomplished by incorporating TAAs 
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at the junction of hydrophilic polymer chains.  These materials are biodegradable and 
biocompatible and intended for use in a variety of applications such as drug delivery 
(Chapter 1.2) and tissue engineering/regenerative medicine (Chapter 1.4). 
 
2.3.1 Design 
 Because of the relatively large amount of material that is necessary for 
applications involving hydrogels, it is impractical to make it comprised entirely of TAAs.  
For this reason TAA cross-linkers were synthesized that could be used to react with 
hydrophilic monomers.  This strategy is advantageous because a small amount of TAA 
could act as a general cross-linker for a large amount of a variety of monomers.  In this 
fashion new properties could be added to traditional materials that are currently in use for 
many biological applications.  Radical polymerization was chosen as the process by 
which gels could be formed because it is fast, can be done using light and therefore 
allows for various polymer processing techniques, and is general for many classes of 
monomers used to make hydrogels.  Figure 18 describes the overall design of the cross-
linkers.  In this instance the site of functionalization on the TAA was used to display a 
PEG chain to provide the cross-linkers with water solubility.  Acrylamide groups were 
chosen as the polymerizable group because there was concern that the cross-linking 
agents would be unstable if more reactive groups were installed.  The tris-acrylamide 
cross-linkers were found to be stable and did not spontaneously self polymerize.  In 
principle more reactive groups could be installed such as methacrylate groups if 
necessary.  The monomers that were used were chosen based on their literature 
precedence as well as their comparable reactivity with the cross-linkers. 
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2.3.2 Cross-linker Synthesis 
 The synthesis began with the creation of a PEG-containing tris amine compound 
(Scheme 28).  This was accomplished by alkylation of 3 with mesylated 750 
poly(ethyleneglycol) monomethylether (76).72  Hydrolysis of this intermediate produced 
the desired tris amine salt (77).  Next acrylamide-containing benzaldehydes with varying 
substitution patterns were synthesized.  In situ activation of compound 13 with 
DCC/NHS followed by reaction with 1-amino-2-azido ethane73 produced the desired 
amide 78.  Reduction of the azido group with triphenylphosphine, amide formation with 
acryloyl chloride, and hydrolysis of the acetal with hydrochloric acid produced the 
desired benzaldehyde 79a.  Benzaldehyde 79b was synthesized easily via ester formation 
with 4-carboxybenzaldehyde and acrylamide 80.74 Synthesis of benzaldehyde 79c proved 
to be slightly challenging due to the instability of the intermediates.  Reaction of 1-
amino-3-bromo propane with acryloyl chloride produced acrylamide 81.  This compound 
was prone to self-polymerization and was taken forward without purification and stored 
Figure 18. Schematic showing (a) generalized TAA trivalent cross-linking agent and (b) 
effects of substitution pattern on hydrogel degradation. 
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at low temperature in the presence of a radical inhibitor.  Alkylation of vanillin produced 
79c in acceptable yield when compound 81 was added to the reaction mixture in portions 
over time as opposed to all at once.  This is presumably because a side reaction occurs 
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where 81 reacts with itself.  The target benzaldehydes were all white solids that remained 
stable upon storage and did not self-polymerize. 
  Cross-linkers 82a-c were synthesized by reaction of 77 with benzaldehydes 79a-c 
(Scheme 29).  As with the synthesis of TAA monomer 56, no side reaction was observed 
between the amino groups in 77 and the electrophillic groups on the benzaldehydes.  All 
three cross-linkers possessed similar size, architecture, and reactive groups but differed in 
their substitution pattern.  Thus, TAA 82a and 82b with electron withdrawing groups 
Figure 19.  Depiction of TAA cross-linked poly(acrylamide) degradation mechanisms under 
acid and basic conditions using different cross-linkers. 
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(amide and ester linkages, respectively) in the para position were expected to be 
comparatively stable in comparison to 82c with 3,4-alkoxy-substituted (electron rich) 
aromatic groups.  Whereas 82a and 82c were designed to be stable to base, ester-
containing 82b was designed to degrade under both acidic and basic conditions (Figure 
19).  
 
2.3.3 Hydrogel Preparation 
 Hydrogels were prepared by polymerizing a solution of a cross-linker and a given 
amount of monomer.  Although chemical means were found to work for polymerization 
(APS and TEMED), photopolymerization was primarily used because of its ease and 
reproducibility.  This was accomplished by the addition of 2-hydroxy-2-methyl 
propiophenone followed by irradiation with a hand held UV lamp of the pre-gel solution 
placed between two glass plates.  After polymerization a punch was used to make 
hydrogel discs of consistent sizes (Figure 20).  No gels were formed by irradiating a 
solution of acrylamide and photoinitiator without the presence of the cross-linker (Figure 
21). 
 Many monomers were screened to investigate the scope of materials that could be 
created.  It was discovered that acrylamide, N-isopropylacrylamide, and 2-hydroxyethyl 
acrylate produced gels only in the presence of TAA cross-linkers.  The use of N-
isopropylacrylamide produced temperature responsive hydrogel discs.  In a room 
temperature solution the discs appeared slightly translucent.  Upon transferring the discs 
to a solution above ~37°C, the discs instantly became opaque and gradually shrank to a 
fraction of their original size.  This process was reversible and took approximately one 
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hour (Figure 22).  This observation was expected and due to the well precedented 
dehydration of poly(N-isopropylacrylamide) at increased temperature.75  2-hydroxyethyl 
methacrylate (HEMA) produced a cross-linked, opaque polymer network instead of a 
a. b. 
c. d. 
Figure 20. Hydrogel preparation involving (a, b) placement of pre-gel solution between 
glass plates, (c) irradiation with light, and (d) punching of hydrogel into a disc. 
Figure 21.  Acrylamide solution polymerized (a) without, and (b) with TAA 82a. 
A mole ratio of 1:99 TAA:acrylamide was used. 
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hydrogel.  This is due to the solubility dependence on molecular weight for 
poly(HEMA).76  Poly(HEMA) ceases to be water soluble above a critical molecular 
weight.  HEMA has been incorporated into hydrogels in the past only when a method to 
control the polymerization was used.  Additionally a variety of PEG acrylates and 
methacrylates were investigated as monomers.  In all cases gels resulted however 
hydrogels were produced in the absence of a cross-linking agent, presumable due to 
physical cross-linking during the course of the reaction.  As with the case for HEMA, 
hydrogels should be attainable using these monomers if an appropriate polymerization 
method, such as a controlled radial polymerization method,77 was used.  Additionally it 
should be noted that cross-linkers could be self-polymerized to form hydrogels.  These 
gels are ultimately impractical because of the high amount of material that is necessary.  
Also most of the degradation by-products are benzaldehyde functionalized 
poly(acrylamide) which is water insoluble and therefore not appropriate for biological 
applications. 
 
 
Figure 22.  Change in physical characteristics of poly(N-ispropylacrylamide) disc 
cross-linked with 82c upon temperature change. 
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2.3.4 Materials Properties 
 The stiffness and swelling ratio of 10 mm diameter poly(acrylamide) hydrogel 
discs was investigated.  Swelling ratio (as defined by hydrated hydrogel mass divided by 
the dehydrated mass) was consistent with hydrogels cross-linked by any of the three 
different cross-linkers (Figure 23a).  Additionally decreasing the ratio of 82c to 
acrylamide resulted in an increase in the swelling ratio as well as a decrease in the 
stiffness of the discs as expected.  Interestingly the stiffness was not the same for 
hydrogels cross-linked with different TAAs at a constant ratio.  The stiffness of discs 
containing 82b and 82c were comparable, however discs containing 82a were 
approximately twice as stiff (Figure 23b,c).  This is presumably due to the restricted free 
rotation around the amide bond.  These results indicate that physical properties of 
hydrogel are significantly controlled with TAA cross-linker at a given polymer 
concentration. 
 
Figure 23. (a) Swelling ratio and (b,c) elastic moduli of 10 mm diameter hydrogel discs 
cross-linked with 82a, 82b, or 82c at varying cross-linker ratios. 
 
 65
2.3.5 Hydrogel Degradation 
 Changes in the aromatic substitution pattern of the TAAs produced a noticeable 
change in the hydrogel degradation rate, as quantified by the increase of hydrogel 
swelling ratio over time.  As the cross-linkers degraded the discs physically increases in 
size.  This was noticeable to the naked eye and the diameter of the discs was measured 
over time using a conventional ruler (Figure 24).  At pH 5.0, gels cross-linked by 1 mole 
% 82c degraded >100-fold faster than gels cross-linked by 82a or 82b (Figure 25a,b).  
Gels prepared using 1 mol % of cross-linker 82c completely degraded within seven 
hours, whereas analogous gels prepared with 82a or 82b slowly swelled over two 
months.  At pH 7.0, polyacrylamide hydrogels prepared from all three cross-linking 
agents (82a-c) remained stable for over 100 days in vitro (Figure 25c).  Discs containing 
82a or 82b degraded very little in this time period however discs containing 82c were 
completely degraded after approximately 100 days.  A further increase to pH = 10 led to 
degradation of only hydrogels cross-linked by 82b as a result of ester hydrolysis (Figure 
25d).  The other TAAs degraded very little under these conditions. 
 For discs that degraded via TAA hydrolysis, the diameter roughly doubled before 
completely degrading.  At this time the discs themselves were very delicate and hard to 
measure.  The degradation behavior of gels containing 82b hydrolyzing at pH 10 was 
noticeably different (Figure 26).  In this case the diameter increased at least threefold 
Figure 24. Image of poly(acrylamide) hydrogel discs cross-
linked with 82c before (left) and after (right) degradation and 
swelling. 
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before degrading.  At this time the discs had a much more swollen appearance than the 
previous example and eventually broke into smaller chunks of gel that eventually 
degraded.  This difference in appearance can be attributed to two factors.  In the case of 
triazaadamantane hydrolysis, no partial hydrolysis intermediates exist.  Upon TAA 
degradation, all three polymer chains that are cross-linked are become free (Figure 19).  
In contrast, basic hydrolysis of the three ester groups in 82b can occur independently, 
making it possible to cleave one ester bond and having the other two intact.  This may be 
partially responsible for the noticeably different physical appearance of the degradation 
process.  The other significant factor that differentiates the two degradation mechanism 
involves the build up of charge.  TAA hydrolysis produces a tris amine component that 
upon protonation would possess a positive charge.  However, this molecule is no longer 
Figure 25. Change in surface area of poly(acrylamide) discs cross-linked with 1 mole % 82a, 
82b, or 82c at (a,b) pH 5.0, (c) pH 7.4, and (d) pH 10.0. 
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attached to the polymer matrix and would be free to diffuse away.  Upon ester hydrolysis, 
a negatively charged carboxylic acid is left remaining on the TAA.  Because the three 
esters can degrade independently of each other the remaining carboxylate remains 
attached to the polymer network.  This negative charge repulsion is most likely the cause 
of the significant swelling that is observed in the basic degradation of discs containing 
82b. 
 The degradation rates were inversely correlated with the Hammett substituent 
constants (σ).50  Thus, for the rapidly degrading gels prepared from 82c, σ = -0.68 
whereas for the more stable hydrogels containing 82a or 82b, the calculated σ values 
were 0.36 and 0.45, respectively.  In this fashion, relative degradation rates of gels can be 
calculated and used to predict degradation trends of TAA containing hydrogels. 
 
2.3.6 Protein Release 
 The utility of the hydrogels was investigated by using them to carry and release 
proteins.  Bovine serum albumin (BSA) was chosen as a model protein because of the 
presence of commercially available detection kits.  By simply incorporating the protein 
Figure 26. Image of poly(acrylamide) hydrogel discs 
cross-linked with 82b before (left) and after (right) basic 
degradation and swelling. 
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into the pre-gel solution, hydrogels encapsulating proteins could be easily prepared.  It 
was discovered that under the conditions used for the degradation study (1 mol % cross-
linker) the hydrogel pore size was significantly larger than the size of the protein and 
diffusion out of the hydrogels occurred independently of degradation.  Increasing the 
cross-linker amount to 5 mole % was sufficient to fully entrap the proteins.  Using these 
conditions, hydrogels cross-linked with 82a and 82c released negligible amount of BSA 
over the course of several days when incubated at pH 7.4 indicating little degradation of 
the TAA cross-linkers (Figure 27a).  However under pH 5.0, protein release was 
observed only for the system that was using the more labile cross-linker (82c) (Figure 
27b). 
 
2.3.7 Biocompatibility Evaluation 
 To determine if the hydrogels synthesized would be acceptable for biomedical 
applications, discs were implanted in chick embryo chorioallantoic membranes (Figure 
Figure 27. Release of bovine serum albumin (BSA) from polyacrylamide hydrogels cross-
linked by TAAs 82a or 82c.  Hydrogels cross-linked with 5 mol % TAA were incubated in 
PBS at (a) pH 7.4 and (b) pH 5.0 and 37.0 °C. 
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28).  This in vivo study is useful because the membranes are sensitive to toxic materials 
which induce scarring and inflammation.78  Hydrogel discs were made as previously 
Figure 28. Microscopic images of the cross-section of polyacrylamide hydrogel  discs (* 
indicates hydrogel or region where hydrogel was present) cross-linked with (a) 82a, (b)
82b, or (c) 82c implanted within chick chorioallantoic membranes (CAM).  The cross-
section was stained with hematoxylin and eosin stain. 
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described except the more nontoxic photoinitiator Irgacure 2959 was used instead of 2-
hydroxy-2-methyl propiophenone.  5 mm diameter discs containing 82a-c were 
implanted in chick eggs and incubated for 4 days.  No embryos died in the process.  
Histological investigated of the membranes showed little inflammation or scarring in all 
cases.  No significant difference was observed when different cross-linkers were used. 
Overall the materials were well tolerated.  Because it is known that cross-linked 
polyacrylamide is non-toxic, this study mainly establishes that the presence of TAAs and 
TAA by-products does not induce inflammation. 
 
2.3.8 Conclusion 
 TAA cross-linkers were synthesized with different substitution patterns and hence 
different degradation kinetics.  Each cross-linker contained a PEG chain for water 
solubility and three acrylamide groups to enable polymerization.  Photopolymerization in 
the presence of monomers such as acrylamide produced degradable hydrogels.  These 
gels were able to release entrapped proteins and did not induce significant scarring when 
implanted in chick embryos.  The degradation trends were the same as those predicted by 
σ values and gels were shown to degrade under a wide range of pHs.  This strategy is 
expected to be general for many more monomers and would give rise to materials with 
novel, controllable degradation properties.  Because TAA synthesis is performed 
stepwise, different reactive functional groups such as methacrylates should be able to be 
incorporated.  In addition, with the use of controlled radical polymerizations it should be 
possible to cross-link virtually any polymer commonly used to make hydrogels.  
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2.4 TAA-Containing Gene Delivery Vehicles 
 Similar to TAA hydrogels, gene delivery vehicles can also be synthesized by 
cross-linking polymers with a degradable cross-linker.  For this to be successful the 
polymers must be cationic to effectively bind and condense nucleic acids (Chapter 1.3).  
For this project, similar TAA cross-linkers can be used because the acrylamide functional 
groups can also undergo conjugate addition reactions with amino groups in addition to 
radical polymerization.  The goal of this project was to create vehicles that maintained 
high transfection efficiencies due to the large molecular weight of the polyamine, 
however would be relatively nontoxic due to the capacity to degrade into small molecular 
weight polyamine by-products (Figure 29).  Although this concept has been demonstrated 
previously,79 the polymer degradation rate was never investigated and no systems have 
been synthesized that allow for the tuning of this property. 
 
Figure 29. Schematic depiction of gene delivery vehicle preparation. 
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2.4.1 Design 
 The design of the gene delivery vehicles is very similar to that for hydrogels.  In 
terms of the TAA cross-linker, two substitution patterns were used.  The ether-based 
TAA was expected to be labile while the amide-based TAA was expected to be relatively 
robust.  The most significant difference between these cross-linkers and those used for 
the hydrogels is the solubility requirements.  Hydrogel cross-linkers needed to be water 
soluble and hence were functionalized with a PEG chain.  For the conjugate addition 
reactions necessary for this project, organic solvents can be used and therefore the cross-
linkers do not need to contain the PEG chain.  This leaves the site of functionalization 
open to other uses.  For this particular project 25 kDA branched polyethyleneimine (PEI) 
as the polymer standard due to its precedent as a non-viral gene delivery vehicle.31  800 
Da branched PEI was used as the low molecular weight polymer that was cross-linked 
because is much less toxic than the high molecular weight PEI.  On its own this polymer 
is incapable of efficiently acting as a delivery vehicle.  In principle many other 
polyamines could be used in the future and libraries of polymers could be created rapidly 
using this methodology. 
 
2.4.2 Synthesis 
 The synthetic scheme developed was the same as for the previous cross-linker 
with the exception that the PEG chain wasn’t present on the trisamine component.  
Condensation with 79a and 79c with 2 resulted in the two products in good yield 
(Scheme 30). 
 73
 A schematic depiction of the cross-linking reaction is shown in Figure 29.  
Because the conjugate addition reaction occurs without the addition of any reagents, all 
which is required for cross-linking is to mix the two components in an appropriate 
solvent.  In this case DMSO was chosen because of the high solubility of both 
compounds.  The reaction was performed at 60 °C for 4 days to assure full reactivity.  For 
consistency sake a mole ratio of 1:2.5 TAA:PEI was used.  It was discovered that if the 
amount of cross-linker was increased above a certain threshold (~1:1.8) an insoluble gel 
resulted instead of a soluble cross-linked polymer.  Also to try and synthesize the largest 
polymers possible, a solution of the cross-linker was added dropwise to concentrated 
solution of PEI over 20 hours.  The polymer solution was precipitated out of ether and 
dried at 100 °C overnight before testing was performed. 
 Because gene delivery efficiency is strongly correlated to the molecular weight of 
the polymer,28 the size of the cross-linked PEI is an important piece of information.  
Acquiring this data was challenging however.  The polymer characterization method of 
choice is analytical size exclusion chromatography (SEC).  Although an aqueous SEC 
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system was available, it did not provide any useful information.  Polycationic polymers 
are notoriously difficult to characterize because they have a strong electrostatic 
interaction with the column material.  It has been reported that changing the pH of the 
elution solvent can produce better SEC traces however this often requires acidification 
which is not an option in this case because the conditions would degrade the polymers 
and give inaccurate data.  Viscometry was also investigated but was not fruitful because 
of the limited amount of material that was available to characterize.  Ultimately the 
polymer sizes were established using light scattering and compared to the 25 kDa PEI 
standard.  PEI cross-linked with 83a was roughly the same size as the standard (104% of 
the size) while PEI cross-linked with 83b was smaller (67% of the size).  Although the 
polymerization method is uncontrolled and expected to inconsistent, another possibility 
for the difference in molecular weight could be due to the flexibility of the cross-linkers.  
83a contains an amide in the para position which has restricted bond rotation while 83b 
contains an ether linkage and is more flexible.  This flexibility may increase the 
likelihood of intramolecular cross-linking of the TAA to the PEI and would diminish the 
number of exposed acrylamide groups available to react and hence produce smaller 
polymers.  
 
2.4.3 Transfection Efficiency and Toxicity 
 Cross-linked polymers made from 83a and 83b were tested to evaluate their gene 
delivery efficiency as well as their cytotoxicity as compared to high and low molecular 
weight PEI.  All assays were performed by Nathan Gabrielson from the Daniel Pack 
research group.  As shown in Figure 30, the transfection efficiencies were for both 
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polymers were comparable to the high molecular weight standard.  When 83a was used 
as a cross-linker, the polymer efficiency was roughly double that of the standard while 
when 83b was used the resulting polymer was about 80% as efficient.  These efficiencies 
correlate with the size of the polymers because polymers cross-linked with 83a are larger 
than those cross-linked with 83b.  A noticeably higher weight ratio is required for 
polymers cross-linked with 83a.  This may be attributable to partial degradation of the 
more labile polymers during the transfection process in addition to the lower molecular 
weight.  The polymer toxicity gives further insight to the polymer properties.  As 
expected degradation rate had a significant effect on the toxicity of the polymers.  The 
robust polymers cross-linked with 83a were only slightly less toxic than high molecular 
weight PEI indicating that very little degradation had occurred (Figure 31a).  However 
when 83b was used the toxicity was comparable to that of the 800 Da PEI that was cross-
linked indicating that the polymer significantly degraded (Figure 31b). 
 The combined data indicates that the use of 83a as a cross-linker produces a PEI 
mimic that is similar in size to 25 kDa branched PEI.  This polymer has a higher 
transfection efficiency however retains the high toxicity of the large molecular weight 
standard.  For these reasons 83a is not a good cross-linker for this application because it 
Figure 30. Normalized luciferase expression of HeLa cells in serum using 800 Da PEI 
cross-linked with (a) 83a and (b) 83b. 
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degrades too slowly.  When 83b is used a polymer is produced that is 67 % the size of the 
large molecular weight PEI.  This polymer has similar gene delivery efficiency as the 
standard and also is relatively non-toxic indicating it degrades readily to low molecular 
weight PEI.  Due to the sensitivity of the cross-linker used, it most likely rapidly 
degrades in the acidic interior of the endosomal compartment (see Chapter 1.3).  This 
cross-linker is well suited for this application because it is capable of cross-linking 
polyamines to maintain a high transfection efficiency but also able to degrade in the 
appropriate time scale to produce non-toxic byproducts. 
 The polyamines cross-linked here (800 Da branched PEI) were chosen because of 
the large precedent of PEI as a gene delivery vehicle.  In principle however any 
polyamine that produces water soluble cross-linked polymers can be used.  Because the 
success of non-viral gene delivery relies on overcoming many different cellular and 
extracellular hurdles, efficient polymers are difficult to design.  For this reason some of 
the most successful polymers synthesized have resulted from the screening of 
combinatorial libraries of polyamines as opposed to rational design.33  The TAA cross-
linkers presented here are well suited for use in combinatorial libraries.  In addition to the 
Figure 31. Normalized toxicity of 800 Da PEI cross-linked with (a) 83a and (b) 83b of HeLa 
cells in serum. 
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amine that is chosen, the substitution pattern as well as the site of functionalization are 
variables that can be utilized.  Minor investigation has been put forth into the second 
variable. 
 
 
2.4.4 Functionalized TAA Cross-linkers 
 The functionalization that was investigated first was PEG.  This was because they 
had already been synthesized for the hydrogel project (see Chapter 2.3, 82a,c).  It was 
expected that this would significantly improve the cell viability and indeed this was 
found to be true.  As shown in figure 32 both polymers were relatively non-toxic.  
However, upon examining the transfection efficiencies it was found that both polymers 
performed poorly (Figure 33).  Degradation rate did not seem to affect either toxicity or 
efficiency.  This result is consistent with several other examples of PEGylated 
polyamines that have been synthesized.80  It has been shown that a large density of 
positive charge on the polyplexes is generally responsible for vector toxicity as well as 
Figure 32. Normalized toxicity of 800 Da PEI cross-linked with 82a 
and 82b compared to 25 kDa PEI using HeLa cells. 
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low efficiencies for in vivo gene delivery.  Highly positive polymers often bind 
electrostatically to negatively charged proteins in blood circulation and are removed from 
the body before they can elicit any therapeutic benefit.  Despite the drawbacks of high 
positive charge density in vivo, this property is generally necessary in vitro.  Due to the 
presence of transmembrane sulfated proteoglycans, cell membranes display a negative 
charge.  Positively charged polyplexes bind electrostatically to cell membranes which is a 
necessary step for polyplex cellular internalization and therefore effective gene delivery.  
Attempts to PEGylate gene delivery vehicles for the purpose of improving cell viability 
have resulted in lower transfection efficiencies because the polyplexes are incapable of 
binding to the cell membrane and becoming endocytosed.  This explanation is consistent 
with the results obtained with polymers cross-linked with 82a and 82b.  These polymers 
most likely do not bind to cells and therefore do not enter cells.  For these vectors to be 
useful a targeting molecule would have to be attached to the end of the PEG chain.81 
Figure 33. Normalized luciferase expression of HeLa cells in serum 
using 800 Da PEI cross-linked with 82a and 82b. 
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 One other functionalized cross-linker was pursued.  This compound was designed 
to release a chloroquine analogue upon degradation.  Chloroquine is an antimalarial drug 
that is no longer in use to widespread resistance to its mode of action.  It is also used as 
an additive in non-viral gene delivery because it enhances efficiency.  This was thought 
to occur because of its ability to act as a buffering agent in the cellular endosome.  It was 
discovered that gene delivery vehicles capable of buffering the acidification of the 
endosomal compartment are better able to escape this trafficking pathway and make their 
way to the nucleus.26  Polymers without this capacity are generally inefficient delivery 
vehicles.  The addition of chloroquine enhances transfection for polymers in general 
however its use is vivo is unfeasible due to the large amount of drug that would have to 
be used to reach its target.82  The design presented here would alleviate this problem 
because the drug would be conjugated to the polymer and only be released upon its 
degradation which should mainly occur in the endosome after the polymer has reached its 
target and gotten inside of the cell. 
 A recent investigation by Cheng and co-workers of the mechanism of chloroquine 
enhancement in gene delivery has indicated that it acts as more than a buffering agent.83  
Through the testing of derivatives it was determined that it is effective because it is 
capable of entering into cells, accumulates in endocytic vesicles, displaces the DNA from 
the cationic polymer via intercalation, buffers the endosome, and protects the free DNA 
from degradation in the cytosol when bound to it.  Structurally the compound needs to 
possess aromatic rings capable of intercalating into DNA and also at least one amino 
group on the side chain possessing buffering capacity.  If the DNA binding is too strong 
the compound becomes too toxic for use.  With these design criteria in hand a prodrug 
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was designed.  This could be attained by attaching a chloroquinoline group to the free 
hydroxyl group of the TAA cross-linker via a convenient spacer.  The trisamine 
degradation byproducts fulfill the buffering requirement of the chloroquine analogue 
because the pKa of the third amino group is below pH 7.4 due to its close proximity to 
the first and second protonated amino groups on the compound.49 
 The synthesis of this cross-linker is shown in Scheme 31.  Reaction of 1,4-
dichloro quinoline (84) with 2-chloroethylamine produced the desire quinoline 85.  
Displacement of the chloro group with sodium azide produced compound 86 which could 
be attached to alkyne 52 using click chemistry to produce the protected form (87) of the 
desired salt.  Hydrolysis of the triazaadamantane produced the quinoline conjugated 
trisamine (88). 
 Compound 88 is an intermediate in the cross-linker synthesis but it is also the 
drug that would be released upon polymer degradation.  Its ability to enhance gene 
transfection using 25 kDa branched PEI was tested in comparison to chloroquine (Figure 
34).  Initially administration of 20 µM chloroquine produced an enhancement in 
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transfection however when the concentration was increased further the efficiency 
dropped off presumably due to toxicity.  Compound 88 gave a similar initial 
enhancement however in contrast continued to become more effective as the 
concentration was increased.  Although the reason for this difference is currently 
unknown, the results were promising and the project was pursued further. 
 TAA cross-linkers were made using trisamine 88 in the same fashion as 
previously demonstrated.  Condensation with either 79a or 79c produced desired cross-
linkers 89a or 89b (Scheme 32).  As before the degradation rates of these cross-linkers 
were different, with 89a being robust and 89b being labile.  Despite the promising initial 
results, gene delivery vehicle made from 89a and 89b were ineffective.  The toxicity 
profile shows a similar trend as for previous cross-linkers (Figure 35).  The slowly 
degrading polymer was more toxic and resembled 25 kDa branched PEI while the 
quickly degrading polymer was relatively non-toxic and resembled 800 Da PEI.  Because 
TAA degradation coincides with release of 88, it was hoped that the transfection 
Figure 34. Luciferase expression in HeLa cells with the addition of varying 
concentrations of chloroquine or chloroquine analogue 88. 
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efficiency of PEI cross-linked with 89b would be significantly enhanced while PEI cross-
linked with 89a would be unaffected because no drug would be released.  Instead the 
transfection trends were the similar to previous examples (Figure 36) where the slowly 
degrading polymer had comparable performance to the PEI standard and the quickly 
degrading one was much less efficient.  These results are similar to those obtained when 
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the quinoline was not appended but with overall lower efficiencies.  One possible 
explanation for these results is that not enough drug was released to have a significant 
effect.  Free chloroquine accumulates in endosomes resulting in an increase in its local 
environment.  For the polymer/drug conjugates synthesized here a limited amount of drug 
can be administered because it has to be attached to the polymer.  Additionally the TAA 
cross-linker takes up a larger ratio of the total polymer therefore at a given molecular 
weight there is less PEI in the polymers cross-linked with 89a and 89b as opposed to 82a 
and 82b.  Because the amount of PEI in the polymer is correlated with transfection 
efficiency, this may be an explanation for the results that were obtained.  One possible 
solution to this problem would be to use a different molecular weight polyamine which 
would change the amount of quinoline in a given polymer. 
 
 
 
Figure 36. Normalized luciferase expression of HeLa cells in serum 
using 800 Da PEI cross-linked with 89a and 89b. 
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2.4.5 Conclusion 
 In summary a successful synthetic platform was developed for cross-linking 
polyamines for the generation of novel gene delivery vehicles.  By using TAA cross-
linkers with different substitution patterns, polymers with different degradation rates can 
be made that give different delivery properties.  Using a robust cross-linker non-
degradable polymers were made that behave similar to standard 25 kDa branched PEI, 
however using a labile cross-linker gene delivery vehicles were made that maintain high 
gene delivery efficiency but display low toxicity because they degrade into small 
molecular weight byproducts.  This proof-of-concept was demonstrated using 800 Da PEI 
as the polyamine that was cross-linked however many different polymer sizes and 
architectures could be providing the potential to create much more efficient and safe 
delivery vehicles.  Additionally different substitution patterns and hence degradation 
rates could be pursued as well as different functionalities appended to the site of 
functionalization.  Preliminary investigation into altering the functionalization of the 
cross-linkers was not successful.  PEGylated polymers were inefficient due to their 
inability to effectively enter into cells and chloroquine analogue releasing polymers were 
less efficient that their unfunctionalized versions.  Despite these results, the ability to 
cross-link polyamines and tune their degradation using TAAs has large potential for the 
synthesis of effective gene delivery vehicles. 
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CHAPTER 3 
FUNCTIONALIZED ALGINATE 
 
3.1 Project Goals 
 As stated in Chapter 1, hydrogels are useful biomaterials for a variety of 
biomedical applications because they are structurally similar to an extracellular matrix 
(ECM).  In addition to the types of polymers used (natural vs. synthetic), there are several 
mechanisms of gelation that can be taken advantage of.  The goal of this project was to 
create a hydrogel platform that would be useful for a large variety of practical 
applications.  This system was designed to be synthetically straightforward to be able to 
easily synthesize large amounts of material quickly.   
The system chosen was a natural/synthetic hybrid between alginate and PEG.  
These polymers were chosen because of their large precedent as biomaterials and ease of 
functionalization.39  Among several mechanisms of gelation, covalent polymer cross-
linking was chosen because it would allow for the control of structural stability of the gel 
over a broad range.  A huge amount of chemistry is available to cross-link polymer 
chains; however most of the methods are not biocompatible.  In principle, conventional 
organic chemical reactions can be used however this would require the reactions to be 
done in organic solvents, which raises a concern that residual solvent may remain in the 
hydrogel.  Due to this issue, the chemistry that can be used is limited to that can be done 
in aqueous conditions.   
There is a small variety of reactions that can be done in water that are commonly 
used for bioconjugations.84  The drawback to these methods is that the reagents have to 
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be fully removed prior to use.  One of the most popular methods to form gels is via 
photopolymerization because light can be irradiated on a sample non-invasively.85  
However, even in this case, a photoinitiator is required which can cause cytotoxicity.  
The goal of this project is to design a system that gels under physiological conditions, 
without the addition of any chemical reagents, and without the production of any reaction 
byproducts.  
 
3.2 Conjugate Addition Alginate/PEG Hydrogels 
 The chemical diversity available to achieve this goal is small.  The conjugate 
addition reaction between a methacrylate group and a thiol group was chosen because it 
fulfilled the criteria.84  The chemical reactions are shown in Scheme 33.  Alginate is a 
natural polysaccharide obtained from algae that is commonly used in drug delivery and 
tissue engineering.  Every monomer unit contains a carboxylic acid group capable of 
being functionalized.  In this case 50,000 g/mol alginate was used.  This was obtained by 
gamma irradiation of high molecular weight (MW = 250,000) alginate. Reaction of a 
commercially available methacrylate-containing amine (2-aminoethyl methacrylate) in 
the presence of a water soluble carbodiimide reagent (EDC) produced the desired reactive 
alginate in one step.  Dialysis of the product mixture completely removed the small-
molecule reagents.  Functionalization was confirmed by 1H NMR by the presence of 
methacrylate peaks that were broadened due to their attachment to the polymer (Figure 
37).  Due to the complexity of the spectra, integration to determine the degree of 
functionalization could not be done.  Instead a yield of 60 % was assumed.  This number 
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was experimentally acquired by a previous study in which alginate was functionalizing 
with radiolabeled peptides using the same chemistry.86 
 PEG was functionalized to display thiol groups at the chain ends.  This was 
achieved by following a literature procedure in which reaction of PEG with 3-
mercaptopropionic acid in the presence of tosic acid catalyst produced the desired thiol-
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displaying polymer via a dehydration reaction (Scheme 33).87  This was performed with 
three different molecular weights of PEG (2000, 8000, and 14000) to investigate the 
effect of chain length on material properties of the hydrogel. 
 With the desired functional groups installed, it was discovered that hydrogel 
formation could be achieved by mixing a solution (3 % alginate, 6.7 % PEG in phosphate 
buffer pH 7.4) of the two polymers in a 1 to 1 stoichiometry of methacrylate to thiol 
(Figure 38).  This reaction took approximately 10 hours and produced a totally 
transparent gel.  The PEG chain length had an effect on the gels properties with longer 
Figure 37.  1H NMR spectra of methacrylate functionalized alginate. 
Figure 38. Hydrogel formation from functionalized alginate and PEG. 
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chain lengths giving softer gels. 
 By incubating the solution between two glass plates, hydrogel discs were punched.  
The degradation rates of the discs were investigated by visual observation over time. It 
was discovered that under physiological conditions the discs were fully degradable within 
four days.  Although appropriate for applications that require quick degradation, it was 
desirable to be able to control the degradation rate of the materials over a broad range.  
Examination of the chemical structure of the hydrogels revealed that each cross-link 
possessed four hydrolysable ester groups (Scheme 33).   
It was hypothesized that decreasing the amount of ester groups would further 
decrease the degradation rate.  Because the reaction rates were meant to be kept constant, 
the methacrylate groups were not changed, however the ester groups present on the PEG 
polymer were removed.  An alternate thiol-functionalized PEG was synthesized that did 
not possess any degradable functional groups (Scheme 34).  This was achieved in three 
steps beginning with activation of the chain ends with mesyl chloride to produce 90.  
Displacement with potassium thioacetate gave intermediate 91 that produced the desired 
polymer (92) after reaction with sodium hydroxide.  Upon reaction of this compound 
with the functionalized alginate, the more stable hydrogel was produced.  Upon 
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incubation in physiological conditions the discs were still intact after three weeks. 
 Although this chemistry was compatible with cell cultures, it is unlikely that it 
will be used to form hydrogels around cells because they would sediment out during the 
long reaction time.  This could be changed if a more reactive electrophile such as a vinyl 
sulfone or maleimide was used in place of the methacrylate group.  The current system is 
better suited to encapsulate material that is fully dissolved in solution and cannot collect 
at the bottom of a culture dish.  For this reason, this hydrogel is being investigated as a 
gene delivery vehicle.  The negative charge of the alginate should electrostatically retain 
the polyplexes and only release them upon degradation.  Also because the platform is 
versatile, addition of further synthetic functionality will retain the gelation properties of 
the current system but be supplemented with additional properties. 
 
3.3 Photodegradable Hydrogels 
 In order to create a hydrogel system with dynamic properties, a stimuli responsive 
version was synthesized.  By using light as a stimulus to degrade polymer cross-links, a 
versatile hydrogel system was created to process and post-functionalize a biomedical 
system in a desired manner.  A similar concept was demonstrated by Shoichet and co-
workers however their system had several limitations.88 In this example, agarose was 
modified to display a nitrobenzyl protected cysteine unit.  Hydrogels were formed by 
cross-linking the modified agarose and were subsequently irradiated with light.  The 
regions that were irradiated underwent deprotection to liberate a free thiol group.  The gel 
was then functionalized solely in the location that was patterned.  Cell adhesion peptides 
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were attached and three dimensional cell migration and neurite outgrowth were 
demonstrated.   
The main limitation with this method is that outgrowth was very poor with 
penetration no deeper than 1 mm.  This was partially due to the low degree of 
functionalization of the agarose.  Agarose forms gels by a thermal cross-linking process 
which is related to the solubility of the polymer.  Functionalization of agarose modified 
its solubility and also the gelation process, and gels could only be formed with low 
degrees of substitution.  Additionally, the gel structure remained intact and physically 
limited cell migration  
Based on this precedent, we assembled the advanced version of a photo-responsive 
hydrogel similar to the version demonstrated by Anseth and coworkers89  The hydrogel 
design created in this study was similar to the system described in section 3.2 with the 
exception that a photodegradable moiety was installed between the methacrylate group 
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which reacted with PEG-thiol and the amino group which reacts alginate.  For this study, 
a photolabile cue which bridged the alginate with 2-aminoethyl methacrylate was first 
synthesized.  Synthesis began by Boc protection of 2-(2-aminoethoxy)-ethanol followed 
by tosylation to produce compound 9390 (Scheme 35).  5-hydroxy-2-nitrobenzyl alcohol 
(95) was synthesized readily from 5-hydroxy-2-nitro-benzaldehyde (94) by quantitative 
reduction with sodium borohydride.91  Attachment of 93 to 95 proceeded in good yields.  
Reaction of the benzyl alcohol 96 with methacryloyl chloride produced compound 97 
which could be deprotected using acidic conditions to give the desired amine (98).  As 
with 2-aminoethyl methacrylate, this compound could be readily attached to alginate 
using EDC. 
 Reaction of the nitrobenzyl-containing alginate with PEG-dithiol proceeded in the 
same fashion as with the previous system to give hydrogels.  Again, the reaction 
proceeded upon heating without the addition of reagents or with the production of 
byproducts.  As shown schematically in Figure 39, upon irradiation of the gels with 
longwave UV irradiation (366 nm) the nitrobenzyl groups underwent photocleavage 
leading to the breakdown of the polymer network (Scheme 36).  Full degradation of a 1 
mm hydrogel was accomplished in approximately one hour by the use of a handheld UV 
lamp. 
Figure 39.  Schematic depiction of hydrogel photodegradation.  Light cleaves the 
photodegradable linkage (red) which degrades the hydrogel network. 
 93
  In this fashion, the structural integrity of the gel could be externally controlled by 
light.  We envision that hydrogel degradation can be controlled by tuning irradiation 
condition in terms of intensity and exposure time.  Additionally, the presence of 
multiphoton laser deprotection should allow for three-dimensional hydrogel degradation 
allowing for the creation of specific hydrogel architectures such as cylindrical channels.  
Also, the photocleavage reaction should generate benzaldehyde groups that can be further 
functionalized (Figure 40).  Compounds containing reactive groups such as hydrazines, 
such as commercially available fluorescein-5-thiosemicarbazide, can be added after 
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degradation to coat the irradiated area and display this desired functionality. This 
property along with the ability to irradiate desired patterns should allow for the creation 
of complex, functionalized hydrogels using straightforward chemistry. 
 
3.4 Conclusion 
 In summary, a photolabile and biocompatible hydrogel systems which can be used 
for drug and cell encapsulation were developed using a simple and versatile chemistry.  
First, alginate and PEG were modified to display methacrylate and thiol groups 
respectively, so they could form a gel via biocompatible cross-linking reaction.    The 
hydrogel degradation rate could be altered by controlling the ester content present on the 
polymers.  The removal of the ester groups on the PEG chain slowed the gel degradation 
rate.  Next, the PEG-alginate hydrogel was further modified by incorporating nitrobenzyl 
group between the alginate backbone and the methacrylate groups.  The presence of 
photolabile groups allowed us to trigger the hydrogel degradation in response to external 
light source.   Overall, we envision that the chemistry used to assemble the hydrogel will 
 
 95
provide a convenient way to assemble a three dimensional architecture with varied 
material properties and chemical composition.  These materials will find a broad array of 
applications in gene delivery and regenerative medicine. 
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CHAPTER 4 
EXPERIMENTAL 
 
4.1 General Methods 
 Reactions were monitored by TLC using silica gel 60 F254 plastic, aluminum, or 
glass plates (Aldrich, Merck or EMD Chemicals, Inc.) or F264 basic aluminum oxide glass 
plates (EMD Chemicals, Inc.).  Gravity and flash chromatography was performed with 
32-63 micron silica gel (Merck) or activated basic aluminum oxide Brockman I with 150 
mesh (Aldrich).  A fluorescent indicator (green 254 nm) was added to the silica gel for 
chromatography performed in a quartz column.  TLC bands were visualized by UV, 
dinitrophenylhydrazine (DNP) stain, or ninhydrin stain.  Solvent ratios used as elutants 
are reported in v/v.  Analytical SEC was performed using a 2x sytragel HR3, 1x styragel 
HR4E column in series with 50mM LiBr in DMF as the eluent at a flow rate of 1.0 
mL/min.  Peak detection was achieved by a Viscotek triple array 300 refractive index 
detector.  SEC-derived molecular weights were based on calibration with linear 
polystyrene however the GPC reported inflated molecular weights consistently for 
several different dendritic compounds ran using this solvent system.  The purity of the 
final products was obtained through 1H NMR, 13C NMR, melting point and/or elemental 
analysis. 
1H NMR and 13C NMR data were obtained on either a 400 or 500 MHz Varian 
U400 or U500 instrument at the VOICE NMR laboratory at the University of Illinois.  
Chemical shifts are reported in parts per million (ppm) and coupling constants were 
reported in Hertz (Hz).  1H NMR spectra obtained in CDCl3 were referenced to 7.26 ppm, 
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D2O was referenced to 4.79 ppm, and DMSO-d6 was referenced to 2.50 ppm.  13C NMR 
spectra obtained in CDCl3 were referenced to 77.16 ppm.  FDMS and ESIMS data were 
collected by the Mass Spectrometry Center at the University of Illinois.  MALDI-MS 
spectra were obtained on an Applied Biosystems Voyager-DE STR mass spectrometer.  
Matrices employed in the collection of MALDI spectra included dithranol, 2-(4-
hydroxyphenylazo)benzoic acid (HABA), and trans-3-indoleacrylic acid (IAA).  Data 
was calibrated to an external standard solution of insulin and cytochrome C.  IR spectra 
were collected on a Matson FTIR 5000.  Melting points were measured with a Thomas 
Hoover melting point apparatus and are uncorrected. 
The following compounds were synthesized according to literature procedures: 7-
(hydroxymethyl)-2,4,6-triphenyl-1,3,5-triazaadamantane (3),48e 2,4,6-tris-prop-2-
ynyloxy-[1,3,5]triazine (11),62 4-prop-2-ynyloxy-benzaldehyde  (12),64 4-
carboxybenzaldehyde dimethoxyacetal (54),67 2-[2-(tert-butyl-diphenyl-silanyloxy)-
ethoxy]-ethylamine (60),68 mPEG750-OMs (76),72 1-amino-2-azido ethane,73 N-(2-
hydroxyethyl)acrylamide (80),74 PEG diester dithiol,87 toluene-4-sulfonic acid 2-(2-tert-
butoxycarbonylamino-ethoxy)-ethyl ester (93),90 and 3-hydroxymethyl-4-nitro-phenol 
(95).91 
 
4.2 Synthesis and Characterization 
  2,2-bis(aminomethyl)-3-amino-propan-1-ol trichloride (2). To a solution of 
53.9 g (166 mmol) of pentaerythritol tribromide in 500 mL DMF was added 68.1 g (1.05 
mol) of sodium azide and the solution was heated to 100˚C for 3 d.  The solution was 
OH
H2N NH2
. 3HClNH2
 98
cooled, poured into 1L H2O, and washed with 400 mL ether three times.  The combined 
organic layers were washed with 400 mL water three times, dried over Na2SO4, filtered, 
and ether was removed in vacuo as dioxane was added.  The solvent swap was continued 
until all the ether had been removed and 500 mL dioxane was added.  The solution was 
cooled in an ice bath and 154 g (581 mmol) of PPh3 was added in portions and the 
solution was stirred for 30 min.  244 mL NH4OH was added and the solution was stirred 
overnight.  The solvent was removed in vacuo and the resulting mixture was dissolved in 
1 L CHCl3.  The organic solution was washed three times with 100 mL of 2.5 M HCl.  
The combined aqueous layers were washed four times with 60 mL CHCl3 and 
concentrated in vacuo.  Addition of EtOH/ether precipitated 32.4 g (81 %) of a 2 as a 
white solid that was filtered and dried in vacuo that matched the 1H NMR of the reported 
compound.53f 
O
O  
 1,4-Bis-prop-2-ynyloxl-benzene (9).  A suspension of 1.23 g (11.2 mmol) of 1,4-
dihydroxy benzene (8) and 6.73 g (48.7 mmol) of potassium carbonate in 20.0 mL DMF 
was stirred at 60˚C for 40 min.  After the suspension cooled to room temperature, 2.9 mL 
(26 mmol) propargyl bromide was added and was stirred for 2 d.  The reaction was 
poured into ice water and the precipitate was filtered.  The solid was partitioned between 
CH2Cl2 and water.  The organic fraction was washed four times with water and brine, 
dried over Na2SO4, filtered, concentrated in vacuo to give 1.51 g (72%) of 9 as a solid: 1H 
NMR (500 MHz, CDCl3) δ 6.94 (s,  4H), 4.65 (d, J = 2.3 Hz, 4 H), 2.51 (t, J = 2.3 Hz, 
2H); 13C NMR (125 MHz, CDCl3) δ 152.5, 116.1, 78.9, 75.5, 56.6; FD-LRMS m/z 186.0 
(M+). 
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 7-(Hydroxymethyl)-2,4,6-Tris-(4-prop-2-ynyloxy-phenyl)-1,3,5-
triazaadamantane (13).  A solution of 703 mg (2.90 mmol) of 2, 1.80 g (11.2 mmol) of 
12, and 1.80 mL (12.9 mmol) of triethylamine in 13 mL of methanol was stirred with 3 Å 
molecular sieves at 65 ◦C for 24 hours.  After filtering through celite, the solution was 
evaporated to dryness.  The mixture was dissolved in CH2Cl2, washed twice with water, 
twice with brine, dried over Na2SO4, filtered, and evaporated.  Purification by flash 
chromatography (1:1:0.2 ethyl acetate: pet ether: TEA) afforded 910 mg (56%) of a 
single diastereomer of 13 as a white foam: 1H NMR (500 MHz, CDCl3) δ 7.73 (d, J = 8.8, 
2H), 7.67 (d, J = 8.7, 4H), 7.04 (d, J = 8.7, 4H), 6.96 (d, J = 8.8, 2H), 5.56 (s, 1H), 5.37 (s, 
2H), 4.72 (d, J = 2.5, 4H), 4.65 (d, J = 2.4, 2H), 3.48 (d, J = 12.9 Hz, 2H), 3.14 (d, J = 
12.8, 2H), 2.91 (s, 4H), 2.55 (t, J = 2.5, 2H), 2.49 (t, J = 2.4, 1H); MS (FD) m/z = 559.2 
(M+). 
N
N
N
OTs
O
O
O
 
 7-[(Toluene-4-sulfonic acid)methyl]-2,4,6-Tris-(4 prop-2-ynyloxy-phenyl)-
1,3,5-triazaadamantane (14).  To a solution of 175 mg (0.312 mmol) of 13 and 90 µL 
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(6.5 x 102 µmol) of triethylamine in 1.5 mL CH2Cl2 was added 91.8 mg (481 mmol) of p-
toluenesulfonyl chloride.  The resulting mixture was stirred for 4 days at 0 ◦C and 
warming to room temperature.  The solution was diluted with CH2Cl2 and washed with 
water and brine.  The combined aqueous layers were washed with CH2Cl2.  The 
combined organic layers were dried over Na2SO4, filtered, and evaporated.  Purification 
by flash chromatography (1:1:0.2 ethyl acetate: pet ether: TEA) afforded 159 mg (71%) 
of 14 as a white foam: 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 8.6, 2H), 7.60 (d, J = 
8.3, 6H), 7.28 (d, J = 8.1, 2H), 7.03 (d, J = 8.8, 4H), 6.95 (d, J = 8.8, 2H), 5.52 (s, 1H), 
5.35 (s, 2H), 4.74 (d, J = 2.4, 4H), 4.65 (d, J = 2.4, 2H), 3.42 (d, J = 12.6, 2H), 3.28 (s, 
2H), 3.18 (d, J = 12.6, 2H), 2.83 (s, 2H), 2.56 (t, J = 2.4, 2H), 2.49 (t, J = 2.4, 1H), 2.43 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 156.9, 156.8, 145.0, 132.5, 132.1, 130.0, 127.8, 
127.7, 127.7, 115.1, 115.0, 82.3, 78.8, 78.7, 75.7, 74.6, 74.0, 55.9, 55.8, 54.3, 45.7, 42.1, 
26.2, 21.7; MS (FD) m/z = 713.1 (M+). 
O
H O
O
 
 4-Formyl-benzoic acid prop-2-ynyl ester (15).  To a solution of 3.57 g (23.8 
mmol) 4-carboxy benzaldehyde in 200 mL THF was added 11.5 mL (129 mmol) of 
oxalyl chloride and the solution was stirred overnight.  10 mL (112 mmol) of oxalyl 
chloride was added and the solution was stirred for 1.5 h.  The solution was concentrated 
in vacuo and 190 mL of THF, 9.0 mL (150 mmol) of propargyl alcohol, and 26.5 mL 
(190 mmol) of triethylamine were added and the reaction was stirred for 3 h.  The 
solution was concentrated in vacuo and purified via flash chromatography (1:2 ethyl 
acetate : petroleum ether) to afford 3.02 g (67 %) of 15 as a yellow solid: 1H NMR (500 
MHz, CDCl3) δ 10.00 (s, 1H), 8.09 (d, J = 7.9 Hz, 2H), 7.85 (d, J = 7.9 Hz, 2H), 4.86 (d, 
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J = 2.6 Hz, 2H), 2.56 (t, J = 2.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 191.5, 164.6, 
139.3, 134.0, 130.2, 129.4, 77.3, 75.6, 52.8; FD-LRMS m/z 188.1 (M+). 
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 7-(Hydroxymethyl)-2,4,6-Tris-(4-benzoic acid prop-2-ynyl ester)-1,3,5-
triazaadamantane (16). A solution of 1.19 g (4.92 mmol) of 2, 2.88 g (15.3 mmol) of 15, 
and 2.6 mL (19 mmol) of triethylamine in 150 mL of methanol was stirred with 3 Å 
molecular sieves at 65 ◦C for 24 hours.  After filtering through celite, the solution was 
evaporated to dryness.  The mixture was concentrated in vacuo  Purification by flash 
chromatography (gradient 1:4 to 2:1 ethyl acetate: petroleum ether) afforded 2.05 g (65%) 
of 16: 1H NMR (400 MHz, CDCl3) δ 8.11 (d, J = 7.7, 4H), 8.06 (d, J = 7.7, 2H), 7.89 (d, 
J = 7.7, 2H), 7.83 (d, J = 7.7, 4H), 5.62 (s, 1H), 5.32 (s, 2H), 4.91 (t, J = 2.1 Hz, 4H), 
4.85 (t, J = 2.1 Hz, 2H), 3.41 (d, J = 13.1 Hz, 2H), 3.21 (d, J = 13.3, 2H), 2.89 (s, 2H), 
2.88 (s, 2H), 2.54 (t, J = 2.5, 2H), 2.48 (t, J = 2.4, 1H); MS (FD) m/z = 644.3 (M+). 
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 7-[(Toluene-4-sulfonic acid)methyl]-2,4,6-Tris-(4-benzoic acid prop-2-ynyl 
ester)-1,3,5-triazaadamantane (17). To a solution of 1.89 g (2.94 mmol) of 16 in 25 mL 
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of pyridine was added 841 mg (4.41 mmol) of p-toluenesulfonyl chloride.  The resulting 
mixture was stirred for 4 days and concentrated in vacuo.  Purification by flash 
chromatography (gradient 1:4 to 3:1 ethyl acetate: petroleum ether) afforded 1.85 g (79%) 
of 17: 1H NMR (500 MHz, CDCl3) δ 8.09 (d, J = 8.1, 4H), 8.04 (d, J = 8.2, 2H), 7.84 (d, 
J = 8.2, 2H), 7.75 (d, J = 8.2, 4H), 7.55 (d, J = 8.2, 2H), 7.22 (d, J = 8.2, 2H),  5.58 (s, 
1H), 5.28 (s, 2H), 4.90 (d, J = 2.2, 4H), 4.84 (d, J = 2.4, 2H), 3.33 (d, J = 12.9, 2H), 3.27 
(s, 2H), 3.22 (d, J = 12.5, 2H), 2.80 (s, 2H), 2.55 (t, J = 2.2, 2H), 2.48 (t, J = 2.4, 1H), 
2.37 (s, 3H); MS (ESI) m/z = 798.4 (M+). 
N
N
N
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7-[(Toluene-4-sulfonic acid)methyl]-2,4,6-triphenyl-1,3,5-triazaadamantane 
(18).   To a solution of 473 mg (1.19 mmol) of 3 and 3.4 x 102 µL (2.44 mmol) of 
triethylamine in 4 mL of CH2Cl2 cooled to 0 ◦C was added 376 mg (1.97 mmol) of 
toluenesulfonyl chloride.  The resulting solution was stirred overnight warming to room 
temperature.  The mixture was washed with water, dried over Na2SO4, filtered, and 
evaporated.  Purification by trituration (1:7 ethyl acetate:pet ether) afforded 347 mg (53%) 
of 18 as a white solid which consists of a 94:6 mol ratio mixture of desired:undesired 
diastereomers: mp (decomp) = 167.0 ◦C; Major diastereomer 1H NMR (400 MHz, CDCl3) 
δ 7.94 (d, J = 8.1, 2H), 7.82 (d, J = 8.1, 2H), 7.75 (d, J = 7.7, 4H), 7.63 (d, J = 8.1, 2H), 
7.45 (t, J = 7.6, 4H), 7.36 (m, 4H), 7.28 (m, 1H), 5.62 (s, 1H), 5.44 (s, 2H), 3.47 (d, J = 
12.8, 2H), 3.30 (s, 2H), 3.26 (d, J = 12.8, 2H), 2.89 (s, 2H), 2.44 (s, 3H); Major 
diastereomer 13C NMR (100 MHz, CDCl3) δ 145.0, 139.4, 139.2, 132.5, 130.0, 128.9, 
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128.8, 127.9, 127.5, 127.3, 126.8, 126.5, 82.7, 75.2, 74.0, 54.5, 45.9, 26.3, 21.7; MS (FD) 
m/z = 551.3 (M+). 
N
N
N
N3
 
7-(Azidomethyl)-2,4,6-triphenyl-1,3,5-triazaadamantane (19).  To a solution 
of 1.29 g (2.33 mmol) of 18 in 35 mL of DMF heated to 100 ◦C was added 514 mg (7.91 
mmol) of sodium azide.  The resulting solution was stirred for 24 hours at 100 ◦C.  The 
reaction mixture was poured into water.  The precipitate was filtered, dissolved in diethyl 
ether, washed twice with water, dried over Na2SO4, filtered, and evaporated.  Purification 
by flash chromatography (1:4 ethyl acetate:pet ether) afforded 859 mg (87%) of 19 as a 
white solid which consists of a 90:10 mol ratio mixture of desired:undesired 
diastereomers: Major diastereomer 1H NMR (500 MHz, CDCl3) δ 7.85 (d, J = 7.9, 2H), 
7.79 (d, J = 7.5, 4H), 7.47 (t, J = 7.5, 4H), 7.36 (m, 4H), 7.27 (t, J = 7.2, 1H); 5.64 (s, 1H); 
5.46 (s, 2H); 3.50 (d, J = 12.9, 2H); 3.22 (d, J = 12.9, 2H); 2.94 (s, 2H); 2.70 (s, 2H); 
Major diastereomer 13C NMR (125 MHz, CDCl3) δ 139.6, 139.4, 128.9, 128.8, 127.5, 
127.3, 126.9, 126.6, 82.9, 75.2, 57.6, 55.6, 47.2, 27.1; MS (FD) m/z = 422.1 (M+);  Anal 
Calcd for C26H26N6:  C, 73.91; H, 6.20; N, 19.89.  Found:  C, 73.34; H, 6.29; N, 19.14. 
H
O O
O  
 4-Formyl-benzoic acid methyl ester (20).  To a suspension of 5.10 g (33.9 mmol) 
of 4-carboxy benzaldehyde in 600 mL of MeOH stirring at 0˚C was added 32.6 mL (434 
mmol) of thionyl chloride and the reaction stirred for 1 d.  The solution was concentrated 
in vacuo.  It was dissolved in EtOAc, washed with water and brine, and concentrated in 
 104
vacuo.  Purification via flash chromatography (1:1 ethyl acetate: petroleum ether and 
again using CH2Cl2) gave an impure solid.  To a solution of the solid in THF was added 
HCl and the resulting solution was stirred for 5 min.  Concentration in vacuo produced 
4.80 g of 20 as a solid: 1H NMR (500 MHz, CDCl3) δ 10.11 (s, 1H), 8.20 (d, J = 8.1 Hz, 
2H), 7.96 (d, J = 8.2 Hz, 2H), 3.97 (s, 3H). 
N
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O
 
 7-(Hydroxymethyl)-2,4,6-Tris-(4-benzoic acid methyl ester)-1,3,5-
triazaadamantane (21). To a solution of 1.60 g (6.60 mmol) of 2 and 6.5 mL (47 mmol) 
of triethylamine in 160 mL of methanol was added 3.40 g (20.7 mmol) of 20 and the 
solution was stirred with 3 Å molecular sieves at 65 ◦C for 24 hours.  A precipitate 
formed that was filtered, dissolved in CH2Cl2, and filtered again.  Purification via flash 
chromatography (1:1 ethyl acetate: petroleum ether) gave 2.24 g (54 %) of 21 as a white 
solid: 1H NMR (500 MHz, CDCl3) δ 8.12 (d, J = 8.2, 4H), 8.05 (d, J = 8.5, 2H), 7.91 (d, J 
= 7.9, 2H), 7.85 (d, J = 8.2, 4H), 5.67 (s, 1H), 5.39 (s, 2H), 3.95 (s, 6H), 3.89 (s, 3H), 
3.47 (d, J = 12.9, 2H), 3.25 (d, J = 12.9, 2H), 2.95 (s, 2H), 2.92 (s, 2H); MS (FD) m/z = 
571.3 (M+). 
N
N
N
OTs
O
O
O
O
O
O
 
 105
 7-[(Toluene-4-sulfonic acid)methyl]-2,4,6-Tris-(4-benzoic acid methyl ester)-
1,3,5-triazaadamantane (22). To a solution of 1.34 g (2.34 mmol) of 21 in 60 mL of 
pyridine was added 738 mg (3.87 mmol) of p-toluenesulfonyl chloride.  The resulting 
mixture was stirred for 1 day and concentrated in vacuo.  Purification by flash 
chromatography (gradient 1:4 to 1:1 ethyl acetate: petroleum ether) afforded 1.07 g (63%) 
of 22: 1H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 8.2, 4H), 8.00 (d, J = 8.2, 2H), 7.81 (d, 
J = 8.2, 2H), 7.73 (d, J = 8.2, 4H), 7.54 (d, J = 8.0, 2H), 7.21 (d, J = 8.2, 2H),  5.55 (s, 
1H), 3.88 (s, 6H), 3.82 (s, 3H), 3.33 (d, J = 12.9, 2H), 3.26 (s, 2H), 3.20 (d, J = 12.5, 2H), 
2.80 (s, 2H), 2.36 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 166.8, 166.6, 145.0, 144.0, 
143.7, 132.2, 130.2, 130.0, 129.8, 129.5, 129.3, 127.6, 126.4, 126.3, 82.4, 75.2, 73.3, 60.3, 
54.2, 52.1, 45.9, 26.0, 21.5; MS (FD) m/z = 725.3 (M+). 
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 7-(Azidomethyl)-2,4,6-triphenyl-1,3,5-triazaadamantane (23).  To a solution 
of 977 mg (1.35 mmol) of 22 in 20 mL of DMF heated to 100 ◦C was added 373 mg (5.74 
mmol) of sodium azide.  The resulting solution was stirred for 24 hours at 100 ◦C.  The 
reaction solution was partitioned between CH2Cl2 and water.  The organic layer was 
washed with water and brine.  The aqueous layer was washed with CH2Cl2.  The 
combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo.  
Purification by flash chromatography (1:1 ethyl acetate:pet ether) afforded 582 mg (72%) 
of 23 as a solid: 1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 8.2, 4H), 8.01 (d, J = 8.2, 2H), 
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7.84 (d, J = 8.2, 4H), 7.78 (d, J = 8.2, 2H), 5.55 (s, 1H), 5.28 (s, 2H), 3.89 (s, 6H), 3.84 (s, 
3H), 3.36 (d, J = 12.9, 2H), 3.14 (d, J = 12.9, 2H), 2.85 (s, 2H), 2.66 (s, 2H); 13C NMR 
(100 MHz, CDCl3) δ 166.8, 166.7, 144.2, 144.0, 130.2, 130.1, 129.5, 129.3, 126.5, 126.4, 
82.5, 75.2, 57.0, 55.3, 52.1, 52.1, 47.2, 26.7; MS (ESI) m/z = 597.3 (M+) 
.
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 Dendron 24.  A solution of 72.3 mg (101 µmol) of 14, 128 mg (304 mmol) of 19, 
14.1 mg (14.9 µmol) of bromotris(triphenylphosphine)copper(I), and 40 µL (2 x 102 
µmol) of disisopropylethylamine in 1.5 mL THF was stirred for 2 days at room 
temperature.  The mixture was concentrated in vacuo.  Purification by flash 
chromatography (20:5:1 ethyl acetate: pet ether:TEA) afforded 0.208 g (100%) of 24 as a 
yellow foam: SEC (THF) Mn = 2.2 x 103 g/mol; MS (MALDI-TOF) m/z = 1981.74 (M+). 
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 Dendron 25.  A solution of 179 mg (90.5 µmol) of 24 and 30.2 mg (464 µmol) of 
sodium azide was stirred in 4 mL of DMF at 100 ◦C for 2 days.  The resulting mixture 
was partitioned between CH2Cl2 and water.  The organic layer was washed twice with 
water and twice with brine.  The combined aqueous layers were washed twice with 
CH2Cl2.  The combined organic layers were dried over Na2SO4, filtered, and concentrated 
in vacuo affording 169 mg (100%) of 25 as a yellow solid: SEC (THF) Mn = 1.9 x 103 
g/mol; MS (MALDI-TOF) m/z = 1851.52 (M+). 
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 Dendron 26.  A solution of 17.8 mg (22.3 µmol) of 17, 40.1 mg (67.2 mmol) of 
23, 2.75 mg (2.90 µmol) of bromotris(triphenylphosphine)copper(I), and 10 µL (59 µmol) 
of disisopropylethylamine in 0.6 mL THF was stirred for 15 min under microwave 
irradiation at 125 °C and 100 W.  The mixture was concentrated in vacuo.  Purification 
by flash chromatography (ethyl acetate) afforded 51.6 mg (90%) of 26: SEC (THF) Mn = 
1.7 x 103 g/mol. 
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 Dendron 27. A solution of 199 mg (77.0 µmol) of 26 and 28.8 mg (444 µmol) of 
sodium azide was stirred in 2.5 mL of DMF for 15 min under microwave irradiation at 
125 °C and 100 W.  The solution was dumped into water and the precipitate was filtered.  
It was brought up in CH2Cl2, washed with water and brine, dried over Na2SO4, filtered, 
and concentrated in vacuo affording 161 mg (85%) of 27: SEC (THF) Mn = 1.8 x 103 
g/mol. 
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 Dendrimer 28.  A solution of 8.44 mg (45.3 µmol) of 9, 59.0 mg (98.9 mmol) of 
23, 2.45 mg (2.58 µmol) of bromotris(triphenylphosphine)copper(I), and 15 µL (11 mmol) 
of triethylamine in 1.5 mL THF was stirred for 15 min under microwave irradiation at 
125 °C and 100 W.  The mixture was concentrated in vacuo.  Purification by flash 
chromatography (4:1 ethyl acetate:petroleum ether) afforded 33.0 mg (53%) of 28: 1H 
NMR (500 MHz, CDCl3) δ 8.12 (d, J = 8.2, 8H), 8.01 (d, J = 8.5, 4H), 7.80 (m, 12H), 
7.29 (s, 2H), 6.84 (s, 4H), 5.46 (s, 2H), 5.36 (s, 4H), 5.05 (s, 4H), 3.94 (s, 12H), 3.87 (s, 
6H), 3.67 (s, 4H), 3.46 (d, J = 12.9, 4H), 3.09 (d, J = 12.9, 4H), 2.93 (s, 4H). 
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 Dendrimer 29. A solution of 3.18 mg (13.1 µmol) of 11, 25.9 mg (43.3 mmol) of 
23, 1.05 mg (1.11 µmol) of bromotris(triphenylphosphine)copper(I), and 10 µL (59 mmol) 
of disisopropylethylamine in 0.60 mL THF was stirred for 15 min under microwave 
irradiation at 125 °C and 100 W.  The mixture was concentrated in vacuo to afford a 
mixture containing 29: SEC (THF) Mn = 1.0 x 103 g/mol. 
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 Dendrimer 30.  A solution of 0.955 mg (5.13 µmol) of 9, 28.3 mg (11.5 mmol) 
of 27, 1.18 mg (1.24 µmol) of bromotris(triphenylphosphine)copper(I), and 15 µL (89 
mmol) of disisopropylethylamine in 1.0 mL THF was stirred for 15 min under microwave 
irradiation at 125 °C and 100 W.  The mixture was concentrated in vacuo to afford a 
mixture containing 30 as verified via MALDI-MS. 
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 Dendrimer 31.  A solution of 2.3 mg (9.5 µmol) of 11, 80.1 mg (32.6 mmol) of 
27, 1.66 mg (1.75 µmol) of bromotris(triphenylphosphine)copper(I), and 15 µL (59 mmol) 
of disisopropylethylamine in 1.2 mL THF was stirred for 15 min under microwave 
irradiation at 125 °C and 100 W.  The mixture was evaporated to dryness to afford a 
mixture containing 31 as verified via MALDI-MS. 
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 4-Formylbenzoic acid allyl ester (32). To a solution of 4.07 g (27.1 mmol) of 4-
carboxybenzoic acid in 240 mL of THF was added 15 mL (170 mmol) of oxalyl chloride 
and the solution was stirred for 3 h and concentrated in vacuo.  To the mixture was added 
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240 mL THF, 12 mL (180 mmol) allyl alcohol, and 25 mL (180 mmol) triethylamine and 
the solution was stirred for 3.5 h.  The reaction was concentrated in vacuo and purified 
via flash chromatography (ethyl acetate) to give 4.09 g (79%) of (32) as a yellow oil: 1H 
NMR (500 MHz, CDCl3) δ 10.11 (s, 1H), 8.23 (d,  J = 8.2 Hz, 2H), 7.96 (d,  J = 8.2 Hz, 
2H), 6.06 (m, 1H), 5.44 (m, 2H), 4.86 (dt, J = 1.3 Hz, 5.9 Hz, 1H); MS (FD) m/z = 191.1 
(M+). 
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 7-(Hydroxymethyl)-2,4,6-Tris-(4-benzoic acid allyl ester)-1,3,5-
triazaadamantane (33). To a suspension of 3.02 g (15.9 mmol) of 32 and 1.18 g (4.86 
mmol) of 2 in 200 mL of DMSO was added 2.30 mL (16.5 mmol) of triethylamine and 
the solution was stirred at 100 °C for 2.5 h.  The reaction was partitioned between 
CH2Cl2 and water.  The aqueous layer was washed with CH2Cl2.  The combined organic 
layers were washed with water and brine, dried over Na2SO4, filtered, concentrated in 
vacuo, and purified via flash chromatography (gradient 0:1 to 2:1 ethyl acetate: 
petroleum ether) to give 1.12 g (36%) of 33: 1H NMR (500 MHz, CDCl3) δ 8.09 (d, J = 
8.5 Hz, 4H), 8.04 (d, J = 8.7 Hz, 2H), 7.88 (d, J = 8.2 Hz, 2H), 7.82 (d, J = 8.2 Hz, 4H), 
6.06-5.91 (m, 3H), 5.59 (s, 1H), 5.42-5.19 (m, 6H), 5.30 (s, 2H), 4.78 (d, J = 5.3 Hz, 4H), 
4.73 (dt, J = 1.3 Hz, 5.5 Hz, 2H), 3.41 (d, J = 12.9, 2H), 3.19 (d, J = 12.9, 2H), 2.89 (s, 
2H), 2.86 (s, 2H), 2.36 (s, 1H); MS (FD) m/z = 649.2 (M+). 
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 7-[(Toluene-4-sulfonic acid)methyl]-2,4,6-Tris-(4-benzoic acid allyl ester)-
1,3,5-triazaadamantane (34). To a solution of 997 mg (1.53 mmol) of 33 in 20 mL 
pyridine was added 441 mg (2.32 mmol) of p-toluenesulfonyl chloride.  The resulting 
mixture was stirred for 1 d and concentrated in vacuo.  Purification by flash 
chromatography (gradient 1:4 to 1:0 ethyl acetate:petroleum ether) afforded 919 mg 
(74%) of 33: 1H NMR (500 MHz, CDCl3) δ 8.13 (d, J = 8.2, 4H), 8.07 (d, J = 8.2, 2H), 
7.87 (d, J = 8.2, 2H), 7.78 (d, J = 8.2, 4H), 7.58 (d, J = 8.2, 2H), 7.26 (d, J = 8.2, 2H), 
6.11-5.95 (m, 3H), 5.62 (s, 1H), 5.47-5.23 (m, 6H), 5.36 (s, 2H), 4.86 (d, J = 5.5, 4H), 
4.79 (d, J = 5.5, 2H), 3.38 (d, J = 12.9, 2H), 3.28 (s, 2H), 3.26 (d, J = 12.9, 2H), 2.83 (s, 
2H), 2.41 (s, 3H). 
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 7-(Azidomethyl)-2,4,6-Tris-(4-benzoic acid allyl ester)-1,3,5-
triazaadamantane (35). To a solution of 860 mg (1.07 mmol) of 34 in 15 mL of DMF 
was added 307 mg (4.73 mmol) of sodium azide and the solution was stirred at 100 °C 
overnight.  The solution was partitioned between CH2Cl2 and water.  The organic layer 
was washed with water and brine, dried over Na2SO4, filtered, and concentrated in vacuo 
affording 573 mg (79%) of 35: 1H NMR (500 MHz, CDCl3) δ 8.15 (d, J = 8.2, 4H), 8.07 
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(d, J = 8.2, 2H), 7.89 (d, J = 8.2, 2H), 7.83 (d, J = 8.2, 4H), 6.12-5.93 (m, 3H), 5.62 (s, 
1H), 5.47-5.22 (m, 6H), 5.36 (s, 2H), 4.84 (s, 4H), 4.78 (s, 2H), 3.41 (d, J = 12.9, 2H), 
3.20 (d, J = 12.9, 2H), 2.88 (s, 2H), 2.69 (s, 2H). 
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 Dendron 36.  A solution of 70.6 mg (88.5 µmol) of 17, 185 mg (274 mmol) of 35, 
10.6 mg (11.2 mmol) of bromotris(triphenylphosphine)copper(I), and 25 µL (148 mmol) 
of triethylamine in 2 mL THF was stirred for 20 min under microwave irradiation at 150 
°C and 200 W.  Reaction was partitioned between CH2Cl2 and water.  The organic layer 
was washed with water and brine, dried over Na2SO4, filtered, and concentrated in vacuo.  
Purification by flash chromatography (gradient 1:24 to 1:19 MeOH:CH2Cl2) afforded 124 
mg (50%) of an intermediate that was dissolved in 3 mL of DMF.  To the solution was 
added 20.8 mg (319 mmol) of sodium azide and the solution was stirred for 15 min under 
microwave irradiation at 125 °C and 100 W.  The reaction was concentrated in vacuo, 
dissolved in CH2Cl2, washed with brine and water, dried over Na2SO4, filtered, and 
concentrated in vacuo.  Purification by flash chromatography (1:19 MeOH:CH2Cl2) 
afforded 110 mg (93%) of 36 as verified by MALDI-MS. 
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 TAA 37. To as solution of 28.0 mg (43.1 μmol) of 33 and 35 μL (0.32 mmol) in 
870 μL of CH2Cl2 was added 5.61 mg (661 μL) generation 2 Grubbs’s catalyst and the 
solution was stirred for 15 min under microwave irradiation at 125 °C and 100 W.  The 
reaction was concentrated in vacuo and purified by flash chromatography (1:1 
EtOAc:petroleum ether) to afford 20.1 mg (50%) of 37: 1H NMR (500 MHz, CDCl3) δ 
8.16 (d, J = 8.6, 4H), 8.10 (d, J = 8.6, 2H), 7.94 (d, J = 8.6, 2H), 7.08 (dt, J = 4.5 Hz, 15.7 
Hz, 2H), 7.02 (dt, J = 4.5 Hz, 15.7 Hz, 1H), 6.14 (dt, J = 1.9 Hz, 15.8 Hz, 2H), 6.08 (dt, J 
= 1.9 Hz, 15.8 Hz, 1H), 5.68 (s, 1H), 5.39 (s, 2H), 5.03 (m, 4H), 4.96 (m, 2H), 4.23 (quart, 
J = 7.0, 4H), 4.19 (quart, J = 7.0, 2H), 3.48 (d, J = 12.9, 2H), 3.26 (d, J = 12.9, 2H), 2.97 
(s, 2H), 2.93 (s, 2H), 1.31 (t, J = 7.1, 6H), 1.27 (t, J = 7.1, 3H); MS (ESI) m/z = 866.4 
(M+). 
N3
H2N NH2
NH2
. 3 HCl 
2-Azido-1,1,1-tris(aminomethyl)ethane trihydrochloride (38).  To a solution of 
82.0 mg (0.194 mmol) of 19 in 3 mL of THF was added 3 mL of 1.25 M HCl.  The 
resulting solution was stirred for 20 min at room temperature.  The solution was 
evaporated until no more THF remained.  The remaining aqueous solution was washed 
with diethyl ether (2 x 5 mL) and evaporated giving 49.5 mg (96%) of 38 as a white solid: 
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1H NMR (500 MHz, D2O) δ 3.86 (s, 2H), 3.29 (s, 6H); 13C NMR (100 MHz, D2O with 
DMSO-D6 internal standard) δ 75.6, 49.8, 37.5. 
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 [3-Azido-2,2-bis-(benzyloxycarbonylamino-methyl)-propyl]-carbamic acid 
benzyl ester (39). To a solution of 122 mg (0.501 mmol) of 38 and 323 mg (3.04 mmol) 
of sodium carbonate in 4 mL of 1:1 water:THF was added 0.23 mL (1.5 mmol) of Cbz-Cl 
and the solution was stirred at 0 °C for 45 min.  5 mL of CH2Cl2 was added and the 
solution was stirred for 1 h. The reaction was partitioned between EtOAc and HCl.  The 
organic layer was washed with water, dried over Na2SO4, filtered, and concentrated in 
vacuo to produce 214 mg (80%) of 39 as a white solid: 1H NMR (500 MHz, CDCl3) δ 
7.36 (m, 15H), 6.03 (t,  J = 6.7 Hz, 3H), 5.10 (s, 6H), 3.15 (s, 2H), 2.91 (d,  J = 6.7 Hz, 
6H). 
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 Aldehyde 40. To a solution of 415 mg (666 µmol) of 39 and 116 mg (616 mmol) 
of 15 in 3 mL of THF was added 24.2 mg (25.5 mmol) of 
bromotris(triphenylphosphine)copper(I) and 70 µL (424 μmol) of diisopropylethylamine 
and the solution was stirred for 24 h.  The reaction was concentrated in vacuo and 
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purified by flash chromatography (gradient 1:3 to 1:1 EtOAc:petroleum ether) to afford 
409 mg (89%) of 40 as a white foam: 1H NMR (500 MHz, CDCl3) δ 10.06 (s, 1H), 8.72 
(s, 1H), 8.24 (d, J = 7.9, 2H), 7.92 (d, J = 7.9, 2H), 7.36 (m, 15H), 6.55 (t,  J = 6.7 Hz, 
3H), 5.53 (s, 2H), 5.15 (s, 6H), 4.13 (s, 2H), 2.89 (d,  J = 6.0 Hz, 6H); 13C NMR (125 
MHz, CDCl3) δ 191.6, 165.2, 157.8, 142.3, 139.2, 136.2, 134.7, 133.3, 130.4, 129.4, 
128.5, 128.2, 128.0, 67.1, 58.6, 49.1, 46.0, 40.2; FD-LRMS m/z 748.3 (M+). Anal. Calcd 
for C40H40N6O9: C, 64.16; H, 5.38; N, 11.22. Found: C, 63.94; H, 5.15; N, 11.04. 
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 TAA 41. To a solution of 45.3 mg (186 μmol) of 2 and 90 μL (65 μmol) of 
triethylamine in 2 mL of DMSO was added 400 mg (535 μmol) of 40 in 4 mL of DMSO 
and the solution was stirred at 120 °C for 1 h.  The reaction was partitioned between 
EtOAc and brine.  The aqueous layer was washed with EtOAc.  The combined organic 
layers were washed twice with brine and twice with water, dried over Na2SO4, filtered, 
concentrated in vacuo, and purified by flash chromatography (1:49 MeOH:CH2Cl2) to 
afford to produce 305 mg (74%) of 41 as an off-white foam: 1H NMR (500 MHz, CDCl3) 
δ 8.70 (s, 2H), 8.63 (s, 1H), 8.16 (d, J = 7.9, 4H), 8.10 (d, J = 7.9, 2H), 7.89 (d, J = 7.9, 
2H), 7.80 (d, J = 7.9, 4H), 7.42-7.29 (m, 45H), 6.54 (br s, 6H), 6.50 (br s, 3H), 5.60 (s, 
1H), 5.53 (s, 4H), 5.47 (s, 2H), 5.31 (s, 2H), 5.16 (s, 12H), 5.12 (s, 6H), 4.12 (s, 4H), 4.07 
(s, 2H), 3.41 (d, J = 12.9, 2H), 3.19 (d, J = 12.9, 2H), 2.95-2.80 (m, 22H); 13C NMR (125 
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MHz, CDCl3) δ 166.2, 166.0, 157.9, 157.9, 144.9, 144.7, 142.9, 142.8, 136.2, 130.5, 
130.5, 130.3, 129.5, 129.2, 128.9, 128.6, 128.6, 128.3, 128.3, 128.1, 127.1, 127.0, 126.6, 
126.5, 82.7, 75.5, 67.2, 67.2, 67.0, 58.2, 58.2, 55.0, 49.1, 49.1, 46.1, 46.0, 40.3, 40.3, 29.7, 
27.2; MALDI-LRMS m/z 2325.8 (M+). 
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 {3-Azido-2,2-bis-[(2-trimethylsilanyl-ethoxycarbonylamino)-methyl]-propyl}-
carbamic acid 2-trimethylsilanyl-ethyl ester (43). To a solution of 1.03 g (3.74 mmol) 
of 38 and 4.74 g (44.7 mmol) of sodium carbonate in 120 mL of 1:1 water:DMF was 
added 2.90 g (11.2 mmol) of 1-[2-(trimethysilyl)ethoxycarbonyloxy]pyrrolidin-2,5-dione 
(42) in DMF over 15 min and the solution was stirred at 0 °C overnight.  The reaction 
was partitioned between EtOAc and water.  The aqueous layer was washed twice with 
EtOAc. The combined organic layer was washed three times with water, dried over 
Na2SO4, filtered, and concentrated in vacuo to produce 2.15 g (97%) of 43 as a tan solid: 
1H NMR (500 MHz, CDCl3) δ 6.09 (br s, 3H), 4.14 (t,  J = 8.2 Hz, 6H), 3.24 (s, 2H), 2.99 
(s, 6H), 0.98 (t,  J = 8.2 Hz, 6H), 0.04 (s, 27H); 13C NMR (125 MHz, CDCl3) δ 157.7, 
63.1, 52.0, 44.4, 40.5, 17.6, -1.66; FD-LRMS m/z 590 (M+). Anal. Calcd for 
C23H50N6O6Si3: C, 46.75; H, 8.53; N, 14.22. Found: C, 46.71; H, 8.73; N, 14.16. 
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 Aldehyde 44. To a solution of 2.10 g (355 mmol) of 43 and 669 mg (355 mmol) 
of 15 in 20 mL of THF was added 124 mg (130 μmol) of 
bromotris(triphenylphosphine)copper(I) and 300 µL (1.82 mmol) of 
diisopropylethylamine and the solution was stirred for 24 h.  108 mg (114 μmol) of 
bromotris(triphenylphosphine)copper(I) was added and the solution was stirred for 3 h.  
The reaction was concentrated in vacuo and purified by flash chromatography (gradient 
1:4 to 1:3 EtOAc:petroleum ether) to afford 1.94 mg (70%) of 44 as an off-white foam: 
1H NMR (500 MHz, CDCl3) δ 10.03 (s, 1H), 8.72 (s, 1H), 8.17 (d, J = 7.9, 2H), 7.87 (d, J 
= 7.9, 2H), 6.36 (t,  J = 6.9 Hz, 3H), 5.46 (s, 2H), 4.12 (t, J = 8.7 Hz, 6H), 4.10 (s, 2H), 
2.82 (d,  J = 6.0 Hz, 6H), 0.95 (t, J = 8.7 Hz, 6H), -0.01 (s, 27H); 13C NMR (125 MHz, 
CDCl3) δ 191.6, 165.2, 158.2, 142.3, 139.2, 134.8, 130.4, 129.5, 127.1, 63.6, 58.6, 49.3, 
46.1, 40.1, 17.7, -1.46; FD-LRMS m/z 779.2 (M+). 
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 TAA 45. To a solution of 189 mg (780 μmol) of 2 and 420 μL (249 mmol) of 
diisopropylethylamine in 20 mL of DMSO was added 1.82 g (2.34 mmol) of 44 in 10 mL 
 120
of DMSO and the solution was stirred at 100 °C for 3 h.  The reaction was partitioned 
between EtOAc and brine.  The organic layer was washed with brine. The combined 
aqueous layers were washed twice with EtOAc.  The combined organic layers were 
washed twice with water and with brine, dried over Na2SO4, filtered, concentrated in 
vacuo, and purified by flash chromatography (gradient 1:3 to 1:1 EtOAc:petroleum ether) 
to afford to produce 1.40 g (74%) of 45: 1H NMR (400 MHz, CDCl3) δ 8.73 (s, 2H), 8.67 
(s, 1H), 8.10 (d, J = 7.9, 4H), 8.04 (d, J = 7.9, 2H), 7.85 (d, J = 7.9, 2H), 7.78 (d, J = 7.9, 
4H), 6.44-6.33 (m, 9H), 5.60 (s, 1H), 5.47 (s, 4H), 5.41 (s, 2H), 5.32 (s, 2H), 4.21-4.05 
(m, 24H), 3.40 (d, J = 12.9, 2H), 3.19 (d, J = 12.9, 2H), 2.93-2.76 (m, 22H), 1.05-0.93 (m, 
18H), 0.03 (s, 54H), 0.02 (s, 27H); 13C NMR (100 MHz, CDCl3) δ 166.2, 166.1, 158.3, 
159.3, 144.8, 144.7, 142.7, 142.6, 130.5, 130.3, 129.2, 129.0 127.2, 127.2, 126.6, 126.6, 
67.2, 63.7, 63.7, 60.5, 58.1, 58.1, 55.1, 49.3, 49.3, 46.2, 46.1, 40.2, 40.2, 27.2, 21.1, 14.2, 
17.8, 17.8, -1.4, -1.4; MALDI-LRMS m/z 2416.8 (M+); SEC (THF) calcd Mn = 2665, PDI 
= 1.01. 
N3
N
H
N
H
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 {3-Azido-2,2-bis-[(9H-fluoren-9-ylmethoxycarbonylamino)-methyl]-propyl}-
carbamic acid 9H-fluoren-9-ylmethyl ester (46). To a solution of 99.2 mg (370 μmol) 
of 38 and 642 mg (6.06 mmol) of sodium carbonate in 10 mL of water was added 728 mg 
(2.16 mmol) of Fmoc-OSu in 8 mL of DMF and the solution was stirred at 0 °C for 1 h.  
EtOAc and added and the organic layer was washed three times with water.  The organic 
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layer was dried over Na2SO4, filtered, concentrated in vacuo, and purified by flash 
chromatography (1:1 EtOAc:petroleum ether) to afford 272 mg (89%) of 46 as a white 
foam: 1H NMR (500 MHz, CDCl3) δ 7.80 (d,  J = 7.4 Hz, 6H), 7.76 (d,  J = 7.4 Hz, 6H), 
7.44 (t, J = 7.6 Hz, 6H), 7.35 (t, J = 7.6 Hz, 6H), 5.98 (t, J = 6.7 Hz, 3H), 4.50 (d, J = 7.0 
Hz, 6H), 4.27 (t, J = 6.8 Hz, 3H), 3.15 (s, 2H), 2.96 (d, J = 6.7 Hz, 6H); 13C NMR (125 
MHz, CDCl3) δ 157.7, 143.9, 141.4, 127.8, 127.1, 125.1, 120.1, 67.1, 52.1, 47.4, 44.6, 
40.8. 
N
FmocHN NHFmoc
NHFmoc
N
N
O
O
H
O
 
 Aldehyde 47. To a solution of 272 mg (330 μmol) of 46 and 60.8 mg (323 μmol) 
of 15 in 14 mL of DMF was added 14.2 mg (56.8 μmol) of CuSO4 . 5H2O and 23.3 mg 
(117 μmol) of sodium ascorbate in 2 mL of water. DMF and water were added until all 
reagents were soluble and the solution was stirred at 60˚C for 24 h.  EtOAc was added.  
The organic layer was washed twice with brine and twice with water, dried over Na2SO4, 
filtered, concentrated in vacuo, and purified by flash chromatography (gradient 1:2 to 1:1 
EtOAc:petroleum ether) to afford 257 mg (79%) of 47 as a white foam: 1H NMR (500 
MHz, CDCl3) δ 10.02 (s, 1H), 8.64 (s, 1H), 8.22 (d,  J = 7.2 Hz, 2H), 7.89 (d,  J = 7.2 Hz, 
2H), 7.78 (d,  J = 7.4 Hz, 6H), 7.66 (d,  J = 7.4 Hz, 6H), 7.42 (t, J = 7.6 Hz, 6H), 7.33 (t, 
J = 7.6 Hz, 6H), 6.56 (s, 3H), 5.53 (s, 2H), 4.49 (d,  J = 7.2 Hz, 6H), 4.28 (t, J = 6.8 Hz, 
3H), 4.08 (s, 2H), 2.86 (br s, 6H); 13C NMR (125 MHz, CDCl3) δ 191.7, 165.3, 158.0, 
143.8, 142.5, 141.4, 139.3, 134.8, 130.5, 129.5, 127.9, 127.3, 127.2, 125.2, 120.2, 67.4, 
58.7, 49.2, 47.3, 46.2, 40.3. 
 122
N
N
N
OH
O O
N
N N
FmocHN
FmocHN
FmocHN
O
O
O
O
N
N N
N N
N
NHFmocFmocHN
NHFmoc
FmocHN
FmocHN
FmocHN
 
 TAA 48. To a solution of 32.0 mg (49.7 μmol) of 16 and 130 mg (158 μmol) of 
46 in 8 mL of DMF was added 8.44 mg (3.38 μmol) of CuSO4 . 5H2O and 11.7 mg (59.0 
μmol) of sodium ascorbate in 1 mL of water and the solution was stirred at 60˚C for 24 h.  
EtOAc was added.  The organic layer was washed twice with brine and with water.  The 
aqueous layer was washed with EtOAc.  The combined organic layers were dried over 
Na2SO4, filtered, concentrated in vacuo, and purified by flash chromatography (gradient 
0:1 to 1:49 MeOH:CH2Cl2) to afford 103 mg (67%) of 48: 1H NMR (500 MHz, CDCl3) δ 
8.64 (s, 2H), 8.58 (s, 1H), 8.09 (m, 6H), 7.84 (br s, 2H), 7.74 (m, 22H), 7.63 (m, 18H), 
7.37 (m, 18H), 7.29 (m, 18), 6.54 (s, 6H), 6.49 (s, 3H), 5.54 (s, 1H), 5.54-5.44 (m, 6H), 
5.26 (s, 2H), 4.49-4.41 (m, 18H), 4.28-4.19 (m, 9H), 4.05 (s, 4H), 3.99 (s, 2H), 3.34 (br s, 
2H), 3.11 (br s, 2H), 2.87-2.74 (m, 22H). 
O O
O
BrBr
Br  
 Tri bromo core (50). To a solution of 7.43 g (24.4 mmol) of 1,1,1-tris(4-
hydroxyphenyl)ethane (49) and 40.0 mL (394 mmol) of 1,3-dibromopropane in 40.0 mL 
acetone was added 14.0 g (101 mmol) of potassium carbonate and the suspension was 
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stirred at 80˚C for 10 min.  2.03 g (7.60 mmol) of 18-crown-6 was added and the solution 
was stirred for 25 h.  10.0 g (72.3 mmol) of additional potassium carbonate and 11.0 mL 
(108 mmol) of 1,3-dibromopropane was added and the reaction was stirred for 16 more 
hours.  The reaction was filtered and purified via flash chromatography (gradient 0:1 to 
1:4 ethyl acetate : petroleum ether) to afford 11.5 g of a white solid that contained the 
desired tri bromo product along with elimination and C-alkylation side products. The 
mixture was taken on to the next step without further purification: major product: 1H 
NMR (500 MHz, CDCl3) δ 6.99 (d, J = 8.7 Hz, 6H), 6.79 (d, J = 8.7 Hz, 6 H), 4.08 (t, J = 
5.7 Hz, 6H), 3.60 (t, J = 5.8 Hz, 6H), 2.31 (quint, J = 5.9 Hz, 6H), 2.10 (s, 3H). 
O O
O
N3N3
N3  
 Tri azido core (51). To a solution of 11.5 g (17.3 mmol) of tri bromo core (50) in 
75 mL of DMF was added 9.05 g (139 mmol) of sodium azide and the solution was 
heated to 80˚C for 20 hours.  The reaction was partitioned between 200 mL of ethyl 
acetate and 100 mL of brine.  The organic fraction was washed four times with 50 mL of 
brine, dried over Na2SO4, filtered, concentrated in vacuo, and purified via flash 
chromatography (gradient 1:9 to 1:4 ethyl acetate: petroleum ether) to give 3.70 g (22 % 
over two steps) of (51) as a clear, colorless oil that solidified over time: 1H NMR (500 
MHz, CDCl3) δ 6.99 (d,  J = 8.8 Hz, 6H), 6.78 (d, J = 8.8 Hz, 6 H), 4.02 (t, J = 5.9 Hz, 
6H), 3.51 (t, J = 6.7 Hz, 6H), 2.10 (s, 3H), 2.04 (quint, J = 6.0 Hz, 6H); 13C NMR (125 
MHz, CDCl3) δ 156.6, 141.9, 129.6, 113.6, 64.3, 50.6, 48.2, 30.7, 28.8; FD-LRMS m/z 
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555.2 (M+). Anal. Calcd for C29H33N9O3: C, 62.69; H, 5.99; N, 22.69. Found: C, 63.03; H, 
5.93; N, 22.24. 
NN
N
O
 
 7-[(3-propynyloxy)methyl]-2,4,6-triphenyl-1,3,5-triazaadamantane (52). To a 
solution of 18.7 g (47.0 mL) of 7-(hydroxymethyl)-2,4,6-triphenyl-1,3,5-
triazaadamantane (3) and 637 mg (1.69 mmol) of tetrabutylammonium iodide in 50 mL 
of THF at 0˚C was added 7.51 g (188 mmol) of sodium hydride and stirred for 30 min.  
30 mL (270 mmol) of propargyl bromide was added and the solution was heated at reflux 
for 4.5 h.  The reaction was cooled in an ice bath and 5 mL of water was added slowly. 
The solution was concentrated in vacuo and partitioned between 300 mL of CH2Cl2 and 
100 mL of water.  The organic layer was washed with 100 mL of brine and 100 mL of 
water.  The combined aqueous layers were washed four times with 50 mL of CH2Cl2.  
The combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo, 
and purified via flash chromatography (1:4 ethyl acetate : petroleum ether) to afford 21.2 
g of a yellow paste that was taken on without any further purification.  Crystallization in 
ethyl acetate/petroleum ether can produce analytically and diastereomerically pure 52 as 
a white solid: 1H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 8.1 Hz, 2H), 7.78 (d. J = 8.1 Hz, 
4H), 7.44 (t, J = 7.8 Hz, 4H), 7.33 (m, 4H), 7.24 (t, J = 7.2 Hz, 1H), 5.64 (s, 1H), 5.42 (s, 
2H), 3.91 (d, J = 2.4 Hz, 2H), 3.51 (d, J = 12.9 Hz, 2H), 3.25 (d, J = 13.0 Hz, 2H), 2.94 (s, 
2H), 2.79 (s, 2H), 2.30 (t, J = 2.3 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 140.0, 139.8, 
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128.8, 128.7, 127.4, 127.1, 126.7, 82.9, 79.8, 75.4, 74.6, 74.6, 58.6, 55.5, 46.9, 26.8; FD-
LRMS m/z 435.2 (M+). Anal. Calcd for C29H29N3O: C, 79.97; H, 6.71; N, 9.65. Found: C, 
80.02; H, 6.73; N, 9.60. 
O
H2N NH2
NH2
. 3 HCl  
 2-Propargyl-1,1,1-tris(aminomethyl)ethane trihydrochloride (53). To a 
solution of 21.1 g (48.4 mmol) of 7-[(3-propynyloxy)methyl]-2,4,6-triphenyl-1,3,5-
triazaadamantane (52) in 440 mL of THF was added 250 mL of 1.25 M HCl and the 
solution was stirred for 1 h.  THF was removed in vacuo and the resultant solution was 
washed three times with 130 mL of ether.  The combined ether layers were washed twice 
with 70 mL of HCl.  The combined aqueous layers were concentrated in vacuo and 
ether/ethyl acetate were added to precipitate out 10.8 g (82 % over 2 steps) of 53 as a 
white solid: 1H NMR (500 MHz, D2O) δ 4.28 (s, 2H), 3.82 (s, 2H), 3.31 (s, 6H), 2.97 (s, 
1H); 13C NMR (125 MHz, 1% MeOH in CDCl3) δ 79.1, 77.8, 69.8, 59.4, 41.1, 39.4; ESI-
LRMS m/z 172.2 (M + H+). Anal. Calcd for C8H20Cl3N3O: C, 34.24; H, 7.18; Cl, 37.90; 
N, 14.97. Found: C, 34.32; H, 7.14; Cl, 38.02; N, 14.59; mp = 257 ˚C (decomp). 
H2N
O
Cl
.HCl  
 2-(2-Chloroethoxy)ethylamine hydrochloride.  To a solution of 7.13 g (66.4 
mmol) of 2-(2-aminoethoxy)-ethanol in 70 mL of toluene was added 5.30 mL (72.8 
mmol) of SOCl2.  The solution instantly turned yellow and gave off heat.  After stirring 
for one hour the solvent was decanted to produce a brown oil that was dried in vacuo to 
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produce 11.4 g (assumed quantitative conversion for calculations in the next step) of a 
brown solid that was taken on without further purification: 1H NMR (500 MHz, CDCl3) δ 
8.33 (br s, 3H), 3.85 (t, J = 5.2 Hz, 2H), 3.81 (t, J = 5.7 Hz, 2H), 3.72 (t, J = 5.7 Hz, 2H), 
3.27 (sext, J = 5.2 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 71.3, 66.7, 43.0, 39.6; ESI-
LRMS m/z 124.1 (M + H+). 
O
H
N
O
O
Cl
H
 
 N-[2-(2-Chloro-ethoxy)-ethyl]-4-formyl-benzamide (55). To a suspension of 
8.52 g (43.4 mmol) of 4-carboxybenzaldehyde dimethoxyacetal (54) and 5.64 g (48.0 
mmol) of N-hydroxysuccinimide in 200 mL of CH2Cl2 was added dropwise a solution 
9.70 g (46.5 mmol) of N,N’-dicyclohexycarbodiimide in 50 mL of CH2Cl2 over 35 
minutes and the solution was stirred for 3 h.  The precipitate that formed was filtered and 
11.4 g (66.4 mmol) of 2-(2-chloroethoxy)ethylamine hydrochloride (theoretical from 
previous step) and 12.2 mL (87.5 mmol) of triethylamine were added.  16.0 mL (206 
mmol) of trifluoroacetic acid was added after 4 hours and 10.0 mL (129 mmol) again 2 
hours later.  After 1 hour the solution was washed with 100 mL NaHCO3.  The organic 
layer was washed twice with 100 mL of NaHCO3, washed with 50 mL of brine, dried 
over Na2SO4, filtered, concentrated in vacuo, and purified via flash chromatography (4:1 
ethyl acetate : petroleum ether) to afford 8.86 g (80 %) of 55 as a white solid: 1H NMR 
(500 MHz, CDCl3) δ 10.08 (s, 1H), 7.95 (s, 4H), 6.82 (br s, 1H), 3.79 (t, J = 5.6 Hz, 2H), 
3.71 (m, 4H), 3.68 (t, J = 5.6 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 191.8, 166.5, 
139.6, 138.2, 129.9, 127.8, 70.9, 69.4, 43.3, 39.8; ESI-LRMS m/z 256.3 (M + H+); Anal. 
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Calcd for C12H14ClNO3: C, 56.37; H, 5.52; Cl, 13.87; N, 5.48. Found: C, 56.28; H, 5.55; 
Cl, 14.41; N, 5.51; mp = 83.8 – 86.4 ˚C. 
N
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 TAA monomer 56. To a solution of 3.14 g (11.2 mmol) of 53 and 5.50 mL (39.5 
mmol) of triethylamine in 50 mL of MeOH was added 8.74 g (34.2 mmol) of 55 in 40 
mL of MeOH and the solution was heated at reflux for 75 min.  The majority of the 
solvent was removed in vacuo and resultant solution was partitioned between 100 mL of 
CHCl3 and 50 mL of H2O.  The organic layer was washed again with 50 mL of H2O.  The 
combined aqueous layers were washed twice with 20 mL of CHCl3.  The combined 
organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and purified via 
flash chromatography (gradient from 2% TEA in CH2Cl2 to 2% TEA and 2% MeOH in 
CH2Cl2) to afford 7.11 g (72%) of 56 as an off-white foam: 1H NMR (500 MHz, CDCl3) 
δ 7.85 (m, 12H), 6.67 (br t, 2H), 6.56 (br t, 1H), 5.65 (s, 1H), 5.37 (s, 2H), 3.91 (d, J = 
2.3 Hz, 2H), 3.80 (t, J = 5.7 Hz, 4H), 3.73 (m, 10H), 3.69 (t, J = 5.7 Hz, 4H), 3.66 (m, 
4H), 3.63 (t, J = 5.7 Hz, 2H), 3.45 (d, J = 13.4 Hz, 2H), 3.24 (d, J = 13.4 Hz, 2H), 2.90 (s, 
2H), 2.77 (s, 2H), 2.31 (t, J = 2.4 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 167.4, 167.1, 
142.9, 142.6, 133.5, 133.3, 127.5, 127.3, 126.5, 126.4, 82.4, 79.3, 75.2, 74.7, 73.8, 70.7, 
70.6, 69.4, 69.4, 58.2, 55.0, 46.6, 43.1, 42.9, 39.5, 39.5, 26.4; FD-LRMS m/z 884.2 (M+); 
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Anal. Calcd for C44H53Cl3N6O7: C, 59.76; H, 6.04; N, 9.50. Found: C, 59.58; H, 6.07; N, 
9.37, SEC (0.05 M LiCl in DMF) calcd Mw = 3189, PDI = 1.03. 
H
O
H
N O OH
O  
 4-Formyl-N-[2-(2-hydroxy-ethoxy)-ethyl]-benzamide (57).  To a solution of 
6.50 mL (83.8 mmol) of DMF in 80 mL of CH2Cl2 was added 10.0 mL (112 mmol) of 
oxalyl chloride and the suspension was stirred for 30 min.  The reaction was concentrated 
in vacuo, 100 mL of THF and 9.96 g (65.0 mmol) of 4-carboxy benzaldehyde were added 
and the suspension was stirred overnight at 0˚C.  15.0 mL (148 mmol) of 2-(2-
aminoethoxy)-ethanol and 19 mL (140 mmol) of triethylamine were added and the 
suspension was stirred for 8 h.  HCl (2.5 M) and brine were added.  The solution was 
washed three times with 100 mL of 10% iPrOH in CHCl3.  The combined organic layers 
were dried over Na2SO4, filtered, concentrated in vacuo, and purified via flash 
chromatography (gradient from 1:49 to 1:9 MeOH:CH2Cl2) to afford 6.80 g (62%) of 57 
as a yellow oil: 1H NMR (500 MHz, CDCl3) δ 10.05 (s, 1H), 7.94 (d, J = 8.3 Hz, 2H), 
7.91 (d, J = 8.0 Hz, 2H), 6.99 (br s, 1H), 3.77 (t, J = 4.5 Hz, 2H), 3.69 (m, 4H), 3.62 (t, J 
= 4.5 Hz, 2H). 
N
N
N
O
HN O
N
H
N
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O
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O
HO  
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 TAA 58. To a solution of 1.98 g (6.97 mmol) of 53 and 3.40 mL (24.4 mmol) of 
triethylamine in 10 mL of MeOH was added 5.13 g (21.6 mmol) of 57 in 15 mL of 
MeOH and the solution was heated at reflux for 1.5 h.  The reaction was concentrated in 
vacuo and dissolved in 70 mL of 10% iPrOH in CHCl3.  The organic layer was washed 
with 20 mL brine.  The aqueous layer was washed with twice with 20 mL of 10% iPrOH 
in CHCl3.  The combined organic layers were washed with 20 mL of NaHCO3.  The 
aqueous layer was washed twice with 20 mL of 10% iPrOH in CHCl3.  The combined 
organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and purified via 
flash chromatography (gradient from 1:9 to 2:3 MeOH:CH2Cl2) to afford 2.84 g (49%) of 
58 as a white foam: 1H NMR (500 MHz, CDCl3) δ 8.14 (d, J = 8.0 Hz, 2H), 7.85 (d, J = 
8.0 Hz, 2H), 7.74 (br s, 2H), 7.61 (br s, 1H), 7.52 (d, J = 8.0 Hz, 4H), 7.03 (d, J = 8.0 Hz, 
4H), 5.43 (s, 1H), 4.74 (s, 2H), 3.89-3.59 (m, 26H), 3.06 (d, J = 13.4 Hz, 2H), 3.00 (d, J 
= 13.4 Hz, 2H), 2.61 (s, 4H), 2.27 (t, J = 2.4 Hz, 1H); ESI-LRMS m/z 829.6 (M + H+). 
N
N
N
O
HN O
N
H
N
H
O
O
O
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O
TsO  
 TAA 59. Procedure A: To a solution of 1.42 g (1.71 mmol) of 58, 12.6 mg (102 
μmol) of DMAP, and 0.60 mL (7.4 mmol) of pyridine in 7 mL of CH2Cl2 was added 1.08 
g (5.70 mmol) of p-toluenesulfonyl chloride and the solution was stirred for 20.5 h.  348 
mg (1.83 mmol) of p-toluenesulfonyl chloride and 0.75 mL (5.4 mmol) of triethylamine 
were added and the solution was stirred for 4 h.  The reaction was concentrated in vacuo.  
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The reaction was partitioned between 50 mL of 10% iPrOH in CHCl3 and 20 mL of brine.  
The aqueous layer was washed twice with 25 mL of 10% iPrOH in CHCl3.  The 
combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and 
purified via flash chromatography (1:19 MeOH:CH2Cl2) and (gradient from 1:49 to 1:9 
MeOH:EtOAc) to afford 1.22 g (55%) of 59 as a white foam. Procedure B: To as solution 
of 1.45 g (5.17 mmol) of 53 and 2.50 mL (17.9 mmol) of triethylamine in 35 mL of 
MeOH was added 6.13 g (15.7 mmol) of 64 and the solution was stirred at reflux for 1 h.  
The reaction was concentrated in vacuo and partitioned between 70 mL of CHCl3 and 30 
mL of water.  The organic layer was washed with 30 mL of water.  The combined 
aqueous layers were washed twice with 20 mL of CHCl3.  The combined organic layers 
were dried over Na2SO4, filtered, concentrated in vacuo, and purified via flash 
chromatography (1:1:98 triethylamine:MeOH:CH2Cl2) to afford 4.90 g (74%) of 59 as a 
white foam: 1H NMR (500 MHz, CDCl3) δ 7.91-7.77 (m, 16H), 7.70 (d, J = 8.0 Hz, 2H), 
7.32 (d, J = 8.0 Hz, 4H), 7.24 (d, J = 8.0 Hz, 2H), 6.66 (br s, 2H), 6.58 (br s, 1H), 5.65 (s, 
1H), 5.37 (s, 2H), 4.23 (t, J = 4.0 Hz, 4H), 4.16 (t, J = 4.0 Hz, 2H), 3.88 (d, J = 2.3 Hz, 
2H), 3.72-3.59 (m, 18H), 3.45 (d, J = 13.4 Hz, 2H), 3.23 (d, J = 13.4 Hz, 2H), 2.90 (s, 
2H), 2.75 (s, 2H), 2.42 (s, 6H), 2.38 (s, 3H), 2.30 (t, J = 2.3 Hz, 1H); 13C NMR (125 
MHz, CDCl3) δ 167.3, 167.1, 144.9, 144.9, 143.0, 142.7, 133.5, 133.3, 132.7, 132.6, 
129.8, 129.7, 127.7, 127.6, 127.4, 126.5, 82.4, 79.3, 75.2, 74.7, 73.8, 69.6, 69.5, 69.2, 
69.1, 68.2, 68.2, 58.2, 55.1, 39.5, 39.4, 26.5, 21.5, 21.4; ESI-LRMS m/z 1291.5 (M + H+); 
SEC (THF) calcd Mn = 1396, PDI = 1.01. 
O
O
O
N
O
O
O  
 131
 4-Dimethoxymethyl-benzoic acid 2,5-dioxo-pyrrolidin-1-yl ester (61).  To a 
solution of 6.86 g (35.0 mmol) of 54 and 4.52 g (38.5 mmol) of N-hydroxysuccinimide in 
350 mL of CH2Cl2 was added 8.03 g (38.5 mmol) of N,N’-dicyclohexycarbodiimide in 
15 mL of CH2Cl2 dropwise over 1 h and the solution was stirred at 0˚C for 3 h.  The 
precipitate was filtered and the solution was concentrated in vacuo and purified via flash 
chromatography (1:1 EtOAc:petroleum ether) to afford 10.1 g (98%) of 61 as a white 
solid: 1H NMR (500 MHz, CDCl3) δ 8.15 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.3 Hz, 2H), 
5.48 (s, 1H), 3.33 (s, 6H), 2.92 (br s, 4H); 13C NMR (125 MHz, CDCl3) δ 169.4, 161.7, 
145.2, 130.5, 127.3, 125.0, 101.8, 52.5, 25.6; FD-LRMS m/z 293.1 (M+); Anal. Calcd for 
C14H15NO6: C, 57.34; H, 5.16; N, 4.78. Found: C, 57.36; H, 5.08; N, 4.89. 
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 Aldehyde 62.  To a solution of 8.94 g (30.5 mmol) of 61 in 150 mL of CH2Cl2 
was added 11.0 g (31.9 mmol) of 60 and the solution was for 6.5 h.  1.0 mL (8.7 mmol) 
of N,N-dimethylethylenediamine was added to sequester unreacted 61 and the solution 
was stirred for 3 h.  10 mL (130 mmol) trifluoroacetic acid was added and the solution 
was stirred for 3 h and 100 mL of water was added.  The aqueous layer was washed twice 
with 50 mL of CH2Cl2.  The combined organic layers were dried over Na2SO4, filtered, 
concentrated in vacuo, and purified via flash chromatography (1:1 EtOAc:petroleum 
ether) to afford 12.1 g (83%) of 62 as a clear, colorless oil: 1H NMR (500 MHz, CDCl3) δ 
10.05 (s, 1H), 7.87 (d, J = 8.3 Hz, 2H), 7.84 (d, J = 8.3 Hz, 2H),7.67 (d, J = 7.6 Hz, 4H),  
7.42-7.33 (m, 6H), 6.57 (br s, 1H), 3.85 (t, J = 4.8 Hz, 2H), 3.66 (m, 4H), 3.61 (t, J = 4.8 
Hz, 2H), 1.03 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 191.7, 167.1, 139.2, 138.3, 135.6, 
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133.6, 129.9, 129.8, 127.8, 127.8, 72.5, 69.4, 63.4, 40.2, 26.8, 19.2; FD-LRMS m/z 476.2 
(M+). 
N
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 TAA 63.  To a solution of 1.51 g (5.32 mmol) of 53 and 2.80 mL (20.1 mmol) of 
triethylamine in 60 mL of MeOH was added 7.90 g (16.6 mmol) of 62 in 60 mL of 
MeOH and the solution was heated at reflux for 3 h.  The solution was concentrated in 
vacuo.  EtOAc was added and insoluble material was filtered.  The solution was 
concentrated in vacuo and purified via flash chromatography (gradient 1:1 to 1:0 
EtOAc:petroleum ether) to afford 6.19 g (75%) of 63 as a white foam: 1H NMR (500 
MHz, CDCl3) δ 7.90-7.74 (m, 12H), 7.73 (d, J = 7.2 Hz, 8H), 7.63 (d, J = 7.2 Hz, 4H),  
7.44-7.36 (m, 12H), 7.33-7.28 (m, 6H), 6.79 (br s, 2H), 6.69 (br s, 1H), 5.63 (s, 1H), 5.32 
(s, 2H), 3.90-3.86 (m, 6H), 3.80 (t, J = 4.5 Hz, 2H), 3.69 (m, 8H), 3.65-3.61 (m, 8H), 
3.57 (t, J = 4.5 Hz, 2H), 3.44 (d, J = 13.4 Hz, 2H), 3.23 (d, J = 13.4 Hz, 2H), 2.88 (s, 2H), 
2.75 (s, 2H), 2.31 (t, J = 2.2 Hz, 1H), 1.08 (s, 18H), 0.96 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 167.4, 167.1, 143.0, 142.7, 142.3, 135.5, 135.4, 133.7, 133.6, 133.5, 133.5, 
133.4, 129.7, 129.6, 127.7, 127.6, 127.4, 126.6, 82.5, 79.3, 75.2, 74.7, 73.9, 72.3, 72.2, 
69.7, 69.5, 63.4, 63.3, 58.3, 56.2, 55.2, 46.7, 39.7, 39.7, 26.8, 26.6, 19.1, 19.0; MALDI-
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LRMS m/z 1543.7 (M+); SEC (0.05 M LiCl in DMF) calcd Mn = 1856, PDI = 1.01; Anal. 
Calcd for C92H110N6O10Si3: C, 71.56; H, 7.18; N, 5.44. Found: C, 71.23; H, 7.22; N, 5.52. 
H
O
H
N O O
O
S
O O  
 Toluene-4-sulfonic acid 2-[2-(4-formyl-benzoylamino)-ethoxy]-ethyl ester 
(64). To a solution of 10.1 (34.3 mmol) of 61 in 10 mL of CH2Cl2 was added 4.20 g (41.3 
mmol) of 2-(2-aminoethoxy)-ethanol and 212 mg (1.72 mmol) of DMAP and the solution 
was stirred for 4 h.  26.2 g (138 mmol) of p-toluenesulfonyl chloride and 17.0 mL (210 
mmol) of pyridine were added and the solution was stirred for 2 h.  The reaction was 
partitioned between 200 mL of CH2Cl2 and 100 mL of 100 mM HCl.  The organic layer 
was washed with 100 mL of 100 mM HCl.  The combined aqueous layers were washed 
twice with 50 mL of CH2Cl2, dried over Na2SO4, filtered, and concentrated in vacuo.  To 
the crude mixture was added 10 mL of CH2Cl2 and 10.0 mL (129 mmol) of 
trifluoroacetic acid and the solution was stirred for 2 h.  The reaction was partitioned 
between 200 mL of CH2Cl2 and 100 mL of NaNCO3.  The organic layer was washed with 
100 mL of NaNCO3.  The combined aqueous layers were washed twice with 50 mL of 
CH2Cl2.  The combined organic layers were dried over Na2SO4, filtered, concentrated in 
vacuo, and purified via flash chromatography (gradient 1:1 to 4:1 EtOAc:petroleum ether) 
to afford 6.56 g (49%) of 64 as a solid: 1H NMR (500 MHz, CDCl3) δ 10.07 (s, 1H), 7.99 
(d, J = 8.2 Hz, 2H), 7.94 (d, J = 8.3 Hz, 2H), 7.76 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.3 Hz, 
2H), 6.86 (br s, 1H), 4.22 (t, J = 4.4 Hz, 2H), 3.72 (t, J = 4.4 Hz, 2H), 3.67-3.65 (m, 4H), 
2.42 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 191.6, 166.3, 144.9, 139.4, 137.9, 132.7, 
129.8, 129.5, 127.7, 127.6, 69.3, 69.1, 68.2, 39.6, 21.4; FD-LRMS m/z 391.2 (M+); Anal. 
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Calcd for C12H21NO6S: C, 58.30; H, 5.41; N, 3.58. Found: C, 58.27; H, 5.39; N, 3.60; mp 
= 79.1-81.4 ˚C. 
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 G1-chloro dendrimer 65.  6 mL of H2O was added to a solution of 207 mg 
(0.373 mmol) of 51 and 1.02 g (1.16 mmol) of 56 in 6 mL CH2Cl2.  To the biphasic 
solution was added 15.0 mg (0.0600 mmol) of CuSO4 . 5H2O quickly followed by 23.0 
mg (0.116 mmol) of sodium ascorbate and it was stirred for 7 h.  The reaction was 
partitioned between 20 mL of CH2Cl2 and 20 mL of NaHCO3.  The aqueous layer was 
washed six times with 10 mL of CH2Cl2.  The combined organic layers were dried over 
Na2SO4, filtered, concentrated in vacuo, and purified via flash chromatography (gradient 
from 2% TEA in ethyl acetate to 2% TEA 10% MeOH in ethyl acetate to remove 
monomer, 10% MeOH in CH2Cl2 to remove product) to produce 1.03 g (86%) of  65 as a 
white foam: 1H NMR (500 MHz, CDCl3) δ 7.85 (m, 18H), 7.78 (m, 18H), 7.35 (s, 3H), 
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6.96 (d, J = 8.9 Hz, 6H), 6.79 (br s 6H), 6.73 (d, J = 8.8 Hz, 6H), 6.68 (br s, 3H), 5.58 (s, 
3H), 5.32 (s, 6H), 4.51 (t, J = 7.0 Hz, 6H), 4.36 (s, 6H), 3.90 (t, J = 5.5 Hz, 6H), 3.77 (t, J 
= 5.0 Hz, 12H), 3.70 (m, 30H), 3.67 (t, J = 5.7 Hz, 12H), 3.64 (m, 12H), 3.61 (t, J = 5.5 
Hz, 6H), 3.38 (d, J = 13.3 Hz, 6H), 3.18 (d, J = 13.3 Hz, 6H), 2.84 (s, 6H), 2.72 (s, 6H), 
2.32 (quint, J = 6.2 Hz, 6H), 2.07 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 167.5, 167.2, 
156.3, 144.5, 142.9, 142.6, 141.9, 133.5, 133.3, 129.4, 127.5, 127.3, 126.4, 126.4, 122.8, 
113.4, 82.3, 75.1, 74.2, 70.6, 70.6, 69.4, 69.4, 64.3, 63.9, 55.0, 50.4, 47.0, 43.1, 43.0, 39.4, 
39.4, 30.6, 29.7, 27.5, 26.6; MALDI-HRMS m/z 3208.3850 (M + H+); SEC (0.05 M LiCl 
in DMF) calcd Mw = 7675, PDI = 1.01. 
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 G1-azido dendrimer 66.  To a solution of 926 mg (0.299 mmol) of 65 in 7 mL of 
DMF was added 632 mg (6.73 mmol) of sodium azide and the solution was heated to 
90˚C for 32 h.  The reaction was cooled to room temperature, the insoluble material was 
filtered, and the solvent was removed in vacuo.  Purification via preparative SEC (1 : 3 
toluene : CH2Cl2) afforded 0.873 g (93 %) of 66 as a white foam: 1H NMR (500 MHz, 
CDCl3) δ 7.85 (m, 18H), 7.78 (m, 18H), 7.34 (s, 3H), 6.96 (d, J = 8.8 Hz, 6H), 7.73 (m, 
12H), 6.63 (br s, 3H), 5.59 (s, 3H), 5.33 (s, 6H), 4.51 (t, J = 7.0 Hz, 6H), 4.36 (s, 6H), 
3.91 (t, J = 5.6 Hz, 6H), 3.74-3.62 (m, 54H), 3.40 (m, 18H), 3.35 (t, J = 4.5 Hz, 6H), 3.18 
(d, J = 13.1 Hz, 6H), 2.85 (s, 6H), 2.73 (s, 6H), 2.34 (quint, J = 6.2 Hz, 6H) 2.07 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ 167.5, 167.2, 156.4, 144.7, 143.0, 142.8, 142.0, 133.5, 
133.4, 129.6, 127.6, 127.4, 126.9, 126.6, 122.8, 113.5, 82.5, 75.3, 74.4, 70.1, 70.0, 69.8, 
69.8, 64.6, 63.9, 55.2, 50.6, 50.5, 50.5, 47.1, 39.7, 39.6, 30.6, 29.9, 27.6, 26.7; MALDI-
HRMS m/z 3266.3512 (M + H+); SEC (0.05 M LiCl in DMF) calcd Mw = 7735, PDI = 
1.02. 
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 G2-chloro dendrimer 67.  5 mL of H2O was added to a solution of 229 mg 
(0.0701 mmol) of 66 and 558 mg (0.631 mmol) of 56 in 5 mL of CH2Cl2.  To the 
biphasic solution was added 7.93 mg (0.0318 mmol) of CuSO4 . 5H2O quickly followed 
by 12.4 mg (0.0626 mmol) of sodium ascorbate and it was stirred for 8 h.  The reaction 
was partitioned between 10 mL of 10% iPrOH in CH2Cl2 and 10 mL of NaHCO3.  The 
aqueous layer was washed four times with 10 mL of 10% iPrOH in CH2Cl2.  The 
combined organic layers were washed three times with 15 mL of brine, dried over 
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Na2SO4, filtered, concentrated in vacuo, dissolved in CH2Cl2 and precipitated out of ethyl 
acetate to produce 0.731 g (93%) of 67 as a white foam: MALDI-LRMS m/z 11227.44 
(M + H+); SEC (0.05 M LiCl in DMF) calcd Mw = 15580, PDI = 1.04. 
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 G2-azido dendrimer 68.  To a solution of 62.1 mg (0.0553 mmol) of 67 in 10 
mL of DMF was added 265 mg (4.08 mmol) of sodium azide and the solution was heated 
to 80˚C for 27 h.  The reaction was cooled to room temperature, the insoluble material 
was filtered, and the solvent was removed in vacuo to produce 604 mg (96%) of 68 as a 
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tan foam that was used without further purification: MALDI-LRMS m/z 11407.22 (M + 
H+); SEC (0.05 M LiCl in DMF) calcd Mw = 16440, PDI = 1.06. 
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 G3-chloro dendrimer 69.  5 mL of H2O was added to a solution of 201 mg 
(0.0176 mmol) of 68 and 423 mg (0.478 mmol) of 56 in 5 mL of CH2Cl2.  To the 
biphasic solution was added 5.84 mg (0.0234 mmol) of CuSO4 . 5H2O quickly followed 
by 9.53 mg (0.0481 mmol) of sodium ascorbate and it was stirred for 26 h.  5.82 mg 
(0.0233 mmol) of CuSO4 . 5H2O, 9.77mg (0.0493 mmol) of sodium ascorbate, and 1 mL 
of MeOH were added and the solution was stirred for an additional 10 h.  The reaction 
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was partitioned between 20 mL of 5% iPrOH in CH2Cl2 and 10 mL of NaHCO3.  The 
aqueous layer was washed four times with 20 mL of 10% iPrOH in CH2Cl2.  The 
combined organic layers were washed with 20 mL of brine and 20 mL of H2O, dried over 
Na2SO4, filtered, concentrated in vacuo, and purified via preparative SEC (CH2Cl2) to 
afford 348 mg (56%) of 69 as a pale green solid: MALDI-LRMS m/z 35279.06 (M + H+); 
SEC (0.05 M LiCl in DMF) calcd Mw = 54419, PDI = 1.38. 
H
O
O
O O Cl 
 4-[2-(2-Chloro-ethoxy)-ethoxy]-3-methoxy-benzaldehyde (73). To a solution of 
4.82 g (31.7 mmol) of vanillin, 9.71 g (34.8 mmol) of toluene-4-sulfonic acid 2-(2-
chloro-ethoxy)-ethyl ester (72),94 and 418 mg (1.57 mmol) of 18-crown-6 in 60 mL of 
DMF was added 8.88 g (64.3 mmol) of K2CO3 and the solution was stirred at 45˚C for 17 
h.  The reaction was cooled to room temperature, filtered, concentrated in vacuo, and 
dissolved in 110 mL EtOAc.  The solution was washed once with 40 mL NaHCO3, twice 
with 40 mL brine, dried over Na2SO4, filtered, concentrated in vacuo, and purified via 
flash chromatography (gradient from 1:3 to 1:1 ethyl acetate : petroleum ether) to afford 
6.57 g (80%) of 73 as a light yellow solid: 1H NMR (400 MHz, CDCl3) δ 9.86 (s, 1H), 
7.44 (dd, J = 1.9 Hz, 8.1 Hz, 1H), 7.41 (d, J = 1.9 Hz, 1H), 7.02 (d, J = 8.1 Hz, 1H), 4.28 
(t, J = 4.8 Hz, 2H), 3.96 (t, J = 4.9 Hz, 2H), 3.92 (s, 3H), 3.85 (t, J = 5.9 Hz, 2H), 3.66 (t, 
J = 5.9 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 191.1, 153.8, 150.0, 130.4, 126.7, 112.0, 
109.4, 71.7, 69.5, 68.6, 56.1, 42.8; FD-LRMS m/z 258.1 (M+). Anal. Calcd for 
C12H15ClO4: C, 55.71; H, 5.84. Found: C, 55.55; H, 5.72. 
 
 
 141
N
N
N
O
O
O
O
O Cl
OCl
O
Cl
O
O
O
 
 TAA monomer 74.  To a solution 2.30 g (8.18 mmol) of 53 and 3.60 mL (25.8 
mmol) of triethylamine in 60 mL MeOH was added 6.38 g (24.7 mmol) of 73 in 80 mL 
of MeOH and the solution was heated at reflux for 10 min.  The solvent was removed in 
vacuo and dissolved in 100 mL of CH2Cl2. The solution was washed in twice with 25 mL 
of NaHCO3 and twice with 25 mL brine.  The combined aqueous layers were washed 
with 25 mL CH2Cl2.  The combined organic layers were dried over Na2SO4, filtered, 
concentrated in vacuo, and purified via flash chromatography (1:49:50 triethylamine : 
petroleum ether : ethyl acetate) to afford 6.36 g (86%) of 74 as a white foam: 1H NMR 
(400 MHz, CDCl3) δ 7.41 (s, 1H), 7.31 (s, 2H), 7.27 (s, 2H), 7.24 (s, 1H), 6.97 (d, J = 8.4 
Hz, 2H), 6.89 (d, J = 8.4 Hz, 1H), 5.54 (s, 1H), 5.25 (s, 2H), 4.24 (t, J = 5.0 Hz, 4H), 4.15 
(t, J = 5.0 Hz, 2H), 3.94 (m, 6H), 3.91 (s, 6H), 3.89-3.84 (m, 6H), 3.81 (m, 5H), 3,67 (t, J 
= 5.9 Hz, 4H), 3.63 (t, J = 5.9 Hz, 2H), 3.50 (d, J = 12.9 Hz, 2H), 3.18 (d, J = 13.0 Hz, 
2H), 2.94 (s, 2H), 2.79 (s, 2H), 2.33 (t, J = 2.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
150.0, 149.9, 147.2, 147.1, 133.2, 133.1, 118.7, 118.6, 114.1, 114.0, 110.2, 110.1, 82.5, 
79.7, 75.0, 74.6, 74.5, 71.6, 71.6, 69.8, 69.7, 68.8, 68.8, 58.5, 56.1, 55.7, 55.3, 46.7, 42.9, 
42.8, 26.4; FD-LRMS m/z 893.5 (M+). Anal. Calcd for C44H56Cl3N3O10: C, 59.16; H, 
6.32; N, 4.70. Found: C, 59.28; H, 6.42; N, 4.70. 
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 2-Polyethyleneglycol methyl ether-1,1,1-tris(aminomethyl)ethane 
trihydrochloride (77). To a solution of 12.6 g (31.7 mmol) of 7-(hydroxymethyl)-2,4,6-
triphenyl-1,3,5-triazaadamantane 3 in 100 mL of THF at 0˚C was added 6.24 g (156 
mmol) of sodium hydride and the solution was stirred for 1 h. 17.5 g (21.2 mmol) of 
mPEG750-OMs (76) was added and the solution was heated to reflux for 20 h. 5 mL of 
MeOH was added and the solution was concentrated in vacuo and partitioned between 
500 mL of CH2Cl2 and 100 mL of brine.  MeOH was added to the resulting emulsion 
until the separate layers were observed.  The organic layer was dried over Na2SO4, 
filtered, and concentrated in vacuo. MeOH was added to the residue and filtered to 
remove insoluble materials.  Concentration in vacuo produced 30.0 g of an orange oil that 
was stirred in HCl (1 M) for 30 min.  The solution was washed once with 300 mL of 
ether and twice with 100 mL of ether and concentrated in vacuo.  CH2Cl2 was added, 
insoluble material was filtered, and the solution was concentrated in vacuo to produce 
15.6 g (76 % over 2 steps) of 77 as a brown paste: 1H NMR (500 MHz, D2O) δ 3.84-3.63 
(br m, ~66H), 3.42 (s, 3H), 3.35 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 72.3, 71.7, 70.3, 
61.4, 58.8; MALDI-TOF LRMS indicates product distribution centered around m/z 918.4 
(M + Na+). 
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 N-(2-Azido-ethyl)-4-dimethoxymethyl-benzamide (78). To a solution of 13.4 g 
(68.3 mmol) of 4-carboxybenzaldehyde dimethoxyacetal 13 and 8.81 g (75.1 mmol) of 
N-hydroxysuccinimide in 300 mL of CH2Cl2 was added dropwise 15.0 g (71.7 mmol) of 
N,N’-dicyclohexylcarbodiimide in 40 mL of CH2Cl2 over 30 min and stirred for an 
additional 1.25 h. The precipitate was filtered and solvent was reduced in vacuo to a total 
of approximately 100 mL.  7.27 g (84.5 mmol) of 1-azido-2-aminoethane, 12.0 mL (86.1 
mmol) of triethylamine, and 415 mg (3.36 mmol) of 4-(dimethylamino)pyridine were 
added and the solution was stirred for 2.25 h. The solution was washed twice with 100 
mL of NaHCO3, dried over Na2SO4, filtered, concentrated in vacuo, and purified via flash 
chromatography (1:1 ethyl acetate : petroleum ether) to afford 14.6 g (81 %) of 78 as a 
white solid: 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 8.3 Hz, 
2H), 6.43 (br s, 2H), 5.44 (s, 1H), 3.65 (q, J = 5.6 Hz, 2H), 3.58 (t, J = 5.6 Hz, 2H), 3.32 
(s, 6H); 13C NMR (125 MHz, CDCl3) δ 167.8, 141.7, 134.1, 127.0, 127.0, 102.3, 52.7, 
50.7, 39.5; ESI-LRMS m/z 265.4 (M+). 
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 Aldehyde 79a. To a solution of 14.3 g (54.0 mmol) of 78 in 100 mL of THF was 
added 16.9 g (63.9 mmol) of triphenylphosphine and the solution was stirred for 5 h.  5 
mL of H2O was added and the solution was stirred for 25 h.  15.0 mL (108 mmol) of 
triethylamine and 339 mg (2.75 mmol) of 4-(dimethylamino)pyridine were added and this 
solution was added dropwise over 1 h to a solution of 9.00 mL (106 mmol) of acryloyl 
chloride in 30 mL of THF at 0° C and the resulting solution was stirred for 4 h.  Insoluble 
material was filtered, the solution was reduced in vacuo, 100 mL of HCl (1M) and 
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CH2Cl2 was added.  The organic layer was washed with 100 mL of HCl (1M), dried over 
Na2SO4, filtered, concentrated in vacuo, and purified via flash chromatography (gradient 
5% to 6%  MeOH in CH2Cl2) to afford 6.93 g (52 %) of 79a as an off-white solid: 1H 
NMR (500 MHz, CDCl3) δ 10.1 (s, 1H), 7.98 (d, J = 8.0 Hz, 2H), 7.95 (d, J = 8.0 Hz, 
2H), 7.64 (br s, 1H), 6.33 (br s, 1H), 6.33 (d,  J = 16.7 Hz, 1H), 6.13 (dd,  J = 10.2 Hz, 
16.7 Hz, 1H), 5.70 (d, J = 10.2 Hz, 1H), 3.63 (br s, 4H); 13C NMR (125 MHz, CDCl3) δ 
191.9, 167.8, 167.1, 139.3, 138.4, 130.4, 130.0, 127.9, 127.7, 42.2, 39.9; ESI-LRMS m/z 
247.2 (M+); Anal. Calcd for C13H14N2O3: C, 63.40; H, 5.73; N, 11.30. Found: C, 63.24; H, 
5.69; N, 11.16. 
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 Aldehyde 79b. To a suspension of 4.63 g (30.2 mmol) of 4-carboxybenzaldehyde, 
4.18 g (36.3 mmol) of N-(2-hydroxyethyl)acrylamide 80, and 379 mg (3.07 mmol) of 4-
(dimethylamino)pyridine in 120 mL of CH2Cl2 was added dropwise 6.98 g (33.5 mmol) 
of N,N’-dicyclohexylcarbodiimide in 50 mL of CH2Cl2 over 2.25 h and the resulting 
solution was stirred for 10 h.  The reaction was filtered, concentrated in vacuo, and 
purified via flash chromatography (gradient 2:1 EtOAc : pet ether to EtOAc) to afford 
6.20 g (83 %) of 79b as a white solid: 1H NMR (500 MHz, CDCl3) δ 10.1 (s, 1H), 8.20 (d, 
J = 8.2 Hz, 2H), 7.97 (d, J = 8.2 Hz, 2H), 6.31 (dd, J = 1.3 Hz, 16.9 Hz, 1H), 6.12 (dd, J 
= 10.2 Hz, 16.9 Hz, 1H), 5.95 (br s, 1H), 5.68 (dd, J = 1.3 Hz, 10.2 Hz, 1H), 4.51 (t, J = 
5.4 Hz, 2H), 3.78 (q, J = 5.5 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 191.8, 166.0, 165.7, 
139.3, 134.8, 130.6, 130.4, 129.6, 127.1, 64.3, 38.8; ESI-LRMS m/z 248.3 (M+); Anal. 
Calcd for C13H13NO4: C, 63.14; H, 5.30; N, 5.67. Found: C, 63.02; H, 5.25; N, 5.90. 
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 N-(3-Bromo-propyl)-acrylamide (81). To a solution of 4.20 mL (49.6 mmol) of 
acryloyl chloride in 50 mL of CH2Cl2 at 0° C was added dropwise a solution of 10.1 g 
(45.3 mmol) of 3-bromopropylamine hydrobromide, 14.0 mL (100 mL) of triethylamine, 
and 288 mg (2.34 mmol) of 4-(dimethylamino)pyridine in 140 mL of CH2Cl2 and the 
resulting solution was stirred for 4.5 h.  The solution was concentrated in vacuo, diluted 
with ethyl acetate, and filtered.  6.3 mg (1.4 mmol) of 2,6-bis(1,1-dimethylethyl)-4-
methylphenol was added and the solution was concentrated in vacuo to afford 10.6 g of 
81 as a yellow liquid that was taken forward without further purification. 
H
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 Aldehyde 79c. To a suspension of 9.12 g (66.0 mmol) of potassium carbonate, 
4.91 g (32.2 mmol) of vanillin, and 488 mg (1.83 mmol) of 18-crown-6 stirring in 50 mL 
of DMF at 80 °C was added 8.70 g, (45.3 mmol; theoretical from previous) of 81 in 50 
mL of DMF in five equal portions each hour over 5 h and stirred for an additional 2 hours 
after the final addition.  The reaction was cooled to room temperature, filtered, and 
reduced in vacuo.  The crude product was dissolved in ethyl acetate, filtered, reduced in 
vacuo, and purified via flash chromatography (gradient EtOAc to 10% MeOH in EtOAc) 
to afford 4.09 g (48 %) of 79c as a white solid: 1H NMR (500 MHz, CDCl3) δ 9.87 (s, 
1H), 7.46 (dd, J = 1.8 Hz, 8.2 Hz, 1H), 7.44 (d, J = 1.8 Hz, 1H), 6.97 (d, J = 8.2 Hz, 1H), 
6.71 (br s, 1H), 6.31 (dd, J = 1.5 Hz, 17.1 Hz, 1H), 6.12 (dd, J = 10.3 Hz, 17.1 Hz, 1H), 
5.66 (dd, J = 1.5 Hz, 10.2 Hz, 1H), 4.24 (t, J = 5.7 Hz, 2H), 3.96 (s, 3H), 3.62 (quart, J = 
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5.7 Hz, 2H), 2.13 (quint, J = 5.7 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 191.8, 165.6, 
153.4, 149.6, 131.1, 130.2, 126.9, 126.0, 111.2, 109.0, 68.5, 55.9, 37.8, 28.5; ESI-LRMS 
m/z 264.4 (M+); Anal. Calcd for C14H17NO4: C, 63.87; H, 6.51; N, 5.32. Found: C, 63.86; 
H, 6.56; N, 5.38. 
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 TAA 82a.  To a solution of 1.37 g (1.41 mmol) of 2-polyethyleneglycol methyl 
ether-1,1,1-tris(aminomethyl)ethane trihydrochloride 77 and 1.00 mL (7.17 mmol) of 
triethylamine in 30 mL of MeOH was added 1.18 g (4.77 mmol) of substituted 
benzaldehyde 79a and the solution was refluxed for 1 h.  The solution was concentrated 
in vacuo and purified via flash chromatography (gradient 10 % MeOH, 0.5 % NH4OH in 
CH2Cl2 to 16 % MeOH, 0.5 % NH4OH in CH2Cl2).  The product was further partitioned 
between 100 mL CH2Cl2 and 50 mL NaHCO3.  The aqueous layer was washed with 50 
mL CH2Cl2. The combined organic layers were dried over Na2SO4, filtered, and 
concentrated in vacuo to afford 1.53 g (70 %) of 82a as a clear, pale tan oil. Major 
diastereomer: 1H NMR (500 MHz, DMSO-d6) δ 8.60 (t, J = 5.3 Hz, 2H), 8.49 (t, J = 5.3 
Hz, 1H), 8.26 (t, J = 5.4 Hz, 2H), 8.19 (t, J = 5.4 Hz, 1H), 7.95 (d, J = 8.3 Hz, 4H), 7.87 
(d, J = 8.5 Hz, 2H), 7.83 (d, J = 8.4 Hz, 2H), 7.79 (d, J = 8.2 Hz, 4H), 6.25-6.13 (m, 3H), 
6.10 (dd, J = 2.2 Hz, 17.1 Hz, 2H), 6.06 (dd, J = 2.2 Hz, 17.2 Hz, 1H), 5.77 (s, 1H), 5.60 
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(dd, J = 2.2 Hz, 10.2 Hz, 2H), 5.56 (dd, J = 2.2 Hz, 10.2 Hz, 1H), 5.26 (s, 2H), 3.23 (s, 
3H), 3.47-3.24 (br m, PEG region +16H), 2.86 (d, J = 10.6 Hz, 2H), 2.73 (s, 2H); 
MALDI-TOF LRMS indicates product distribution centered around m/z 1647.1 (M + 
Na+). 
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 TAA 82b.  To a solution of 1.32 g (1.35 mmol) of 2-polyethyleneglycol methyl 
ether-1,1,1-tris(aminomethyl)ethane trihydrochloride 77 and 1.00 mL (7.17 mmol) of 
triethylamine in 30 mL of MeOH was added 1.14 g (4.62 mmol) of substituted 
benzaldehyde 79b and the solution was refluxed for 1 h.  Insoluble material was filtered 
and the solution was concentrated in vacuo.  EtOAc was added and the insoluble material 
was filtered. The solution was concentrated in vacuo and purified via flash 
chromatography (gradient 10 % MeOH, 0.5 % NH4OH in CH2Cl2 to 12 % MeOH, 0.5 % 
NH4OH in CH2Cl2) to afford 1.28 g (61 %) of 82b as a clear, pale tan oil. Major 
diastereomer: 1H NMR (400 MHz, CDCl3) δ 8.11 (d, J = 8.3 Hz, 4H), 8.04 (d, J = 8.3 Hz, 
2H), 7.90 (d, J = 8.3 Hz, 2H), 7.83 (d, J = 8.3 Hz, 4H), 6.37-6.00 (m, 9H), 5.67 (dd, J = 
1.3 Hz, 10.1 Hz, 2H), 5.65 (s, 1H), 5.62 (dd, J = 1.3 Hz, 10.1 Hz, 1H), 5.34 (s, 2H), 4.49 
(t, J = 5.2 Hz, 4H), 4.43 (t, J = 5.2 Hz, 2H), 3.77 (quart, J = 5.4 Hz, 4H), 3.71 (quart, J = 
5.4 Hz, 2H), 3.68-3.39 (br m, PEG region +4H), 3.37 (s, 3H), 3.32 (t, , J = 4.7 Hz, 2H), 
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3.24 (d, J = 12.7 Hz, 2H), 2.88 (s, 2H), 2.72 (s, 2H); MALDI-TOF LRMS indicates 
product distribution centered around m/z 1606.3 (M + Na+). 
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 TAA 82c.  To a solution of 1.34 g (1.37 mmol) of 2-polyethyleneglycol methyl 
ether-1,1,1-tris(aminomethyl)ethane trihydrochloride 77 and 1.00 mL (7.17 mmol) 
triethylamine in 40 mL of MeOH was added 1.23 g (4.67 mmol) of substituted 
benzaldehyde 79c and the solution was refluxed for 1 h.  The solution was concentrated 
in vacuo and purified via flash chromatography (8 % MeOH, 0.5 % NH4OH in CH2Cl2) 
to afford 1.59 g (73 %) of 82c as a clear, pale tan oil. Major diastereomer: 1H NMR (400 
MHz, CDCl3) δ 7.44 (s, 1H), 7.33 (s, 2H), 7.31-7.25 (m, 3H), 7.00 (t, J = 5.2 Hz, 2H), 
6.97-6.89 (m, 1H), 6.93 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 8.4 Hz, 1H), 6.33 (dd, J = 1.5 Hz, 
17.1 Hz, 2H), 6.27 (dd, J = 1.5 Hz, 17.1 Hz, 1H), 6.16 (dd, J = 10.1 Hz, 17.1 Hz, 2H), 
6.09 (dd, J = 10.1 Hz, 17.1 Hz, 1H), 5.65 (dd, J = 1.5 Hz, 10.1 Hz, 2H), 5.59 (dd, J = 1.5 
Hz, 10.1 Hz, 1H), 5.56 (s, 1H), 5.36 (s, 2H), 4.19 (t, J = 5.4 Hz, 4H), 4.11 (t, J = 5.4 Hz, 
2H), 3.94 (s, 6H), 3.85 (s, 3H), 3.70-3.45 (br m, PEG region +8H), 3.38 (s, 3H), 3.36 (t, J 
= 4.7 Hz, 2H), 3.23 (d, J = 12.7 Hz, 2H), 2.91 (s, 2H), 2.74 (s, 2H), 2.10 (quint, J = 5.6 
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Hz, 4H), 2.03 (quint, J = 5.6 Hz, 2H); MALDI-TOF LRMS indicates product distribution 
centered around m/z 1589.1 (M + H+). 
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 TAA 83a.  To a solution of 255 mg (1.05 mmol) of 2 and 0.50 mL (3.6 mmol) of 
triethylamine in 8 mL of MeOH was added 776 mg (3.14 mmol) of 79a and the solution 
was heated at reflux for 1 h.  The reaction was concentrated in vacuo and partitioned 
between 15 mL of 20% MeOH in CH2Cl2 and 10 mL of NaHCO3.  The aqueous layer 
was washed repeatedly with 20% MeOH in CH2Cl2 until any cloudiness was gone.  The 
combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and 
purified via flash chromatography (1:4 MeOH:CH2Cl2) to afford 738 g (86%) of 83a as a 
white foam: 1H NMR (500 MHz, DMSO-d6) δ 8.63 (br s, 2H), 8.52 (br s, 1H), 8.30 (br s, 
2H), 8.22 (br s, 1H), 7.95 (d, J = 8.4 Hz, 4H), 7.88 (d, J = 8.4 Hz, 2H), 7.84 (d, J = 8.4 
Hz, 2H), 7.79 (d, J = 8.4 Hz, 4H), 6.25-6.13 (m, 3H), 6.10 (dd, J = 2.2 Hz, 17.1 Hz, 2H), 
6.06 (dd, J = 2.2 Hz, 17.2 Hz, 1H), 5.75 (s, 1H), 5.60 (dd, J = 2.2 Hz, 10.2 Hz, 2H), 5.56 
(dd, J = 2.2 Hz, 10.2 Hz, 1H), 5.25 (s, 2H), 3.39-3.24 (m, 16H), 2.83 (br s, 2H), 2.69 (d, J 
= 5.2 Hz, 2H). 
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 TAA 83b.  To a solution of 135 mg (555 μmol) of 2 and 270 μL of triethylamine 
in 5 mL of MeOH was added 441 mg (1.68 mmol) of 79c in 5 mL of MeOH and the 
solution was heated at reflux for 1 h.  The reaction was concentrated in vacuo and 
dissolved in 15 mL of CH2Cl2.  The organic layer was washed three times with 10 mL of 
NaHCO3.  The combined aqueous layers were washed twice with 5 mL of CH2Cl2.  The 
combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and 
purified via flash chromatography (gradient 1:10:189 to 1:20:179 NH4OH:MeOH:CH2Cl2) 
to afford 406 g (84%) of 83b as a off-white solid: 1H NMR (500 MHz, CDCl3) δ 7.44 (s, 
1H), 7.33 (s, 2H), 7.38-7.19 (m, 3H), 6.97 (br s, 2H), 6.93 (d, J = 8.4 Hz, 2H), 6.90 (br s, 
1H), 6.86 (d, J = 8.4 Hz, 1H), 6.32 (dd, J = 1.5 Hz, 17.1 Hz, 2H), 6.26 (dd, J = 1.5 Hz, 
17.1 Hz, 1H), 6.15 (dd, J = 10.1 Hz, 17.1 Hz, 2H), 6.08 (dd, J = 10.1 Hz, 17.1 Hz, 1H), 
5.65 (dd, J = 1.5 Hz, 10.1 Hz, 2H), 5.59 (dd, J = 1.5 Hz, 10.1 Hz, 1H), 5.57 (s, 1H), 5.38 
(s, 2H), 4.19 (t, J = 5.4 Hz, 4H), 4.11 (t, J = 5.4 Hz, 2H), 3.93 (s, 6H), 3.85 (s, 3H), 3.62 
(m, 4H), 3.56 (m, 2H), 3.53 (d, J = 12.7 Hz, 2H), 3.18 (d, J = 12.7 Hz, 2H), 3.00-2.95 (m, 
4H), 2.09 (quint, J = 5.6 Hz, 4H), 2.03 (quint, J = 5.6 Hz, 2H); 13C NMR (125 MHz, 
CDCl3) δ 165.6, 165.6, 149.4, 149.2, 146.9, 146.8, 133.0, 132.7, 131.2, 131.1, 125.8, 
125.7, 118.8, 118.7, 112.8, 112.7, 109.8, 109.7, 82.9, 82.4, 74.8, 68.6, 68.5, 67.1, 55.8, 
55.5, 55.0, 46.5, 38.2, 28.5, 28.4, 26.9; ESI-LRMS m/z 869.5 (M+). 
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 (2-Chloro-ethyl)-(7-chloro-quinolin-4-yl)-amine (85).  To a suspension of 2.03 
g (9.95 mmol) of 4,7-dichloroquinoline (85) and 4.80 g (41.0 mmol) of 2-
chloroethylamine monohydrochloride in 90 mL of MeCN was added 1.00 mL (7.17 
mmol) of triethylamine and reaction was stirred at reflux for 5 h.  1.28 g (11.0 mmol) of 
2-chloroethylamine monohydrochloride and 1.00 mL (7.17 mmol) of triethylamine were 
added and the solution was stirred at reflux for 8 h.  The reaction was concentrated in 
vacuo and partitioned between 50 mL of CH2Cl2 and 25 mL NaHCO3.  The aqueous layer 
was washed four times with 10 mL of CH2Cl2.  The combined organic layers were dried 
over Na2SO4, filtered, concentrated in vacuo, and purified via flash chromatography (1:19 
MeOH:CH2Cl2) to afford 1.45 g (61%) of 85 as a white solid: 1H NMR (500 MHz, 
CDCl3) δ 8.54 (d, J = 5.5 Hz, 1H), 8.00 (d, J = 2.1 Hz, 1H), 7.79 (d, J = 8.9 Hz, 1H), 7.41 
(dd, J = 2.1 Hz, 8.9 Hz, 1H), 6.46 (d, J = 5.5 Hz, 1H), 5.71 (br s, 1H), 3.87 (t, J = 5.7 Hz, 
2H), 3.75 (d, J = 5.7 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 152.0, 149.3, 149.2, 135.3, 
128.8, 125.8, 121.2, 117.4, 99.3, 44.5, 42.6; FD-LRMS m/z 240.1 (M+). 
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 (2-Azido-ethyl)-(7-chloro-quinolin-4-yl)-amine (86).  To a solution of 711 mg 
(2.95 mmol) of 85 in 14 mL of DMF was added 533 mg (8.20 mmol) of sodium azide 
and the reaction was stirred at 90 °C for 12 h.  The solid was filtered.  The solution was 
concentrated in vacuo and partitioned between 50 mL CH2Cl2 and 15 mL of NaHCO3.  
The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo to afford 
715 mg (98%) of 86 as a tan solid: 1H NMR (500 MHz, CDCl3) δ 8.56 (d, J = 5.2 Hz, 
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1H), 7.99 (d, J = 2.1 Hz, 1H), 7.74 (d, J = 8.7 Hz, 1H), 7.41 (dd, J = 2.1 Hz, 8.9 Hz, 1H), 
6.46 (d, J = 5.5 Hz, 1H), 5.43 (br s, 1H), 3.72 (t, J = 5.7 Hz, 2H), 3.56 (d, J = 5.7 Hz, 2H); 
13C NMR (125 MHz, CDCl3) δ 152.0, 149.4, 149.3, 135.3, 128.9, 125.8, 121.2, 117.4, 
99.3, 49.9, 42.3; FD-LRMS m/z 247.1 (M+); mp = 142.6-144.2 ˚C. 
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 Triazaadamantane 87.  To a biphasic solution of 1.10 g (2.52 mmol) of 52 and 
603 mg (2.43 mmol) of 86 in 40 mL of 1:1 CH2Cl2:water was added 3.18 mg (127 μmol) 
of CuSO4 . 5H2O quickly followed by 5.07 mg (256 μmol) of sodium ascorbate and the 
solution was stirred for 7 h.  The reaction was partitioned between 40 mL of CH2Cl2 and 
30 mL of brine.  The organic layer was washed with 20 mL of brine and twice with 20 
mL of water, dried over Na2SO4, filtered, concentrated in vacuo, and purified via flash 
chromatography (1:19 MeOH:CH2Cl2) to afford 1.14 g (69%) of 87 as a solid: 1H NMR 
(500 MHz, CDCl3) δ 8.44 (d, J = 5.5 Hz, 1H), 7.99 (d, J = 2.0 Hz, 1H), 7.81 (d, J = 8.0 
Hz, 2H), 7.75 (d, J = 8.0 Hz, 4H), 7.42 (t, J = 7.5 Hz, 4H), 7.39-7.22 (m, 8H), 6.38 (br s, 
1H), 6.38 (d, J = 5.6 Hz, 1H), 5.61 (s, 1H), 5.41 (s, 2H), 4.71 (t, J = 5.1 Hz, 2H), 4.37 (s, 
2H), 3.87 (quart, J = 5.3 Hz, 2H), 3.46 (d, J = 12.7 Hz, 2H), 3.20 (d, J = 12.7 Hz, 2H), 
2.90 (s, 2H), 2.76 (s, 2H); 13C NMR (125 MHz, CDCl3) δ 151.9, 149.2, 149.1, 145.3, 
139.7, 139.7, 135.2, 128.7, 128.6, 128.5, 127.3, 126.7, 126.5, 126.5, 125.7, 123.2, 121.8, 
117.4, 98.8, 82.8, 75.3, 75.2, 64.8, 55.3, 48.4, 46.7, 42.6, 26.9; FD-LRMS m/z 683.2 (M+). 
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 Tris amine 88.  To a solution of 813 mg (1.19 mmol) of 87 in 5 mL of THF was 
added 5 mL of 1.25 M HCl and reaction was stirred for 1h.  The organic solvent was 
removed in vacuo and the aqueous solution was washed three times with 5 mL of ether.  
The aqueous layer was concentrated in vacuo to afford 616 mg (92%) of 88 as an off-
white solid: 1H NMR (500 MHz, D2O) δ 8.09 (br s, 2H), 7.66 (d, J = 8.9 Hz, 1H), 7.33 (d, 
J = 1.8 Hz, 1H), 7.22 (dd, J = 2.0 Hz, 8.9 Hz, 1H), 6.50 (d, J = 7.1 Hz, 1H), 4.74 (br s, 
2H), 4.66 (s, 2H), 4.01 (br s, 2H), 3.75 (s, 2H), 3.28 (s, 6H); ESI-LRMS m/z 419.4 (M+). 
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 TAA 89a.  To a solution of 500 mg (0.885 mmol) of 88 and 0.550 mL (3.94 
mmol) of triethylamine in 7 mL of MeOH was added 655 mg (2.66 mmol) of 79a and the 
solution was stirred at reflux for 1h.  The reaction was concentrated in vacuo and 
dissolved in 15 mL of 20% MeOH in CH2Cl2.  The organic layer was washed with 3 mL 
of NaHCO3.  The aqueous layer was washed five times with 20% MeOH in CH2Cl2.  The 
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combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and 
purified via flash chromatography (gradient 1:4 to 7:13 MeOH:CH2Cl2) to afford 864 mg 
(88%) of 89a as a white foam: 1H NMR (500 MHz, DMSO-d6) δ 8.62 (t, J = 5.2 Hz, 2H), 
8.51 (t, J = 5.5 Hz, 1H), 8.39 (d, J = 5.5 Hz, 1H), 8.29 (t, J = 5.4 Hz, 2H), 8.21 (t, J = 5.2 
Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 8.6 Hz, 4H), 7.88 (d, J = 7.6 Hz, 2H), 7.84-
7.80 (m, 3H), 7.76 (d, J = 7.9 Hz, 4H), 7.51 (d, J = 8.5 Hz, 1H), 6.52 (d, J = 8.5 Hz, 1H), 
6.22 (dd, J = 10.1 Hz, 17.1 Hz, 2H), 6.15 (dd, J = 10.1 Hz, 17.1 Hz, 1H), 6.10 (dd, J = 
2.0 Hz, 17.1 Hz, 2H), 6.05 (dd, J = 2.0 Hz, 17.1 Hz, 1H), 5.71 (s, 1H), 5.60 (dd, J = 2.2 
Hz, 10.1 Hz, 2H), 5.56 (dd, J = 2.2 Hz, 10.1 Hz, 2H), 5.24 (s, 2H), 4.59 (d, J = 5.9 Hz, 
2H), 4.24 (s, 2H), 3.77 (br s, 2H), 3.50-3.04 (m, 12H), 2.83-2.78 (m, 4H), 2.64-2.60 (m, 
4H). 
N
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 TAA 89b.  To a solution of 364 mg (0.645 mmol) of 88 and 0.400 mL (2.87 
mmol) of triethylamine in 7 mL of MeOH was added 511 mg (1.94 mmol) of 79c and the 
solution was stirred at reflux for 1 h.  The reaction was concentrated in vacuo and 
partitioned between 30 mL of CH2Cl2 and 15 mL of NaHCO3.  The organic layer was 
washed twice with 10 mL of EDTA and with 15 mL of NaHCO3, was dried over Na2SO4, 
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filtered, concentrated in vacuo, and purified via flash chromatography (gradient 1:10:189 
to 1:20:179 MeOH:CH2Cl2) to afford 612 mg (82%) of 89b as a cream colored foam: 1H 
NMR (500 MHz, CDCl3) δ 8.52 (d, J = 5.3 Hz, 1H), 7.95 (d, J = 2.2 Hz, 1H), 7.72 (d, J = 
9.0 Hz, 1H), 7.41 (s, 1H), 7.37 (dd, J = 2.1 Hz, 8.9 Hz, 1H), 7.31-7.28 (m, 4H), 7.26-7.23 
(m, 2H), 6.97-6.88 (m, 5H), 6.85 (d, J = 8.3 Hz, 1H), 6.39 (d, J = 5.4 Hz, 1H),  6.30 (dd, 
J = 1.6 Hz, 17.1 Hz, 2H), 6.26 (dd, J = 1.6 Hz, 17.1 Hz, 1H), 6.14 (dd, J = 10.3 Hz, 17.1 
Hz, 2H), 6.08 (dd, J = 10.3 Hz, 17.1 Hz, 1H), 5.61 (dd, J = 1.5 Hz, 10.2 Hz, 2H), 5.58 
(dd, J = 1.5 Hz, 10.2 Hz, 1H), 5.53 (s, 1H), 5.35 (s, 2H), 4.65 (t, J = 5.5 Hz, 2H), 4.38 (s, 
2H), 4.17 (t, J = 5.7 Hz, 4H), 4.10 (t, J = 5.7 Hz, 2H), 3.92 (s, 6H), 3.86-3.81 (m, 5H), 
3.60 (m, 4H), 3.55 (m, 2H), 3.46 (d, J = 12.7 Hz, 2H), 3.14 (d, J = 12.7 Hz, 2H), 2.91 (s, 
2H), 2.77 (s, 2H), 2.07 (quint, J = 5.5 Hz, 4H), 2.02 (quint, J = 5.5 Hz, 2H). 
O
HO
OH
O
NHO
O
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OH
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OO
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O O
 
 Methacrylic alginate.  To a solution of 1.16 g (23.3 μmol) of alginate (MW = 
50,000), 315 mg (1.71 mmol) of 2-aminoethyl methacrylate, and 305 mg (2.60 mmol) of 
N-hydroxysuccinimide in 30 mL of MES buffer (100 mM, pH 6.4) was added 490 mg 
(2.55 mmol) of EDC and the solution was stirred for 37 h.  The solution was dialyzed for 
2 d (gradient 10 to 0 g/L NaCl, 2000 MW cutoff), frozen, and lyophilized to afford 986 g 
of product as an off-white fabric:  1H NMR (500 MHz, D2O) shown in Figure 36.  
Degree of functionalization is assumed to be 60% of the theoretical degree of 
functionalization. 
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 PEG dimesyl 90.  To a solution of 4.99 g (2.50 mmol) of PEG2000 in 35 mL of 
CH2Cl2 was added 0.78 mL (10 mmol) of MsCl and 1.40 mL (10.0 mmol) of 
triethylamine and the solution was stirred for 17 h.  The reaction was washed twice with 
50 mL of 1M HCl, 100 mL of NaOH, and 100 mL of brine, dried over Na2SO4, filtered, 
and concentrated in vacuo to afford 5.34 g (99%) of 90 as a tan paste: 1H NMR (500 
MHz, CDCl3) δ 4.35 (m, 4H), 3.74 (m, 4H), 3.63-3.61 (m, PEG), 3.06 (s, 6H). 
S
O
Sn
OO
 
 PEG dithioester 91.  To a solution of 1.18 g (0.548 mmol) of 90 in 20 mL of 
THF was added 159 mg (1.36 mmol) of potassium thioacetate and the solution was 
stirred at reflux for 24 h.  The reaction was partitioned between 50 mL of CH2Cl2 and 50 
mL of brine.  The organic layer was dried over Na2SO4 and filtered.  Activated charcoal 
was added, the solution was filtered and concentrated in vacuo to afford 1.04 g (90%) of 
91 as a yellow solid: 1H NMR (500 MHz, CDCl3) δ 3.66-3.61 (m, PEG), 3.59 (t, J = 6.7 
Hz, 4H), 3.08 (t, J = 6.4 Hz, 4H), 2.33 (s, 6H). 
HS
O
SHn  
 PEG dithiol 92.  A solution of 988 mg (0.467 mmol) of 91 in 15 mL of 1M 
NaOH was stirred for 1 h.  19 mL of 1M HCl was added and the solution was washed 
three times with 15 mL of CH2Cl2.  The combined organic layers were dried over Na2SO4, 
filtered, and concentrated in vacuo to afford 909 mg (96%) of 92 as a yellow solid: 1H 
NMR (400 MHz, CDCl3) δ 3.64-3.60 (m, PEG), 2.86 (t, J = 6.7 Hz, 4H), 2.67 (quart, J = 
7.2 Hz, 4H), 1.57 (t, J = 8.1 Hz, 2H). 
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 {2-[2-(3-Hydroxymethyl-4-nitro-phenoxy)-ethoxy]-ethyl}-carbamic acid tert-
butyl ester (96).  To a solution of 4.44 g (26.3 mmol) of 95 and 10.3 g (28.6 mmol) of 93 
in 70 mL of DMF was added 8.03 g (58.1 mmol) of potassium carbonate and 707 mg 
(2.65 mmol) of 18-c-6 and the suspension was stirred at 70 °C for 29 h.  100 mL of 
CH2Cl2 was added and the solution was filter, concentrated in vacuo and purified via 
flash chromatography (gradient 2:1 to 4:1 EtOAc:petroleum ether) to afford 8.81 g (94%) 
of 96 as an orange oil: 1H NMR (500 MHz, CDCl3) δ 8.18 (d, J = 9.1 Hz, 1H), 7.32 (br s, 
1H), 6.92 (d, J = 9.2 Hz, 1H), 5.02 (d, J = 6.2 Hz, 2H), 4.94 (br s, 1H), 4.26 (br s, 2H), 
3.85 (t, J = 4.4 Hz, 2H), 3.60 (t, J = 4.2 Hz, 2H), 3.35 (quart, J = 4.3 Hz, 2H), 2.66 (t, J = 
6.1 Hz, 1H), 1.44 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 163.5, 156.2, 141.0, 140.2, 
127.8, 114.0, 113.8, 79.6, 70.6, 69.3, 68.2, 62.6, 40.4, 20.5; FD-LRMS m/z 357.2 (M+). 
O N
H
O O O
NO2O
O  
 2-Methyl-acrylic acid 5-[2-(2-tert-butoxycarbonylamino-ethoxy)-ethoxy]-2-
nitro-benzyl ester (97).  To a solution of 8.24 g (23.1 mmol) of 96, 4.20 mL (30.1 mmol) 
of triethylamine, and 145 mg (1.18 mmol) of DMAP stirring at 0 °C in 100 mL of 
CH2Cl2 was added 2.50 mL (25.8 mmol) of methacryloyl chloride in 20 mL CH2Cl2 
dropwise over 45 min and the solution was stirred at room temperature for 4.5 h.  The 
reaction was washed twice with 50 mL of NaHCO3, dried over Na2SO4, filtered, 
concentrated in vacuo, and purified via flash chromatography (gradient 1:2 to 1:1 
EtOAc:petroleum ether) to afford 8.10 g (80%) of 97 as a yellow oil: 1H NMR (500 MHz, 
CDCl3) δ 8.15 (d, J = 9.1 Hz, 1H), 7.05 (d, J = 2.8 Hz, 1H), 6.90 (dd, J = 2.7 Hz, 9.2 Hz, 
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1H), 6.20 (s, 1H), 5.64 (t, J = 1.5 Hz, 1H), 5.58 (s, 2H), 4.91 (br s, 1H), 4.18 (t, J = 4.6 
Hz, 2H), 3.82 (t, J = 4.6 Hz, 2H), 3.57 (t, J = 5.1 Hz, 2H), 3.31 (quart, J = 5.2 Hz, 2H), 
1.98 (s, 3H), 1.40 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 166.6, 163.1, 156.0, 140.4, 
135.9, 135.8, 128.0, 126.5, 114.1, 113.3, 79.4, 70.6, 69.1, 68.1, 63.4, 40.3, 28.4, 18.4; 
ESI-LRMS m/z 425.3 (M+). 
H2N
O O O
NO2
O.TFA  
 2-Methyl-acrylic acid 5-[2-(2-amino-ethoxy)-ethoxy]-2-nitro-benzyl ester (98). 
To a solution of 7.40 g (17.4 mmol) of 97 in 100 mL of CH2Cl2 was added 15.0 mL (193 
mmol) of trifluoroacetic acid and the solution was stirred for 5 h.  The reaction was 
precipitated out of ether.  The reaction was dissolved in CH2Cl2 and precipitated again 
out of ether to afford 5.56 g of 98 as a tan solid.  Slow evaporation of the combined ether 
fractions produced 1.66 g (7.22 g total, 94%) of addition 98 via crystallization: 1H NMR 
(500 MHz, DMSO-d6) δ 8.19 (d, J = 9.1 Hz, 1H), 7.92 (br s, 3H), 7.18 (d, J = 2.7 Hz, 
1H), 7.15 (dd, J = 2.9 Hz, 10.1 Hz, 1H), 6.11 (t, J = 1.4 Hz, 1H), 5.78 (t, J = 1.6 Hz, 1H), 
5.51 (s, 2H), 4.29 (t, J = 4.3 Hz, 2H), 3.83 (t, J = 4.3 Hz, 2H), 3.67 (t, J = 5.2 Hz, 2H), 
3.01 (br s, 2H), 1.93 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 166.0, 162.6, 140.2, 135.4, 
134.7, 128.0, 126.7, 114.8, 113.8, 68.5, 68.0, 66.8, 63.1, 38.5, 18.0; ESI-LRMS m/z 325.3 
(M+); Anal. Calcd for C17H21F3N2O8: C, 46.58; H, 4.83; N, 6.39. Found: C, 46.17; H, 
4.66; N, 6.17. 
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 Nitrobenzyl methacrylic alginate.  To a solution of 1.13 g (22.7 μmol) of 
alginate (MW = 50,000), 710 mg (1.62 mmol) of 98, and 285 mg (2.43 mmol) of N-
hydroxysuccinimide in 50 mL of MES buffer (100 mM, pH 6.4) was added 465 mg (2.42 
mmol) of EDC and the solution was stirred for 48 h.  The solution was dialyzed for 2 d 
(gradient 10 to 0 g/L NaCl, 2000 MW cutoff), frozen, and lyophilized to afford 843 g of 
product as an off-white fabric. Degree of functionalization is assumed to be 60% of the 
theoretical degree of functionalization. 
 
4.3 Analytical Techniques 
Degradation Study: 
To a solution of dendrimer 67 (84.5 mg, 7.52 µmol) in THF/MeOH (0.70 mL/0.10 mL) 
was added 1.00 mL 1M HCl.  The solution was stirred for one hour after which it was 
partitioned between CH2Cl2 (5 mL) and H2O (10 mL).  The aqueous layer was washed 
with CH2Cl2 (3 x 5 mL).  The combined organic layers were dried over Na2SO4, filtered, 
concentrated in vacuo to afford 49.1 mg (0.192 mmol) of 55 as a white solid.  This 
structure was confirmed by 1H NMR and ESI-LRMS.  The aqueous layer was 
concentrated in vacuo to afford 49.2 mg of a tan solid that consisted of a mixture of the 
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hydrolyzed dendrimer core 70 and aldehyde 71. Core 70: 1H NMR (500 MHz, D2O) δ 
7.99 (s, 3H), 6.70 (d, J = 8.7 Hz, 6H), 6.50 (d, J = 8.7 Hz, 6H), 4.66 (s, 6H), 4.49 (t, J = 
6.9 Hz, 6H), 3.79 (m, 12H), 3.70 (s, 18H), 2.24 (quint, J = 6.3 Hz, 6H), 1.88 (s, 3H); ESI-
LRMS m/3z 357.4 (M + 3H+); Aldehyde 71: 1H NMR (500 MHz, D2O) δ 9.96 (s, 1H), 
8.01 (s, 1H), 7.96 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 8.0 Hz, 2H), 4.60 (t, J = 4.9 Hz, 2H), 
4.45 (s, 2H), 3.95 (t, J = 4.9 Hz, 2H), 3.70 (s, 2H),  3.67 (t, J = 5.3 Hz, 2H), 3.49 (t, J = 
5.2 Hz, 2H), 3.29 (s, 6H); ESI-LRMS m/z 256.2 (M + H+); Mixture consists of a 1:9 ratio 
or 70:71 as evidenced by 1H NMR (See Table 2 for combined data and Section 4.4 for 
spectra). 
 
DNC Cytotoxicity Measurement: 
Cytotoxicity was characterized as a decrease in metabolic rate using an MTT assay.  D1 
cells were plated in a 96 well plate at an initial density of 10,000 cells per well in 200 μL 
of DMEM.  After 24 h, medium was replaced with fresh medium containing DNC.  After 
3 days the medium was removed, cells were washed with 200 μL PBS.  The PBS was 
removed, and 100 μL medium followed by 10 μL MTT solution was added.  After 4 h, 
100 μL stop solution (20 % SDS in H2O/DMF(50:50)) was added.  After 2 h, the 
absorbance at 570 nm was measured relative to blank wells prepared without cells and 
normalized to cells prepared without any polymer added. 
 
General Hydrogel Syntheses: 
A solution of a given monomer was dissolved in water to the desired concentration (mass 
%) and added to a vial containing 82a, 82b, or 82c at an amount that gives the desired 
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molar ratio of monomer to cross-linker.  0.5 wt % 2-hydroxy-2-methyl propiophenone 
was added and the solution was sterilized via filtration if necessary.  The solution was 
placed in between 2 glass slides separated by 1 mm thick microscope slides and irradiated 
at 366 nm for 5 minutes using a hand help UV lamp (Entela, model UVGL-58).  
Hydrogel discs were made using a 10 mm diameter punch. 
 
Elastic Modulus Determination: 
Poly(acrylamide) hydrogel discs were made using the general synthesis method.  10 mass 
% acrylamide solutions were used for all studies.  For cross-linkers 82a and 82b a 1:99 
mole ratio of cross-linker:acrylamide was used.  For 82c a mole ratio of 1:99, 1:299, and 
1:900 was used.  All hydrogel discs were incubated in deionized water at 37 °C for 40 
minutes and the elastic modulus was measured using a 1 kN MTS Insight 
Electromechanical Testing System. 
 
In vitro Degradation Study: 
Poly(acrylamide) hydrogel discs were made using the general synthesis method.  9 mass 
% acrylamide solutions were used for all studies.  For cross-linkers 82a and 82b a 1:99 
mole ratio of cross-linker:acrylamide was used.  For 82c a mole ratio of 1:99, 1:299, and 
1:900 was used.  Hydrogel discs were incubated in 100 mM PBS pH 5.0 buffer, 100 mM 
PBS pH 7.4 buffer, or 100 mM carbonate pH 10.0 buffer at room temperature of 37 °C.  
Over time the hydrogel disc diameter was measure to the nearest millimeter using a ruler 
and converted to surface area.  Reported data points are an average of two experiments 
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with the exception of the degradation study of discs made from 3c incubated at pH 5.0 at 
37 °C which is the average of four experiments. 
 
In vivo Degradation Study Using Chick Embryo Chorioallantoic Membrane: 
10 mass % acrylamide solutions were used for all studies.  A 1:99 mole ratio of cross-
linker:acrylamide was used for all studies.  0.7 wt % Irgacure 2959 was added and 
solutions were filtered through 0.2 μm filters.  Solutions were placed between glass plates 
and irradiated at 366 nm for 10 minutes.  Four discs were made using 82a, five were 
made from 82b, and five were made from 82c.  All discs were punched at a diameter of 5 
mm.  Discs were incubated in ethanol at 37 °C for 1 h followed by sterile PBS pH 7.4 for 
19 h.  The ethanol and buffer were each exchanged once during incubation.  Discs were 
implanted in 11 day old chick eggs that had been opened 3 days prior.  Eggs were 
incubated at 37 °C for 4 more days after which formalin was added.  24 h later 
chorioallantoic membranes were cut out, imbedded in paraffin, sectioned, and stained 
with hematoxylin and eosin. 
 
Protein Release Study: 
The general hydrogel syntheses procedure was used.  Pre-gel solutions were made to 
contain 0.5 % Bovine Serum Albumin and 15 % acrylamide in phosphate buffer (100 
mM, pH 7.4).  A molar ratio of 1:19 TAA:acrylamide was used.  Ten 5 mm discs were 
made using TAA 82a; five were incubated at pH 7.4 (100 mM PBS) and five at pH 5.0 
(100 mM PBS).  Discs were incubated in a 24 well plate with one disc per well 
submerged in 1 mL buffer.  Nine discs were made using TAA 82c; four were incubated at 
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pH 7.4 and five at pH 5.0.  At each time point 20 μL samples were removed for analysis 
and replaced by an equal volume of appropriate buffer.  BSA amount was calculated 
using a commercially available BCA protein assay kit. 
 
Polyamine Synthesis: 
To a vial containing a solution of the desired cross-linker in DMSO (140 mg/mL) stirring 
at 60 °C was added a solution of 800 Da branched PEI in DMSO (1.4 g/mL) dropwise 
over 20 h.  A 1:2.5 mole ratio of cross-linker:PEI was used.  The reaction was 
precipitated out of ether and rinsed further with ether before drying under high vacuum at 
100 °C overnight before testing was performed.  Transfection and cytotoxicity assays 
were performed in an analogous fashion to previously reported protocols.65b 
 
PEG/Alginate Hydrogel Synthesis: 
A 3 mass % alginate solution in phosphate buffer (100 mM, pH 7.4) was mixed with a 
6.7 mass % solution of PEG in phosphate buffer (100 mM, pH 7.4).  Volumes were used 
that gave a 1:1 ratio of thiol group to methacrylate group.  The solution was placed 
between two glass plates and heated at 37 °C for 10 h.  Hydrogels were punched into 
discs for testing. 
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4.4 Spectra 
Degradation Study 1H NMR: 
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Cross-linker MS: 
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